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Although traditionally perceived as being of little clinical significance,
enterococci have emerged as major nosocomial pathogens, primarily due to the
emergence ofmulti-drug resistant strains. In cases of serious enterococcal infection,
the optimal therapeutic option is the synergistic combination of a cell wall-active
agent with an aminoglycoside. By the late 1980s, high-level resistance to both
penicillin and the aminoglycosides was increasing in prevalence amongst clinical
enterococcal isolates, thus compromising this synergistic combination. It was the
emergence of glycopeptide resistance in the late 1980s, however, that truly rendered
some strains untreatable by proven therapeutic agents.
There are currently five distinct phenotypes of glycopeptide resistance in
enterococci, the most prominent being VanA, which is characterized by high-level,
inducible resistance to vancomycin and teicoplanin, and is conferred by the Tni-
related transposon, Tn1546. Whilst glycopeptide-resistant enterococci (GRE) are a
significant nosocomial pathogen, their epidemiology is extremely complex and is not
restricted to the hospital setting. In Europe, GRE can be readily isolated from a
variety of environmental and animal sources, as well as from healthy non-
hospitalized individuals.
The aim of this study was to investigate the epidemiology of VanA GRE in
Scotland, and to determine the degree of diversity amongst the Tn/54d-related
elements conferring resistance. GRE were collected over a five-year period from
eight hospitals across Scotland. Fifty-five GRE isolates were collected in total, 48 of
which were found to be vanA-positive. In addition, a five-month survey of
enterococcal epidemiology was performed, during which time 94 enterococcal
isolates were collected, two ofwhich were found to be v<m4-positive.
All isolates were examined by PFGE analysis. Twenty-six of the 55 nosocomial
GRE isolates collected during the five-year study period were isolated during the
course of an outbreak of GRE infection in the renal unit of the Royal Infirmary of
Edinburgh in 1995. Many isolates arising from the outbreak were clonal in nature,
with an outbreak strain ofVanA E. faecium being identified. However, outwith the
outbreak situation, GRE isolates were more diverse in nature, with only small
clusters of related isolates being identified, and many deemed to be unrelated. PFGE
analysis of the 94 isolates from the five-month study of enterococcal epidemiology
revealed a heterogeneous enterococcal population, with only small clusters of related
isolates recognized. Whilst the two VanA isolates arising from this study were
unrelated to the nosocomial strains, some glycopeptide-sensitive enterococci were
shown to be related to nosocomial GRE isolates.
Despite the ready transfer of glycopeptide resistance from the majority of the 48
nosocomial VanA GRE, attempts to identify plasmids harbouring Tn1546 were
unsuccessful. Despite this, the results ofPFGE and hybridization studies suggested
that many of the VanA E. faecium isolated from Edinburgh harbour a Tn1546-
bearing plasmid ofapproximately 160-kilobases in size.
The Tn/54<5-related elements, responsible for conferring resistance in the 48
nosocomial VanA GRE, were assessed for diversity. Whilst complete
characterization was not possible for all VanA elements, the majority could be
assigned to one of ten different Tn/545-types on the basis of insertion and deletion
events. Different Tn/545-types varied in their geographical distribution. The
insertion sequence IS1542 and an IS/2/<5F-related element were identified within the
orf2-vanR and vanX-vanY intergenic regions respectively. Further variation, at least
partly attributable to the presence of an IS/2/bF-related element, was common
within the orfllorf2 regions of the transposon. A hybrid promoter located upstream
of vanR was identified, being generated by the insertion of IS/542 immediately
adjacent to the native -10 (TATAAT) box of the vanR promoter. This hybrid
promoter is thought to be responsible for moderate-level constitutive expression of
the glycopeptide resistance genes that was seen in those isolates harbouring the
IS/542 insertion within the VanA transposon. This hybrid promoter supplements,
rather than replaces, the normal inducible expression from the native vanR promoter
that follows glycopeptide challenge. A media-dependent increase in the level of
teicoplanin resistance was seen in those strains harbouring the hybrid promoter.
Whilst it is thought that this increase is attributable to the hybrid promoter, the exact
mechanism is unclear.
In summary, this study reveals a heterogeneous GRE population within Scottish
hospitals, both in terms of chromosome analysis by PFGE, and of genotyping of the
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VanA resistance transposon. In so doing, a novel mechanism of van gene expression
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As recently as the early 1980s, enterococci were perceived "with the exception of
endocarditis and rare cases of meningitis ... [as] not ... a major cause of serious
infection" (Kaye, 1982). However, within the last decade enterococci have become
firmly established as major nosocomial pathogens, causing a wide variety of human
infections. They are the fourth leading cause of hospital-acquired infection and the
third leading cause of bacteraemia in the United States (Jett et al., 1994). The rapid
emergence of antibiotic resistance amongst enterococci has undoubtedly contributed
to their emergence as a major nosocomial pathogen, rendering them amongst the
most difficult oforganisms to treat.
1.1.1 An historical perspective
In 1899, MacCallum and Hastings described a fatal case of endocarditis and
identified the causative agent as a facultative Gram-positive coccus that they named
Micrococcus zymogenes (MacCallum & Hastings, 1899). They noted the organism
as being "very hardy and tenacious of life", withstanding desiccation, temperatures in
excess of 60°C, and many antiseptics. This was the first description of the biological
properties and pathogenicity of the organism that would ultimately be known as
Enterococcus faecalis.
By the early 1930s, enterococci were classed as group D streptococci on the basis
of the serological typing scheme established by Rebecca Lancefield (Lancefield,
1933), which exploited differences in cell wall polysaccharide antigens. In 1937,
Sherman divided the group D streptococci into two physiologically different groups.
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Streptococcus bovis and S. equinus were placed in the viridans division, whilst S.
faecalis and S.faecium were placed in the enterococcus division (Sherman, 1937).
In 1970, Kalina proposed that both S. faecalis and S. faecium be transferred to the
genus 'Enterococcus' (Kalina, 1970). However, it was not until 1984, when DNA-
DNA and DNA-RNA hybridization studies showed a more distant relationship
between these two species and other non-enterococcal streptococci, that such a
transfer took place (Schleifer & Kilpper-Balz, 1984). The genus name was thus
adopted for the bacteria previously named S. faecalis and S. faecium (Schleifer &
Kilpper-Balz, 1984). Subsequently, novel organisms and other streptococci have
followed S. faecalis and S. faecium into the genus Enterococcus.
1.1.2 Enterococcus species
Since the genus was established in 1984 with the descriptions of Enterococcus
faecalis and E. faecium, a further 17 species have been added to the Enterococcus
genus on the basis of chemotaxonomic and phylogenetic studies (Devriese et al.,
1993). Many of the more recent additions do not fit the typical reactions of the genus
that were described by Sherman (Sherman, 1937). Instead, these additions were
based on evidence provided by 16S rRNA sequencing studies. Members of the
genus are listed in table 1.1.
Since the descriptions of E. seriolicida and E. solitarius, phylogenetic studies
indicate they are more closely related to Lactococcus garviae and Tetragenococcus
species respectively (Collins et al., 1990; Eldar et al. 1996; Williams et al., 1991).
3
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Table 1.1: List ofEnterococcus species described.
Present name Description of the species Previous name
Enterococcus
faecalis Schleifer & Kilpper-Balz (1984) Streptococcus faecalis
faecium Schleifer & Kilpper-Balz (1984) Streptococcus faecium
avium Collins et al. (1984) Streptococcus avium
casseliflavus Collins etal. (1984) Streptococcus casseliflavus
gallinarum Collins et al. (1984) Streptococcus gallinarum
durans Collins et al. (1984) Streptococcus durans
malodoratus Collins et al. (1984) Streptococcus faecalis subsp.
malodoratus
hirae Farrow & Collins (1985) ND
mundtii Collins et al. (1986) ND
pseudoavium Collins et al. (1989) ND
raffinosus Collins et al. (1989) ND
solitarius Collins et al. (1989) ND
cecorum Williams et al. (1989) Streptococcus cecorum
columbae Devriese et al. (1990) ND
saccharolyticus Rodrigues & Collins (1990) Streptococcus
saccharolyticus
sulfureus Martinez-Murcia & Collins (1991) ND
seriolicida Kusuda et al. (1991) ND
dispar Collins etal. (1991) ND
flavescens Pompei et al. (1992) ND
ND, New description Adapted from Devriese et al. (1993)
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In addition to identifying Enterococcus species, comparative 16S rRNA sequence
analysis has also revealed the presence of several 'species groups' within the genus
(Williams et al., 1991). There are currently three species groups: the E. faecium
group (E. faecium, E. durans, E. hirae and E. mundtii), the E. avium group (E. avium,
E. pseudoavium, E. raffinosus and E. malodoratus), and the E. casseliflavus/E.
gallinarum group. In general, members of a species group have >99% 16S rRNA
sequence similarity with one another. It was proposed that E. jlavescens would join
the E. casseliflavus/E. gallinarum species group, although no 16S rRNA sequencing
data of E. flavescens were available at the time (Devriese et al., 1993). It has since
been suggested, on the basis of 16S rDNA sequence analysis, that E. flavescens and
E. casseliflavus comprise a single species (Patel et al., 1998). The remaining
enterococcal species, including the type species E. faecalis, form distinct lineages.
1.1.3 Identification of the Enterococcus
Whilst current tests, in general, enable identification of those Enterococcus
species which most frequently occur in humans, many of the more recent
enterococcal species cannot readily be identified by such tests. The 'original'
Enterococcus species, E. faecalis and E. faecium, have several common
characteristics that enable them to be distinguished from other catalase-negative,
Gram-positive facultative cocci. These include the presence of Lancefield group D
antigen, and their ability to grow at both 10 and 45°C, at pH 9.6, and in 6.5% sodium
chloride broth (Schleifer & Kilpper-Balz, 1984). However, many of the new
enterococcal species fail to react with Lancefield group D antisera and fail to grow in
the conditions that are characteristic of E. faecalis and E. faecium (Collins et al.
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1989; Devriese et al., 1990; Facklam & Collins, 1989; Martinez-Murcia & Collins,
1991). Furthermore, it is not only enterococci that may give positive reactions in
these tests, with several streptococcal species, lactococci, pediococci, aerococci and
leuconostocs liable to give positive reactions (Facklam et al., 1989).
Other routinely applied tests include aesculin hydrolysis in conjunction with
resistance to 40% bile, tests for urease, P-glucosidase and p-glucuronidase activities,
and an array of carbohydrate acidification tests (Devriese et al., 1993). Whilst none
of these tests, or their combinations, are unique to enterococci, they remain valid
tests to use when seeking only the classical Enterococcus species.
1.1.4 Natural habitat of enterococci
Enterococci are commensals of the gastrointestinal (GI) tract, being found in the
intestine of nearly all animals, from cockroaches to humans. In human faeces they
are typically found in numbers of 105-107 CFU per gram (Jett et al., 1994), being the
predominant Gram-positive coccus in stools. They are, however, found in a number
ofenvironments, being readily recovered from a variety ofoutdoor sources (Hancock
& Gilmore, 2000; Huycke et al., 1998). This is likely to be attributable to their
ability to persist in the environment following its contamination by sewage or animal
excrement.
Whilst enterococci can also colonize the oral cavity and vaginal tract, their




E. faecalis accounts for approximately 80% of human enterococcal infections,
with the majority of the remainder caused by E. faecium (Huycke et al., 1998). This
disparity between the two species may reflect the varying natural abundance of E.
faecalis and E. faecium; E. faecium viable counts in human faeces are, on average,
100-fold lower than those of E. faecalis (Noble, 1978). An alternative explanation
for the preponderance ofE. faecalis infections is that this species may have enhanced
virulence over E. faecium. Many virulence factors have only been reported in E.
faecalis (see section 1.3), although it is likely that further investigation of E. faecium
will reveal virulence determinants not yet identified in that species. Infections
caused by enterococcal species other than E. faecalis and E. faecium are rare.
A significant risk factor for enterococcal infection is the use of broad-spectrum
antibiotics such as third-generation cephalosporins and other antibiotics with
significant activity against anaerobes, including metronidazole, imipenem and
clindamycin (Edmond et al., 1995; Graninger & Ragette, 1992; Livornese et al.,
1992). Such broad-spectrum therapy enables intestinal overgrowth of enterococci.
Other risk factors for infection include prolonged hospitalization, a high severity of
illness, intra-abdominal surgery and exposure to contaminated equipment or
environmental surroundings (Edmond et al., 1995; Graninger & Ragette, 1992;
Livornese et al., 1992; Wells et al., 1990).
The most common enterococcal infections are urinary tract infections,
bacteraemia, endocarditis and intra-abdominal infections.
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1.2.1 Urinary tract infections (UTIs)
Over the last two decades, the proportion ofUTIs caused by enterococci has risen
significantly, in some cases being reported as the second most common cause of
nosocomial UTI (Felmingham et al., 1992; Morrison & Wenzel, 1986). It has
recently been estimated that enterococci account for 110,000 UTIs annually in the
United States (Huycke et al., 1998). It is thought this increase in enterococcal UTIs
is attributable to increasing use of urethral catheters and broad-spectrum antibiotic
therapy, particularly the increasing use of cephalosporins (Felmingham et al., 1992).
The bladder, kidney and prostate are common infection sites, particularly in those
patients with urinary tract abnormalities or indwelling catheters (Jett et al., 1994). In
one study, 95% of enterococcal UTI cases were preceded by urethral catheterization
(Morrison & Wenzel, 1986).
1.2.2 Bacteraemia
Nosocomial surveillance data between October 1986 and April 1997 identified
enterococci as the third most common cause of nosocomial bacteraemia, accounting
for 12.8% ofall isolates (Jarvis et al., 1997). The ability ofenterococci to translocate
across intact intestinal epithelia is thought to lead to many bacteraemias with no
identifiable source (Wells et al., 1990). Many cases of enterococcal bacteraemia do,
however, have an identifiable source, including intravenous lines, abscesses, UTIs
and contaminated hospital equipment (Graninger & Ragette, 1992; Livornese et al.,
1992).
The primary risk for enterococcal bacteraemia is the use of broad-spectrum
antibiotics which leads to intestinal overgrowth of enterococci, with bacteraemia
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developing following growth to high numbers (Edmond et al., 1995; Livornese et al.,
1992; Wells et al., 1990).
1.2.3 Endocarditis
One of the most significant enterococcal infections, associated with considerable
morbidity and mortality, is infective endocarditis. Enterococci are the third most
common cause of infective endocarditis, behind streptococci and Staphylococcus
aureus (Megran, 1992). When the source of infection is identifiable it is most
frequently the genitourinary tract, usually attributable to either urinary tract infection
or diagnostic/operative procedures (Kaye, 1985; Megran, 1992).
Due to the prevalence of degenerative valvular disease and genitourinary
conditions in the elderly, enterococcal endocarditis tends to be a disease of older
individuals, with a mean age ofmore than 60 years (Besnier et al., 1994).
1.2.4 Intra-abdominal infections
Enterococci alone have little potential for causing intra-abdominal infections or
soft tissue infections, with only a limited ability to infect in pure culture (Jett et al.,
1994). However, when enterococci are mixed with an otherwise avirulent anaerobic
microorganism the infection is much more severe (Onderdonk et al., 1976). Such
microbial synergy between enterococci and anaerobes is well documented, although
the mechanism by which it occurs is not understood (Brook, 1988; Hite et al., 1949;
Matlow et al., 1989; Onderdonk et al., 1976). Despite the accepted idea ofmicrobial
synergy, the exact role played by enterococci in such mixed infections, and their
clinical significance, remains controversial. Whilst some advocate the administration
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of anti-enterococcal therapy in the treatment of such mixed infections, others regard
the enterococci as being non-pathogenic and consider anti-enterococcal therapy
unnecessary (Brook, 1988).
1.2.5 Other enterococcal infections
Enterococci are frequently isolated from burn wound infections and infections of
indwelling foreign devices such as intravascular catheters. Whilst they are also
known to infect other sites, including the central nervous system, lungs, ears and
eyes, such infections occur less frequently (Jett et al., 1994).
1.3 Molecular basis of enterococcal disease
Many aspects of enterococcal pathogenicity are poorly understood. One of the
key issues remaining unanswered is how, in a nosocomial setting, multiply-resistant
enterococcal isolates that have been exogenously acquired appear to out-compete the
indigenous enterococci that are already present. Many studies have attempted to
address this issue, comparing the potential virulence factors expressed by infection-
derived and non-infection-derived isolates.
Most attention has focussed on the expression of cell surface adhesion molecules
and extracellular products that may have a role in virulence.
1.3.1 Cell surface adhesion molecules
Several studies have attempted to identify cell surface molecules that are enriched
in infection-derived strains and thus may have a role in enterococcal adherence and
subsequent infection. Lowe et al. described E. faecalis antigen A (EfaA), antibodies
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against which were only seen in individuals with enterococcal endocarditis (Lowe et
al., 1995). Thus they hypothesized that EfaA may function as an important adhesin
in endocarditis, the molecule showing significant homology to other streptococcal
adhesins. There are, however, no experimental data to support this hypothesis.
A common finding ofmany studies, including that by Lowe and colleagues, is that
the expression of many E. faecalis adhesion molecules is serum-dependent. In one
study, whilst urinary isolates of E. faecalis adhered more readily to urinary tract
epithelial cells than to heart cells, adherence of UTI isolates to cardiac cells was
enhanced following growth in serum (Guzman et al., 1989; Guzman et al., 1991).
Such observations led to the hypothesis that UTI isolates that establish a bacteraemic
infection through invasion of the kidneys undergo alterations in their surface antigen
expression following persistence in the blood (Guzman et al., 1989). This may then
result in enhanced adhesion to cardiac cells, enabling infection of the endocardium.
Such a process could at least partly explain the long-established link between UTIs
and endocarditis.
Aggregation substance is a plasmid-encoded cell-surface protein that is produced
in response to sex pheromone secretion by recipient cells. Expression of aggregation
substance causes aggregation of donor and recipient cells, thus facilitating plasmid
transfer (Dunny et al., 1995). Kreft et al. demonstrated that aggregation substance
mediates binding, not only to other prokaryotic cells, but also to eukaryotic cells, by
way of an amino acid motif that facilitates binding to integrins (Kreft et al., 1992).
They also demonstrated that expression of aggregation substance could be induced
by unidentified serum components. Subsequent studies have supported this finding,
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demonstrating aggregation substance-promoted adherence and internalization to
eukaryotic cells (Sartingen et al., 1998; Suessmuth et al., 1998).
1.3.2 Extracellular products of enterococci
Enterococci secrete few known extracellular products, however two have been
identified as being potential virulence factors in E. faecalis: cytolysin and gelatinase.
Haemolysin activity in E. faecalis was first reported in 1934 (Todd, 1934). On the
basis of its broad target cell range (which includes eukaryotic and prokaryotic cells)
the term haemolysin has now been superseded by the more general term, cytolysin
(Jett et al., 1994). Cytolysin lyses human, horse and rabbit erythrocytes, as well as
having bacteriocin activity against many Gram-positive organisms (Basinger &
Jackson, 1968). A higher incidence of cytolysin activity has been reported in clinical
isolates ofE. faecalis over faecal isolates (Ike et al., 1987). The role of cytolysin in
the virulence of enterococcal infection has also been well documented in animal
models (Chow et al. 1993; Ike et al., 1984; Jett et al., 1992). However, many clinical
strains are non-haemolytic, thus indicating that whilst cytolysin may play a role in
virulence, it is certainly not an essential prerequisite.
Gelatinase, an extracellular metalloendoprotease, can hydrolyse gelatin, collagen,
casein, haemoglobin and bioactive peptides (Makinen et al., 1989). The medical
importance of such metalloendoproteases is well-documented (Hase & Finkelstein,
1993), the enzymes frequently being associated with inflammatory processes and as
potential virulence factors. Sequence analysis of the E. faecalis gelatinase gene,
gelE, reveals significant homology to the elastase of Pseudomonas aeruginosa
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(Fukushima et al., 1989; Su et al., 1991), and some evidence suggests gelatinase may
contribute to the virulence ofE. faecalis (Coque et al., 1995; Dupont et al., 1998).
1.3.3 Enterococci and the host immune system
1.3.3.i Inflammatory response to enterococcal infection
Acute inflammation is a major pathological change associated with enterococcal
infection. One of the factors involved in eliciting this inflammatory response is
lipoteichoic acid (LTA), also known as group D streptococcal antigen (Toon et al.,
1972; Wicken et al., 1963).
Bhakdi and colleagues demonstrated enterococcal LTA to be a potent inducer of
monokine production, stimulating production to a higher level than that achieved by
the LTA of other Gram-positives, and to a level similar to those achieved following
exposure to Gram-negative LPS (Bhakdi et al., 1991). Tsutsui et al. also
demonstrated the stimulation of tumour necrosis factor (TNF) and interferon by
enterococcal LTA (Tsutsui et al., 1991).
The pheromones of E. faecalis are chromosomally encoded peptides (7-8 amino
acids in length) that promote conjugative transfer of plasmid DNA. They have also
been identified as pro-inflammatory mediators. Pheromone-responsive plasmids
encode a peptide that acts as a competitive inhibitor of its corresponding pheromone.
Some, but not all, pheromones and their peptide inhibitors are chemotactic for human
and rat polymorphonuclear leucocytes in vitro, as well as stimulating granule enzyme
secretion and respiratory burst (Ember & Hugli, 1989). Binding assays have shown
these peptides to bind to the neutrophil receptors for formylmethionyl peptides, a
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major class of bacterial chemotactic agents (Ember & Hugli, 1989; Sannomiya et al.,
1990).
1.3.3.H Immune evasion
For pathogens to maintain an infection, they must successfully evade both specific
and non-specific host defence mechanisms. Studies into the ability of enterococci to
evade the host immune system suggest possible roles for some virulence traits,
particularly in the protection against phagocytic cells. A particularly significant
response to enterococcal infection is polymorphonuclear leucocyte-mediated killing
that is primarily dependent on complement activation (Arduino et al., 1994). Whilst
strains capable of expressing gelatinase, cytolysin or aggregation substance appeared
no more resistant to phagocytosis by neutrophils than strains lacking these traits
(Arduino et al., 1994; Jett et al., 1994), studies have highlighted a potential
protective role for aggregation substance against phagocytosis by macrophages
(Suessmuth et al., 1998). It should be noted, however, that the neutrophil-killing
assay was performed under conditions that may not have supported the expression of
cytolysin, gelatinase and aggregation substance, and so a potential protective role
cannot be ruled out.
Peroxide and superoxide dismutase enzymes produced by enterococci may
promote their survival within macrophages, catalysing hydrogen peroxide and
superoxide that is found in phagolysosomes (Jett et al., 1994).
Finally, a novel surface protein, Esp, which is enriched in infection-derived E.
faecalis strains, may play a role in immune evasion. The structural gene allows for
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alternate forms of Esp expression, generating variation at the bacterial cell surface
that may aid immune evasion (Shankar et al., 1999).
1.4 Antibiotic resistance in enterococci
The past two decades have witnessed the rapid emergence of multi-drug resistant
enterococci, with the result that they are now firmly established as major nosocomial
pathogens. Whilst E. faecalis causes the vast majority of human enterococcal
infections, it is with E. faecium that the problem of multi-drug resistance is most
prominent (Huycke et al., 1998). Although E. faecalis exhibits many virulence traits,
it is a species more likely to retain sensitivity to one or more effective antibiotics.
However, E. faecium, whilst virtually devoid of known virulence traits, is more
likely to be multi-drug resistant, with resistance now encompassing those antibiotics
previously considered drugs of last resort (Huycke et al., 1998).
Whilst enterococci are intrinsically resistant to many antibiotics, it is their
propensity to acquire antibiotic resistance determinants through the exchange of
plasmids and conjugative transposons which has rendered some clinical isolates
resistant to all standard therapies.
1.4.1 The genetics of antibiotic resistance in enterococci
Enterococci can acquire antibiotic resistance determinants by three main methods:
pheromone-responsive plasmids, broad host-range plasmids and conjugative





The phermone-responsive plasmids ofE. faecalis are perhaps the most extensively
studied of the three mechanisms for gene transfer within enterococci (Clewell, 1981;
Dunny et al., 1995; Murray, 1998). E. faecalis secrete chromosomally-encoded
pheromones (small peptides) which show specificity for different types of plasmids.
When a potential donor cell containing a pheromone-responsive plasmid comes into
contact with its corresponding pheromone, aggregation substance (encoded by the
pheromone-responsive plasmid) is expressed on the surface of the cell. This
facilitates aggregation (clumping) of donor and recipient cells, enabling highly
efficient plasmid transfer. Transfer of pheromone-responsive plasmids can occur at
frequencies as high as 5 x 10"1, and occurs efficiently in both broth and filter matings.
Once the recipient cell has acquired this particular plasmid, the synthesis of the
corresponding pheromone is shut off to prevent self-clumping.
1.4.1.ii Broad host-range plasmids
Less well understood is the conjugation of broad host-range plasmids (Clewell,
1981; Murray, 1998). Unlike the pheromone-responsive plasmids that are restricted
to E. faecalis, broad host-range plasmids occur across the Enterococcus genus, and
have the potential to transfer to other Gram-positive organisms, including
Staphylococcus aureus. This conjugation system is much less efficient than the
pheromone-induced conjugation system, with filter matings resulting in much higher




The third method of conjugation is that of the conjugative transposons.
Conjugative transposons are DNA elements that are normally integrated into the
bacterial genome, but that have the capacity for intercellular transposition through a
process of excision, conjugation and re-integration (Clewell & Gawronburke, 1986;
Murray, 1998). They have a broad-host range and are found in Gram-positive and
Gram-negative organisms.
One of the first conjugative transposons identified was Tn916, described in E.
faecalis and carrying the tetracycline resistance determinant tetM (Franke & Clewell,
1981). Many other conjugative transposons have since been described, many of
these being related to Tn916 (Salyers et al., 1995). The majority of conjugative
transposons carry the tetracycline resistance determinant and as such have played a
significant role in its dissemination.
1.4.2 Antibiotic resistance in enterococci
Most enterococci are intrinsically resistant to a wide variety of antibiotics,
including cephalosporins, the anti-staphylococcal penicillins, and clinically
achievable concentrations of aminoglycosides and clindamycin (Gray & Pedler,
1992; Murray, 1998). The activity of trimethoprim-sulphamethoxazole is, at best,
controversial, with in vivo studies demonstrating poor efficacy of this antibiotic
combination (Chenoweth et al., 1990; Grayson et al., 1990). This inherent in vivo
resistance may be attributable to the ability of enterococci to utilize exogenous
folates (Zervos & Schaberg, 1985), although the ability of E. faecalis to do so has
been disputed (Hamilton-Miller & Purves, 1986).
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In addition to these inherent resistance traits, enterococci have readily acquired
plasmid or transposon-mediated resistance to various other antibiotics, including
chloramphenicol, tetracyclines, macrolides, and high-level resistance to both
clindamycin and trimethoprim (Murray, 1998). Target site alterations in GyrA and
ParC have rendered many available fluoroquinolones unsuitable for treatment of
enterococcal infections (El-Amin et al., 1999; Kanematsu et al., 1998; Tankovic et
al., 1996).
The scope of these intrinsic and acquired resistance determinants, which are
summarized in table 1.2, has left few reliable therapeutic options for multi-drug
resistant enterococci. In cases of serious enterococcal infection, the optimal
therapeutic option is the synergistic combination of a cell wall-active agent (|3-lactam
or glycopeptide) with an aminoglycoside (Hewitt et al., 1966; Moellering &
Weinberg, 1971). The emergence of high level resistance to these antibiotics has,
however, compromised this combination.
1.4.3 Penicillin resistance in enterococci
In comparison with streptococci, enterococci are relatively resistant to the
penicillins, a feature attributable to low affinity of the penicillin-binding proteins
(PBPs) (Gray & Pedler, 1992). E.faecalis MICs typically range from 1-8 mg/L,
with E. faecium displaying even higher levels of resistance owing to the PBPs of E.
faecium having significantly lower affinities for the antibiotics than the PBPs of E.
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Furthermore, enterococci are tolerant to the bactericidal effect of cell wall-active
agents, both P-lactam and non-P-lactam antibiotics (Fontana et al., 1990; Krogstad &
Parquette, 1980). This tolerance to killing is most likely attributable to a defective
auto lytic enzyme system (Fontana et al., 1990), although it has been suggested that
rather than tolerance being due to an inherent defect, it may be acquired following
exposure to the antibiotics (Hodges et al., 1992). This tolerance to killing is the
reason why systemic enterococcal infections require the synergistic combination of a
cell wall-active agent and an aminoglycoside.
As with any synergistic combination of antibiotics, synergy is abolished by the
emergence of high-level resistance to either of the antibiotics in the combination.
High-level penicillin resistance in enterococci can arise through two distinct
mechanisms: P-lactamase production and PBP overproduction.
1.4.3-i p-lactamase-producing enterococci
P-lactamases in enterococci are primarily, though not exclusively, restricted to E.
faecalis (Murray, 1992). The first P-lactamase-producing (Bla+) strain ofE. faecalis
was reported in 1983 (Murray & Mederski-Samoraj, 1983). The enterococcal
penicillinase has subsequently been shown to be identical to the staphylococcal type
A penicillinase, and has greatest activity against penicillin, ampicillin and the
ureidopenicillins (Murray, 1992). In sensitivity tests, the levels of resistance
conferred by enterococcal p-lactamases are very dependent on the inoculum size, so
much so that at routinely used inocula (105 CFU/mL), Bla+ enterococci are often no
more resistant to penicillin than other enterococci (Murray, 1992). Increasing the
inoculum to 107 CFU/mL can elevate penicillin MICs to 1000 mg/L or more
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(Murray, 1992). Whilst an inoculum effect is characteristic of Bla+ organisms, it is
particularly exaggerated in enterococci, as other Bla+ organisms are usually readily
detectable at routinely used inocula.
Unlike staphylococci, the p-lactamase of enterococci does not appear to be
released into the extracellular medium (Murray et al., 1986). Instead, the enzyme
remains cell-associated, most likely due to either a failure to be cleaved from its
signal peptide sequence, or binding of the enzyme to other cellular components
(Murray, 1992). The cell-associated nature of the enzyme somewhat contradicts the
extreme inoculum effect that is characteristic of the enterococcal penicillinase.
Usually this effect is attributable to the extracellular release of the enzyme.
However, in the case of the enterococcal enzyme, it may rather be due to low-level
expression ofthe enzyme (Zscheck & Murray, 1991).
Several sporadic outbreaks of P-lactamase-producing E. faecalis have been
reported although these are largely restricted to the US (Murray et al., 1991; Wells et
al., 1992). p-lactamase-producing enterococci remain uncommon in Europe, with
typically less than 1% ofE. faecalis isolates displaying ampicillin resistance (Iwen et
al., 1997; Klare et al., 1999a).
1.4.3.H Overproduction of penicillin-binding proteins (PBPs)
High-level penicillin resistance (>200 mg/L) has also been reported in enterococci
(primarily E. faeciurri) that do not produce P-lactamase enzymes (Bush et al., 1989;
Sapico et al., 1989). This form of resistance has been associated with
overproduction of a low affinity PBP (PBP5) that is seemingly able to perform the
functions of the other PBPs (Fontana et al., 1996; Williamson et al., 1985). As well
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as overproduction of PBP5, amino acid substitutions within the protein appear to
cause a further decrease in its affinity for penicillin (Fontana et al., 1996).
Overproduction may be associated with a deletion in a region upstream of the pbp5
gene that ordinarily negatively controls synthesis ofPBP5 (Fontana et al., 1996).
This mechanism of high-level penicillin resistance appears to be more common
than resistance through P-lactamase production; typically over 70% of E. faecium
isolates are ampicillin resistant (Iwen et al., 1997; Klare et al., 1999a).
1.4.4 Aminoglycoside resistance in enterococci
Enterococci are ordinarily relatively resistant to aminoglycosides due to
impermeability, with gentamicin MIC values typically ranging from 4 to 64 mg/L
(Gray & Pedler, 1992). The combination of a cell wall-active agent with an
aminoglycoside, however, provides a synergistic bactericidal effect that is most
likely attributable to increased uptake of the aminoglycoside in the presence of the
cell wall-active agent (Moellering & Weinberg, 1971). In addition to resistance
mediated by impermeability, E. faecium is intrinsically aminoglycoside resistant due
to the activity of a chromosomal acetyltransferase enzyme that modifies the
antibiotic (Chen, 1986).
Whilst high-level streptomycin resistance is sometimes mediated by alteration in
ribosomal protein S12 (Eliopoulos et al., 1984), high-level aminoglycoside resistance
is usually due to plasmid-encoded aminoglycoside-modifying enzymes. Plasmid-
encoded high-level streptomycin resistance (MIC >2000mg/L) was first identified in
E. faecalis in 1970 (Moellering et al., 1971). Such resistance, conferred by the
production of streptomycin adenyltransferase, is now common in both E. faecalis and
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E. faecium (Gray & Pedler, 1992). Nine years after the emergence of high-level
streptomycin resistance, high-level gentamicin resistance (HLGR) was reported in E.
faecalis (Horodniceanu et al., 1979), associated with the production of a Afunctional
6'-aminoglycoside acetyltransferase 2"- aminoglycoside phosphotransferase enzyme
that confers resistance to all clinically-available aminoglycosides, with the exception
of streptomycin (Ferretti et al., 1986). However, many HLGR strains also produce
streptomycin adenyltransferase (Gray & Pedler, 1992).
Other aminoglycoside modifying enzymes include a 4',4"-aminoglycoside
nucleotidyltransferase that confers resistance to tobramycin, kanamycin, neomycin
and dibekacin (Carlier & Courvalin, 1990), and the gentamicin-modifying enzymes,
encoded by the aph(2")-lb, aph(2")-lc, and aph(2")-ld genes, which confer
clinically-significant gentamicin resistance (Chow et al., 1997a; Chow, 2000).
High-level aminoglycoside resistance is now common in E. faecalis and E.
faecium, with prevalence typically ranging from 20-50% (Iwen et al., 1997; Klare et
al., 1999a; Watanakunakorn, 1989).
By the late 1980s, high-level penicillin resistance and high-level aminoglycoside
resistance were increasing in prevalence amongst clinical enterococcal isolates. The
previously reliable synergistic combination of a cell wall-active agent and an
aminoglycoside was becoming increasingly compromised and therapeutic failures
ensued (Fernandez-Guerrero et al., 1988). The biggest surprise, however, came with
the emergence of acquired vancomycin resistance, first reported in 1988 (Leclercq et
al., 1988; Uttley et al., 1988). After 30 years of clinical use, many had been lulled
into thinking that acquired resistance to vancomycin would not appear. However, its
emergence and rapid dissemination amongst primarily nosocomial enterococci has
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rendered some enterococcal infections unbeatable by commercially available,
clinically proven therapies, and has brought the prospect of a "post-antimicrobial
era" (Cohen, 1992) somewhat closer.
1.5 The glycopeptide antibiotics
There are two clinically significant glycopeptide antibiotics in use today,
vancomycin and teicoplanin. Vancomycin has been in use since the late 1950s, with
its usage increasing rapidly throughout the 1980s and early 1990s as it became
recognized as sometimes the only reliable antibiotic for the treatment of multiply
resistant staphylococci (Kirst et al., 1998; Wegener, 1998). However, vancomycin
usage is associated with well-known side effects, including ototoxicity,
nephrotoxicity, neutropenia and severe allergic reactions (van Laethem et al., 1988).
These disadvantages drove the investigation of other potential glycopeptide agents
giving rise to teicoplanin, which is licensed for use in Europe. Both vancomycin and
teicoplanin are produced naturally by the soil-living bacteria Amycolatopsis
orientalis and Actinoplanes teichomyceticus respectively (Marshall et al., 1997;
Parenti et al., 1978).
A third glycopeptide, which will be discussed later, is avoparcin. Avoparcin was
used extensively throughout Europe for over 20 years as a growth-promoting agent
in animal livestock production. Its use within the European Union was withdrawn in
1997 owing to concerns over a potential risk to human health.
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1.5.1 Activity spectrum of the glycopeptides
The glycopeptide antibiotics are large polar molecules and as such cannot
penetrate the outer membrane of Gram-negative organisms (Reynolds, 1985). Their
activity is thus restricted to Gram-positive organisms, both anaerobes and aerobes.
The structures of vancomycin and teicoplanin are shown in figure 1.1.
Figure 1.1: Structures of the glycopeptide antibiotics, vancomycin and
teicoplanin (From Gilpin & Milner, 1997)
(a) Structure of vancomycin
Manoase




The spectrum of activity of vancomycin and teicoplanin, although similar, is not
identical (Greenwood, 1988). Teicoplanin is generally more active against
streptococci and Gram-positive anaerobes than is vancomycin, whilst vancomycin
has the greatest activity against coagulase-negative staphylococci. The activity of
the two agents is comparable against S. aureus, including those strains that are
methicillin-resistant. The main indications for glycopeptide usage are in the
treatment of MRSA infections, Clostridium difficile infections, and serious Gram-
positive infections in patients allergic to p-lactams.
1.5.2 Mode of action of the glycopeptides
All glycopeptide antibiotics inhibit the latter stages of cell wall synthesis by
forming complexes with peptidoglycan precursors. Within the cytoplasm of the cell,
a D-alanyl-D-alanine (D-Ala-D-Ala) ligase produces the dipeptide D-Ala-D-Ala that is
added to UDP-iV-acetylmuramyl-L-Ala-y-D-Glu-L-Lys (Neuhaus, 1962; Walsh,
1989). Once the peptidoglycan precursor is complete, it is translocated across the
cytoplasmic membrane by a lipid carrier, and it is at this stage that the glycopeptides
inhibit cell wall synthesis (Arthur et al., 1996b). Following translocation of the
precursors to the outer surface of the cytoplasmic membrane, the glycopeptides bind
to the carboxy-terminal D-alanine residues of the cell wall precursors. This binding
blocks the incorporation of the peptidoglycan precursors into the nascent cell wall by
transglycosylation, and leads to the accumulation of cytoplasmic precursors.
Binding of the antibiotics to D-Ala-D-Ala-terminating peptide stems within nascent
peptidoglycan is also believed to inhibit cell wall synthesis through inhibition of the
transpeptidase and carboxypeptidase steps of cell wall synthesis.
26
Chapter 1: Introduction
1.6 Glycopeptide resistance in enterococci
High-level resistance to the glycopeptides in clinical enterococcal isolates was
first reported in 1988 by Uttley and colleagues (Uttley et al., 1988). Further
enterococcal isolates displaying a similar resistance phenotype were described later
that same year (Leclercq et al., 1988). These two publications described what was to
become known as VanA phenotype glycopeptide resistance, characterized by high-
level inducible resistance to both vancomycin and teicoplanin. Whilst predominantly
found in E. faecium, VanA-type resistance also occurs in E. faecalis and occasionally
in other enterococcal species (Woodford, 1998).
The year after the description of VanA-type glycopeptide resistance, a second
phenotype was reported (Williamson et al., 1989). This VanB phenotype is
characterized by low to moderate levels of vancomycin resistance but susceptibility
to teicoplanin, and is found predominantly in E. faecalis and E. faecium (Woodford,
1998).
VanA and VanB phenotype glycopeptide resistance are the two most clinically
significant forms of glycopeptide resistance in enterococci. However, since their
description, other glycopeptide resistance phenotypes have been described. VanC
phenotype glycopeptide resistance is an intrinsic property of E. casseliflavus, E.
gallinarum and E. flavescens, and is characterized by low-level resistance to
vancomycin and susceptibility to teicoplanin (Dutka-Malen et al., 1992; Navarro &
Courvalin, 1994). The recently described VanD and VanE phenotypes are acquired
resistance traits seen in E. faecium and E. faecalis respectively (Fines et al., 1999;
Perichon et al., 1997). These five resistance phenotypes are summarized in table 1.3.
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A further two glycopeptide resistance gene clusters have been identified, termed
vanF and vanG. The vanG resistance locus was identified in E. faecalis isolates that
displayed the VanB phenotype but were negative by PCR for all the previously
recognized van genes (McKessar et al., 2000). No data is available concerning the
nature of the terminal amino acid of the peptidoglycan precursors of these isolates.
The genetic organization of the vanG locus is shown in figure 1.4 (page 39)
The vanF resistance locus is a cluster of five genes identified in Paenibacillus
popilliae, a vancomycin-resistant organism that has been used as a biopesticide in the
United States for over 50 years (Patel et al., 2000). It has been proposed that the
resistance genes in P. popilliae may have been precursors to those seen in GRE (see
section 1.7.6).
1.6.1 Molecular basis of glycopeptide resistance
The five resistance phenotypes summarized in table 1.3 share the same basic
mechanism of resistance. As discussed in section 1.5.2, the glycopeptides bind to the
carboxy-terminal D-Ala residues of cell wall precursors, thus preventing their
incorporation into the nascent peptidoglycan. Substituting the terminal D-Ala residue
with either D-lactate (VanA, VanB and VanD phenotypes) or D-serine (VanC and
VanE phenotypes) confers resistance (Arthur et al., 1996b).
The D-lactate (D-Lac) substitution causes the replacement of a peptide bond by an
ester bond within the cell wall precursor. This replacement causes the loss of a
single hydrogen bond, that ordinarily forms between vancomycin and the cell wall
precursor (Bugg et al., 1991a). The loss of this hydrogen bond results in a 1000-fold
decrease in affinity for vancomycin binding, thus resulting in vancomycin resistance
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(Bugg et al., 1991a). The binding of vancomycin to the terminal D-Ala-D-Ala
residues via hydrogen bonds is illustrated in figure 1.2, alongside the structure of the
D-Ala-D-Lac depsipeptide.
Figure 1.2: Binding of vancomycin to D-Ala-D-Ala, and the structure of the
altered precursor, D-Ala-D-Lac
.V-Acetyl-O-Ala-D-Ala
C-terminus of the D-Ala-D-Lactate peptide
Hydrogen bonds formed between vancomycin and the terminal D-Ala-D-Ala residues
are illustrated, with the hydrogen bond that is lost by the substitution of D-Ala with
D-lactate depicted in red. (Adapted from Gilpin & Milner, 1997)
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In comparison with other antibiotic resistance traits that are conferred by a single
gene product or mutation in a single gene, acquired glycopeptide resistance occurs by
a complex mechanism involving a series of enzymatic reactions. VanA-type
resistance, for example, discussed in depth in section 1.7, is conferred by seven
different genes, involved in the regulation of resistance gene expression, the
production of altered cell wall precursors (terminating in D-lactate) and the
degradation of native cell wall and cell wall precursors (terminating in D-Ala)
(Arthur et al., 1996b). In general, a cell co-producing D-Ala-D-Ala and D-Ala-D-
Lac-terminating cell wall precursors will not be glycopeptide resistant, as antibiotic
will bind to those D-Ala-D-Ala-terminating precursors as they are translocated across
the cytoplasmic membrane, thus sequestering the lipid carrier necessary for their
translocation (Arthur et al., 1996b).
1.6.2 Glycopeptide-dependent enterococci
In 1994, variants of glycopeptide-resistant E. faecalis and E. faecium, derived
from both VanA and VanB phenotypes, were isolated from patients who had
undergone vancomycin therapy (Fraimow et al., 1994; Woodford et al., 1994).
These variants, known as glycopeptide-dependent enterococci, grow only in the
presence of glycopeptide antibiotics or if supplied with the dipeptide D-Ala-D-Ala.
This suggested that these variants are unable to produce the ^/-encoded ligase
normally responsible for production of the D-Ala-D-Ala dipeptide. Recent studies
have confirmed this, showing mutations in the ddl gene leading to either amino acid
substitutions or deletions (van Bambeke et al., 1999). With the impaired host D-Ala-
D-Ala ligase, cell wall synthesis can only proceed in the presence of glycopeptides
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that induce the VanA or VanB ligase, resulting in synthesis of the D-Ala-D-Lac
depsipeptide.
Vancomycin-independent revertants can arise from previously dependent strains
through two distinct mechanisms. Compensatory mutations in the ddl gene can
restore ligase activity, or alternatively, a mutation in the glycopeptide-resistance
regulatory genes can result in constitutive expression of the VanA/VanB ligase (van
Bambeke et al., 1999).
Whilst glycopeptide-dependent enterococci have been described as 'superbugs'
(Farrag et al., 1996), it is generally accepted that they are more of a curiosity than a
major clinical concern, carrying no more implication than normal GRE, with the
exception that they are not readily detected by standard screening techniques.
1.7 Tn1546 - the VanA transposon
The genetic element responsible for conferring high-level glycopeptide resistance
in E. faecium BM4147, one of the first clinical GRE isolates, was fully characterized
in 1993 (Arthur et al., 1993). The element, designated Tn1546, is now known to
confer VanA phenotype glycopeptide resistance, with all VanA enterococci
harbouring Tn/J4d-related elements.
Tn1546 (10,851-bp) is a TnJ-related transposon encoding nine polypeptides
involved in the regulation of resistance, the resistance mechanism itself, and the
transposition functions of Tn1546. The basic structure of Tn1546 is well conserved
and is depicted in figure 1.3. Variation within Tni546-related elements and the use
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1.7.1 ORF1 and ORF2: Transposition functions
Analysis of Tn1546 and its transposition functions showed that it conformed to
the Tni family of transposons (Arthur et al., 1993). Tni-related transposons
typically harbour two genes that are essential for transposition (encoding transposase
and resolvase enzymes), and a res site that serves to complete the transposition
process. The transposase enzyme mediates formation of a cointegrate intermediate
during which the transposon is replicated. The resolvase enzyme then mediates site-
specific recombination between the res sites of the two transposons thus resolving
the cointegrate.
The orfl and orf2 genes ofTiU546 encode proteins that are structurally related to
transposases and resolvases respectively (Arthur et al., 1993). As in Tni, the
transposase and resolvase genes ofTill546 are transcribed in opposite directions and
are separated by a putative res site (Arthur et al., 1993). However, despite the
structural similarities between Tn1546 and Tni, sequence similarity between the
transposase and resolvase genes of the two transposons is low (around 30%) (Arthur
et al., 1993). Whilst Tn1546 transposition has been shown to be replicative via
cointegrate formation, studies in E. coli deficient in general recombination have
failed to demonstrate ORF2-mediated resolution of cointegrates, suggesting the
Tn1546 resolvase is nonfunctional (Arthur et al., 1993). Sequence alignment of
ORF2 with other resolvase enzymes has revealed two apparent amino acid
substitutions within ORF2 that may be responsible for its impaired resolvase activity.
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1.7.2 VanR and VanS: Two-component regulatory system
VanR is related to members of the OmpR class of response regulators, whilst
VanS is related to membrane-associated protein histidine kinases. Together they
form a two-component regulatory system that activates expression of the van gene
cluster in response to glycopeptide challenge (Wright et al., 1993).
Gel shift experiments and DNasel footprinting using phosphorylated VanR (P-
VanR) have demonstrated P-VanR binding sites at both the vanR and vanH promoter
regions, located upstream of vanR and within the vanS-vanH intergenic region
respectively (Holman et al., 1994). Whilst unphosphorylated VanR is capable of
binding at these sites, phosphorylation to yield P-VanR greatly increases the binding
affinity (Holman et al., 1994). P-VanR has a markedly higher affinity for the vanH
promoter region than the vanR promoter region, and has a protected footprint at the
vanH promoter twice the size of the footprint at the vanR promoter. These findings
are consistent with the oligomerization ofP-VanR on the vanH promoter (Holman et
al, 1994).
Analysis of the P-VanR footprinted regions have led to the identification of a 12-
bp consensus sequence that may act as a recognition site for P-VanR binding
(Holman et al., 1994). One copy of this consensus sequence is present within the
vanR promoter region, whereas two copies are present at the vanH promoter. This
further supports the oligomerization ofP-VanR on the vanH promoter.
Whilst it was initially proposed that P-VanR binding had a negative effect on the
vanR promoter and a positive effect on the vanH promoter (Holman et al., 1994),
subsequent studies have shown P-VanR binding to have a positive role at both
promoters (Arthur et al., 1997; Haldimann et al., 1997). Thus P-VanR binding at the
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vanR promoter establishes a positive amplification loop for vanRS expression, whilst
binding at the vanH promoter activates cotranscription of the van gene cluster and
thus expression ofglycopeptide resistance.
1.7.3 VanH, VanA & VanX: Essential gene products
The remaining genes of Tn1546, vanHAXYZ, can be assigned to two functional
groups: those which are essential for glycopeptide resistance {vanH, vanA and vanX)
and those that encode non-essential accessory proteins (vanY and vanZ) (Evers et al.,
1996). Of the three essential gene products, two (VanH and VanA) are required for
the production of the altered peptidoglycan precursors that terminate in D-Ala-D-Lac,
whilst VanX is required for the elimination of D-Ala-D-Ala dipeptides, preventing
their incorporation into peptidoglycan precursors.
The VanA protein shows significant amino acid sequence homology to the D-Ala-
D-Ala ligases of E. coli (Dutka-Malen et al., 1990b). Whilst VanA displays D-Ala-
D-Ala ligase activity, the catalytic efficiency of the enzyme is considerably lower (ca.
100-fold) than those of the E. coli ligases (Bugg et ah, 1991b). Unlike other D-Ala-
D-Ala ligases, VanA displays broad substrate specificity, capable ofproducing mixed
dipeptides including D-alanine-D-methionine, D-alanine-D-phenylalanine and D-
alanine-D-aminobutyrate (Bugg et ah, 1991b). These results led to the conclusion
that the synthesis of a D-Ala-D-X compound by VanA enabled cell wall synthesis to
proceed in the presence of glycopeptides. The exact nature of this X compound was
established as a result of studies on the VanH protein and analysis of peptidoglycan
precursors of glycopeptide-resistant and susceptible enterococci (Arthur et ah, 1991;
Arthur et ah, 1992a; Bugg et ah, 1991a; Handwerger et ah, 1992). It is now known
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that the preferred reaction catalysed by the VanA ligase enzyme is ester bond
formation between D-alanine and D-lactate, forming the depsipeptide D-Ala-D-Lac
(Arthur et al., 1992a). This depsipeptide replaces D-Ala-D-Ala in the formation of
peptidoglycan precursors. The VanH enzyme, a dehydrogenase that reduces 2-keto
acids to D-hydroxy acids, provides the substrate for VanA by reducing pyruvate to D-
lactate (Bugg et al., 1991a).
As discussed in section 1.6.1, a cell co-producing D-Ala-D-Ala- and D-Ala-D-Lac-
terminating peptidoglycan precursors will not be glycopeptide resistant. There must,
therefore, be a mechanism for the degradation of cell wall precursors terminating in
D-Ala-D-Ala. VanX, a D,D-dipeptidase, plays a key role in the elimination of such
precursors. VanX hydrolyses the D-Ala-D-Ala dipeptide prior to its incorporation
into the disaccharide pentapeptide precursors (Reynolds et al., 1994). As well as
serving to prevent the formation of D-Ala-D-Ala-terminating peptidoglycan
precursors, the function of VanX recycles D-Ala, thus ensuring substrate for the
VanA ligase.
1.7.4 VanY & VanZ: Accessory proteins
Downstream of the vanHAX gene cluster are the vanY and vanZ genes encoding
non-essential accessory proteins.
The vanY gene encodes a D,D-carboxypeptidase that can remove the terminal D-
alanine of peptidoglycan precursors terminating in D-Ala-D-Ala, thus generating the
tetrapeptide precursor UDP-V-acetylmuramyl-L-Ala-y-D-Glu-L-Lys-D-Ala (Arthur et
al., 1992b; Arthur et al., 1994). Whilst VanY also displays carboxyesterase activity,
hydrolysing the D-Ala-D-Lac-terminating precursors generated by VanH and VanA,
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it is likely that its main role is as a 'back-up' mechanism, preventing the
incorporation of D-Ala-D-Ala-terminating precursors into nascent peptidoglycan
(Arthur et al., 1994; Wright et al., 1992). Whilst the VanX dipeptidase would
ordinarily be expected to prevent the incorporation of D-Ala-D-Ala-terminating
precursors by hydrolysis of the D-Ala-D-Ala dipeptide, it is feasible that in the
presence of excess D-alanine some dipeptides are not hydrolysed by VanX.
Following the incorporation of these residual D-Ala-D-Ala peptides into
peptidoglycan precursors, VanY cleaves the terminal D-alanine, generating a
tetrapeptide precursor that is insensitive to the glycopeptides.
The vanZ gene of Tn1546 has been shown to confer low-level teicoplanin
resistance in the absence of the other van genes that are involved in
pentadepsipeptide synthesis (Arthur et al., 1995). Analysis of peptidoglycan
precursors shows that VanZ-mediated resistance is not achieved through the
alteration of D-Ala-D-Ala-terminating precursors (Arthur et al., 1995). The
mechanism ofVanZ-mediated resistance has yet to be established.
1.7.5 Homology of Tn1546with other glycopeptide-resistance determinants
On the basis of the relatedness of their van operons, two distinct phylogenetically-
related groups of glycopeptide resistance phenotypes have been identified (Abadio
Patino et al., 2000). The VanA, VanB and VanD phenotypes form one group, whilst
VanC and VanE form the second. The glycopeptide resistance loci identified to date
in enterococci are compared in figure 1.4.
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Figure 1.4: Comparison of glycopeptide resistance loci in enterococci
vanA gene cluster
vanR vanS vanH vanA vanX vanY vanZ
vanB gene cluster
% Identity vs vanA
vanRji vanSB vanYB vanW vanHB vanB
34 23 30 67 76 71
vanD gene cluster
vanRD vanSD vanYD vanIID vanD vanXD
% Identity vs van.4 58 42 13 59 69 68
vanC gene cluster
vanC vanXYc vanTc vanRc vanSc
vanE gene cluster
vanE vanXYE vanTE vanRE
% Identity vs vanC 53 45 43
vanG gene cluster
vanRc, vanSa vanYoi vanWovanG van YG2 vanTa
Colouring indicates those genes with similar functions between the gene clusters. Un-coloured
arrows indicates that the genes are of unknown function. The vanYGi and vanYG2 genes encode
two putative D,D-peptidases that may be similar to the bifunctional enzymes of the vanC and vanE
gene clusters. "% Identity" indicates amino acid identity with the homologous proteins encoded
by the specified gene cluster (van.4 or vanC.). vanRE has only been partially sequenced.
Figures adapted from Woodford (1998), Casadewall & Courvalin (1999), McKessar et al. (2000)
& Abadio Patino et al. (2000)
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There is significant homology between the vanA, vanB and vartD gene clusters,
and the proteins that they encode, particularly within the essential genes/gene
products (vanHAX and homologues). The vanZ and vanW genes are unique to the
vanA and vanB gene clusters respectively. The vanYo gene of the vanD gene cluster
encodes a penicillin-sensitive carboxypeptidase enzyme with greater homology to
catalytic serine PBPs (26%) than to the penicillin-insensitive carboxypeptidases
encoded by the vanA and vanB gene clusters.
Given the relationship between the VanC and VanE phenotypes and their operons,
it has been proposed that the VanE-type resistance seen in E. faecalis is due to the
acquisition of the chromosomal vanC operon found in other enterococcal species
(Abadio Patino et al., 2000; Fines et al, 1999). However, the gene clusters differ
significantly in their GC content, and in the amino acid identity of their encoded
proteins (Abadio Patino et al., 2000). This suggests that the vanE operon has not
been acquired directly from the intrinsically-resistant Enterococcus species.
Based on the racemase gene (vanTG) and the putative bifunctional peptidase
enzymes (vanYoi and vanYci) encoded within the vanG locus, it may be that the
VanG phenotype is related to the VanC and VanE phenotypes. Both the vanC and
vanE gene clusters encode a serine racemase (vanTc and vanTg) and a bifunctional
enzyme with dipeptidase and carboxypeptidase activities (vanXYc and vanXYg).
1.7.6 The origin of glycopeptide resistance genes
In the case of VanA and VanB-type resistance, the D-Ala-D-Lac terminating
precursors are synthesized by ligase enzymes encoded by the vanA and vanB genes
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respectively. Several studies have therefore concentrated on trying to identify vanA
and vanB homologues in an attempt to identify the origin of these genes.
Lack of homology between the vanA or vanB genes and DNA from glycopeptide-
sensitive enterococci suggested the resistance genes did not originate from the
Enterococcus (Arthur et al., 1993; Dutka-Malen et al., 1990a; Evers et al., 1994).
Early studies with vanA and vanB probes also failed to identify a possible origin for
the genes, the probes failing to hybridize with DNA from organisms intrinsically
resistant to the glycopeptides (Leuconostoc spp., Lactobacillus spp., and Pediococcus
spp.) or from the glycopeptide-producing organisms Amycolatopsis orientalis and
Actinoplanes teichomyceticus (Dutka-Malen et al., 1990a). Whilst these studies
suggest the inherent resistance of the glycopeptide-producing organisms is by a
different mechanism from that seen in clinical GRE, a more recent study has
suggested an evolutionary relationship between the two mechanisms.
Using degenerate primers, Marshall and colleagues amplified intragenic fragments
of genes likely to encode the D-Ala-D-Ala ligases (ddl genes) of glycopeptide-
producing organisms (Marshall et al., 1997). Sequence comparison of the ddl PCR
products obtained with the sequences of the vanA and vanB genes showed the ddl
genes of the glycopeptide-producing organisms to have a significantly higher GC
content than the vanA or vanB genes. This is consistent with there having been no
recent direct transfer from the antibiotic-producers to enterococci. However,
comparison of the predicted amino acid sequences of the D-Ala-D-Lac ligases of
glycopeptide-producing organisms showed significant homology to the amino acid
sequences of the VanA and VanB ligases (>60%). In contrast, the ligases of
glycopeptide-producing organisms had low homology to other D-Ala-D-X ligases. It
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was therefore proposed that the vanA and vanB resistance genes might have
transferred from a related antibiotic producer, or via at least one intermediate species.
Recently Marshall and colleagues have also identified VanH and VanX
homologues in glycopeptide-producing organisms, further supporting the hypothesis
that clinical glycopeptide resistance in enterococci originated in the glycopeptide-
producing organisms (Marshall et al., 1998). VanH and VanX are two proteins that
are essential for glycopeptide resistance in VanA GRE (see section 1.7.3). The
VanH homologues found in glycopeptide-producing organisms have 54-61% amino
acid homology with the VanH protein of clinical GRE, whilst the VanX homologues
have 61-64% homology with VanX. Significantly, the orientation of the homologous
gene clusters identified in the glycopeptide-producing organisms is identical to that
seen in GRE, and the overlap of the vanH and vanA genes is conserved (Marshall et
al., 1998). Recently, vanR and vanS homologues have also been identified within the
glycopeptide-producing organisms (Neu &Wright, 2000).
As outlined in section 1.6, a vancomycin resistance gene cluster has been
identified within the biopesticide organism, Paenibacillus popilliae (Patel et al.,
2000). Five genes encoding homologues of VanY, VanZ, VanH, VanA and VanX
were identified. On the basis of amino acid sequences of the homologous proteins,
and the G+C contents of the genes, Patel et al. (2000) concluded that the resistance
gene cluster in P. popilliae is more similar to that in GRE than are the gene clusters
in the glycopeptide-producing organisms. They concluded that the genes in P.




Wherever the resistance genes originated, it is clear that such a complex resistance
mechanism will have taken a considerable length of time to evolve into the form now
apparent in clinical isolates of enterococci. The genes found on the VanA resistance
transposon Tn1546 (see section 1.7) differ significantly from each other in their GC
content (Arthur et al., 1993), suggesting the genes may have different origins. It is
therefore unsurprising that the emergence of acquired glycopeptide resistance in the
clinics came after 30 years of vancomycin usage.
1.8 The impact of glycopeptide resistance in enterococci
The prevalence of glycopeptide resistance amongst clinical isolates of enterococci
increased 20-fold over a four-year period from 1989-1993 (Edmond et al., 1995).
This was mostly attributable to increasing prevalence amongst enterococci isolated
from intensive care units. With this increase continuing, many studies have
compared the clinical outcomes of infections caused by glycopeptide-resistant and
glycopeptide-sensitive enterococci.
1.8.1 Hospitalization and mortality rates
Many studies report that patients with vancomycin-resistant enterococcal
bacteraemia have significantly longer hospital stays than those with vancomycin-
sensitive enterococcal bacteraemia (Lucas et al., 1998; Mainous et al., 1997).
However, it is not always clear how much of this lengthened hospitalization is due to
longer therapy following onset of bacteraemic infection, as opposed to simply the
length of time prior to onset of bacteraemia. Prolonged hospitalization is well
recognized as a primary risk factor for enterococcal infection (Edmond et al., 1995).
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Likewise, comparisons of mortality rates attributable to vancomycin-resistant and
vancomycin-sensitive infections are often problematic. Most studies have concluded
that vancomycin resistance is not associated with increased mortality (Lucas et al.,
1998; Mainous et al., 1997) although Linden et al. report otherwise, finding
significantly higher mortality rates amongst patients with bacteraemia due to
vancomycin-resistant E. faecium than amongst those infected with vancomycin-
sensitive E.faecium (Linden et al., 1996). Shortcomings of such studies frequently
include the failure to adequately take into account the severity of illness, and the fact
that whilst the majority of cases of vancomycin-resistant infection will be caused by
E. faecium, the majority of vancomycin-sensitive infections will be caused by E.
faecalis. Direct comparisons are thus difficult to make.
1.8.2 Therapeutic options for infections caused by GRE
One implication of glycopeptide resistance in enterococci is that there may be no
therapeutic agents commercially available and/or of established efficacy for patients
with serious infection caused by multi-resistant E. faecium. Successful therapy
currently depends on the antibiotic resistance profile of the particular infecting strain.
Whilst it is sometimes possible to treat infections caused by GRE with 'traditional'
antibiotics such as chloramphenicol (Norris et al., 1995), infections sometimes
require treatment with experimental antibiotics or unproven antibiotic combinations.





Glycopeptide resistance arises through alteration of the drug target conferring
cross-resistance to all naturally occurring glycopeptides. Thus it was widely thought
that the glycopeptide class of antibiotics would be an unlikely source of potential
replacements to overcome the problem ofvancomycin resistance (Nicas et al., 1997).
Furthermore, unlike the P-lactam class of antibiotics, the glycopeptide molecule has
limited potential for chemical modification (Nicas et al., 1997). Recent attention,
however, has turned to iV-alkylated glycopeptides with these semisynthetic
derivatives displaying high potency against VanA and VanB enterococci (Nicas et
al., 1996). These compounds have the unusual property of being bactericidal against
enterococci, as well as exhibiting good activity against a range of Gram-positive
organisms (Nicas et al., 1997). The mechanism for their superior activity over their
parent molecules has yet to be established.
1.8.2.ii Quinupristin-Dalfopristin
One of the non-glycopeptide alternatives to vancomycin for which there is the
most clinical experience is quinupristin-dalfopristin, known as Synercid™, an
antibiotic of the streptogramin class (Nicas et al., 1997; Pechere, 1996). Synercid,
licensed in late 1999, has received particular attention owing to its in vitro activity
against a range of glycopeptide-resistant Gram-positive organisms, including VanA
and VanB E.faecium (Collins et al., 1993). Its clinical use may be limited, however,
by its lack ofactivity against the predominant enterococcal species E. faecalis and its
lack of bactericidal activity against E. faecium (Nicas et al., 1997). Emergence of
resistance to the quinupristin-dalfopristin combination during Synercid therapy ofE.
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faecium infection has been reported (Chow et al., 1997c), as has E. faecalis
superinfection (Chow et al., 1997b). Despite these problems, it is still thought likely
that Synercid will prove a useful antibiotic for the treatment of infections caused by
glycopeptide-resistant E. faecium.
1.8.2.iii Glycylcyclines
Whilst tetracycline resistance is common amongst enterococcal isolates, partly
due to the widespread dissemination of Tn976-borne tetM, interest has focussed on
semisynthetic tetracycline derivatives which may have activity against those isolates
resistant to the parent compounds (Nicas et al., 1997). AvV-dimethylglycylamido
derivatives, referred to as glycylcyclines, have shown good activity against Gram-
positive bacteria, including strains of multi-drug resistant E. faecium (Eliopoulos et
al., 1994). These semisynthetic derivatives are poor substrates for the transporters
mediating drug efflux and show greater affinity for ribosomes than the parent
compounds, hence their activity against tetracycline and minocycline-resistant strains
(Bergeron et al., 1996; Someya et al., 1995). Like the parent compounds, however,
the glycylcyclines are only bacteriostatic.
1.8.2.iv Fluoroquinolones
A large number of quinolones with enhanced activity against GRE, including
trovafloxacin and clinafloxacin, are undergoing development (Gootz & Brighty,
1996; Nicas et al., 1997). These newer compounds generally have much improved
activity against enterococci than earlier class members, such as ciprofloxacin or
ofloxacin (Cohen et al., 1995), and their bactericidal activity suggests they may be of
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use in the treatment of systemic enterococcal infections. Mutation studies with these
newer fluoroquinolones have, however, demonstrated comparable mutation rates
with those obtained with ciprofloxacin (Cohen et al., 1995) and thus their therapeutic
potential may be short-lived through the rapid acquisition of resistance.
1.8.2.V Oxazolidinones
Oxazolidinones are novel synthetic, broad-spectrum, bacteriostatic agents that
inhibit protein synthesis (Nicas et al., 1997). They were initially investigated in the
late 1980s but recent attention has focussed on novel fluorinated oxazolidinones that
demonstrate bactericidal activity against Gram-positive organisms, anaerobes and
some Gram-negative species (Jones et al., 1996). No cross resistance to other
antibiotic classes has yet been described and it is thought that these compounds show
potential for the treatment of infections caused by various organisms, including GRE
(Nicas et al., 1997).
1.8.3 The threat of dissemination of vancomycin resistance genes
Arguably the main concern that was raised by the emergence of glycopeptide
resistance in enterococci was the threat of its transfer to other organisms, particularly
the 'first-rate' pathogens such as MRSA or penicillin-resistant pneumococci. The
potential for the spread of the glycopeptide resistance genes has already been
illustrated, with vanA being identified in various bacterial species, although not
necessarily associated with Tn/57<5-like elements (French et al., 1992; Ligozzi et al.,
1998; Power et al., 1995). However, despite MRSA and GRE coexisting in the
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nosocomial setting for over a decade, transfer into S. aureus in the clinical setting has
not been detected.
Noble and colleagues have demonstrated the transfer of vanA into S. aureus under
laboratory conditions (Noble et al., 1992), although the strains used were not MRSA.
In the clinical setting MRSA appear to develop resistance to the glycopeptides by an
alternative method: that of augmented cell wall production and PBP expression
(Hanaki et al., 1998). Such MRSA strains exhibiting reduced susceptibility to
vancomycin were first reported in Japan (Hiramatsu et al., 1997), and subsequently
in Europe and the USA (CDC, 1997; Howe et al., 1998; Ploy et al., 1998), although
they remain rare. Their clinical significance remains uncertain, as doubling the
thickness of the bacterial cell wall is unlikely to be an efficient resistance
mechanism, and the levels of glycopeptide resistance conferred are significantly
lower than those mediated by VanA in enterococci.
Finally, it is interesting to speculate that vanT-mediated glycopeptide resistance
will not arise in MRSA due to incompatibility of the two resistance mechanisms.
The methicillin resistance mechanism of MRSA and glycopeptide resistance
conferred by the vanA gene cluster arise through altering either the structure of the
cell wall or components involved in cell wall synthesis. It is possible, therefore, that
the lack of -mediated glycopeptide resistance in MRSA is due to the inability of
the two resistance mechanisms to coexist within the bacterial cell.
1.9 Epidemiology of glycopeptide-resistant enterococci
Reports that followed the initial identification of acquired glycopeptide resistance
in enterococci in the late 1980s were consistent with the glycopeptide resistance trait
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being another example of a nosocomial resistance trait, similar in many respects to
methicillin resistance in S. aureus. Glycopeptide resistance was found
predominantly, if not exclusively, in the nosocomial setting (Murray, 1997).
However, European studies in the 1990s began to reveal a significant reservoir of
GRE in various non-hospital sources and it is now recognized that the epidemiology
ofGRE is extremely complex and potentially influenced by several factors.
1.9.1 The European-American paradox
GRE have become a major infection control problem in the United States, far
more so than in Europe (Woodford, 1998). Despite their prevalence in US hospitals,
no GRE have been isolated from community or non-human sources within the States
(Coque et al., 1996), with the exception of one VanA GRE isolated from a sample of
dry dog food (Dunne et al., 1996) and one multi-resistant VanB GRE from animal
feed (Schwalbe et al., 1999). This is in stark contrast to the situation now being
reported in many European countries. Whilst the scale of the problem of nosocomial
GRE in Europe is not at the level being witnessed in the States, within Europe GRE
are isolated from a variety ofnon-hospital sources including the community, pet and
farm animals, raw meat and sewage (Aarestrup et al., 1996; Bates et al., 1994;
Devriese et al., 1996; Klare et al., 1995a).
A study in Belgium by van der Auwera and colleagues reported the recovery of
GRE from 28% of community-based volunteers with no known hospital or
glycopeptide exposure, the isolates being primarily polyclonal VanA (van der
Auwera et al., 1996). In the same report they describe the isolation of GRE from
64% of healthy volunteers who had been administered oral vancomycin or
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teicoplanin (van der Auwera et al., 1996). No GRE were detected in the faecal flora
prior to glycopeptide administration. As acquired glycopeptide resistance in
enterococci does not arise through spontaneous mutation, these findings suggest that,
in Europe at least, GRE are frequent colonizers of the GI tract of healthy, non-
hospitalized individuals, albeit in low numbers. These GRE may only reach
detectable levels following glycopeptide therapy. It is therefore possible that GRE
observed in the nosocomial setting within Europe actually have a community origin
and are only seen following the intense selective pressures encountered in hospitals.
With the isolation of GRE from uncooked chickens and minced-meat products in
Europe (Bates et al., 1993; Howarth & Poulter, 1996), it seems such meat and
poultry products may act as a source for these community-based GRE. The
ruggedness and heat tolerance of enterococci would be expected to enhance their
ability for survival once having entered the food chain.
1.9.2 GRE in animal husbandry
1.9.2.i E. faecium as an animal food supplement
A potential source ofGRE in animal livestock that has received little attention is
the use of E. faecium as an animal food supplement (Murray, 1997). E. faecium has
a long history of use, being fed to livestock to stabilize and modulate the intestinal
flora. The rationale behind its use is that E. faecium will confer colonization
resistance, lactic acid and possibly bacteriocin production by E. faecium acting as a
barrier to pathogenic bacteria. Ironically, it is the very multi-drug resistant nature of
E. faecium that has made it a popular candidate for use as a food supplement. It is
possible that GRE were amongst those E. faecium strains used as a food supplement.
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Prior to the initial description of enterococci with acquired glycopeptide resistance,
the routine testing of clinical enterococcal isolates for this resistance trait was not
widespread. It is possible, therefore, that E. faecium strains destined for use as a
food supplement were not screened for glycopeptide resistance.
1.9.2.ii GRE and avoparcin
In the late 1960s, a report was commissioned to examine the use of antibiotics in
animal husbandry and veterinary medicine (HMSO, 1969). Amongst the
recommendations of the report was that non-prescription use of antibiotics in animal
feed should be restricted to those antibiotics which would not impair the efficacy of
therapeutic antibiotics through the development of resistance (HMSO, 1969).
Despite this recommendation, the glycopeptide antibiotic avoparcin went into use as
a growth-promoting agent in animal husbandry in 1975, even though resistance to
avoparcin confers cross-resistance to vancomycin and teicoplanin.
Antibiotic growth promoters have been used in animal husbandry since the 1940s,
particularly in the rearing of pigs and poultry (Bonner, 1997). It is well established
that animals reared in a germ-free environment grow fester than those reared in
conventional surroundings (Coates et al., 1963). Coates et al. demonstrated that the
growth rate of conventionally-reared animals can, however, be increased almost to
that of the germ-free animals by administering low-level antibiotics continuously in
their feed (Coates et al., 1963). The exact mechanism by which antibiotics improve
growth and feed conversion efficiency is unknown, but it is thought that the
subtherapeutic levels administered are able to control "low-level" diseases which
would otherwise stunt the growth of the animals (Bonner, 1997). All effects are
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limited to the intestinal bacteria, as the agents used are administered orally and are
poorly absorbed.
Whilst it has been proposed that the low-level use of antibiotics as growth-
promoters does not select resistant strains amongst the intestinal flora (Smith, 1993),
there is increasing evidence to suggest otherwise. In Denmark, Aarestrup and
colleagues reported high levels of vancomycin and avoparcin resistance amongst
faecal isolates from animals (Aarestrup et al., 1996). As vancomycin is not used
therapeutically in veterinary medicine, they concluded that the use of avoparcin was
responsible for the selection of GRE. Aarestrup et al. also proposed that, owing to
the passage of avoparcin through the digestive system both largely unabsorbed and
unmetabolized, the concentration of antibiotic in the GI tract is probably in excess of
the avoparcin MIC for susceptible enterococci (Aarestrup et al., 1996). Several
studies have now reported a correlation between the use of avoparcin for growth
promotion and isolation ofVanA GRE from farm animals (Aarestrup, 1995; Klare et
al., 1995b). In the face of such findings, the use of avoparcin in the European Union
was banned in 1997, owing to the potential risk it posed to human health through the
selection ofGRE.
The use of growth promoters has long been recognized as having economic
advantages (Bonner, 1997; MacKinnon, 1993) and it was therefore considered likely
that alternative antimicrobial growth-promoting agents would be used in place of
avoparcin following its withdrawal (Woodford, 1998). If resistance to these
alternative antimicrobials is linked to glycopeptide resistance genes, it could be
anticipated their use would continue to select GRE following the withdrawal of
avoparcin (Woodford, 1998). Early indications are, however, that avoparcin
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withdrawal has led to a decreased incidence ofGRE in animal livestock (Aarestrup et
al., 2000; Klare et al., 1999b) and, perhaps more surprisingly, the complete
withdrawal of antimicrobial growth promoters in poultry production was not
associated with economic loss (Emborg et al., 1999).
Based on the above, there has certainly been the potential for GRE to be
introduced and/or selected in animal livestock, with these GRE subsequently entering
the food chain through the contamination of meat products. Following ingestion,
these GRE strains may colonize the human gut or transfer their resistance
determinants to the endogenous enterococcal flora. The relative importance of
avoparcin use versus the clinical use of vancomycin and teicoplanin as factors
promoting the selection and dissemination of GRE is still unclear. In the United
States avoparcin has never been licensed for use, a fact which may at least partly
explain the lack of GRE in community and non-human sources in the US. The
problem of GRE in the US is most likely due to the use and abuse of vancomycin in
the clinics. The contrasting picture in Europe suggests avoparcin was certainly
implicated to an extent in the widespread dissemination of GRE, but the clinical
significance of its use remains uncertain.
1.9.3 Epidemiology of nosocomial GRE
1.9.3.i Diversity of nosocomial GRE
On the basis ofpulsed-field gel electrophoresis (PFGE) analysis and their isolation
from at least two patients in at least two hospitals, five epidemic strains of
vancomycin-resistant E. faecium (designated EVREM) have been defined
(Woodford, 1998). Of these five strains, EVREM-3 is causing the greatest concern,
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being isolated from many hospitals in the London area. EVREM-3 exhibits high-
level resistance to the aminoglycosides, penicillins, and various other antibiotics, as
well as VanA glycopeptide resistance.
With the exception of these epidemic strains, GRE isolated from hospitals within
the UK are generally very diverse, with PFGE analysis revealing considerable
heterogeneity, both within individual hospitals and between different hospitals
(Woodford, 1998). This is likely to be due, at least in part, to the transposable nature
of the vanA gene cluster and the frequent association of TnJ546 with transmissible
plasmids. This association will have aided the widespread dissemination of VanA
glycopeptide resistance to diverse strains of enterococci.
Outbreaks of GRE infection usually occur within specialized units, including
renal, haematological and intensive care units (Murray, 1997; Woodford, 1998).
Whilst some hospitals may report a predominant strain ofGRE, responsible for such
outbreaks, predominant strains from different hospitals usually differ, and sporadic
isolates tend to be unique by PFGE (Woodford, 1998). This is once again in contrast
to the epidemiology of GRE in the US, where hospitals frequently report the
predominance of a single strain (Murray, 1997). Evidence suggests that GRE
isolated in hospitals across the UK have emerged independently at these different
centres, consistent with their endemicity in the community and their subsequent
selection following antibiotic therapy in the hospital setting (Woodford, 1998).
1.9.3.ii Prevalence of VanA versus VanB phenotypes
Ofthe GRE referred from hospitals in England and Wales to the PHLS Laboratory
ofHospital Infection in the period from 1987 to 1996, 87.5% were VanA and 12.5%
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VanB (Morrison et al., 1997). Whilst low detection rates ofVanB isolates owing to
their sometimes borderline-levels of resistance may partly explain the discrepancy
between the two phenotypes, it is unlikely to be the sole reason. Although interest in
the VanB phenotype and the apparent differences in the prevalence of the VanA and
VanB phenotypes have led to studies being more rigorous in their detection systems
for VanB enterococci, the discrepancy remains. Numerous studies addressing the
prevalence of GRE in the community and from non-human sources have failed to
demonstrate the presence ofVanB phenotype enterococci outwith the hospital setting
(Woodford, 1998). Globally there is only one, unsubstantiated, report of a VanB
Enterococcus isolated from a non-human source, being isolated from a cow in
Australia in 1997 (John Ferguson; personal communication). The vanB gene has
also been identified in Streptococcus gallolyticus, isolated from veal calves in The
Netherlands (Mevius et al., 1998)
Differing prevalence ofVanA and VanB phenotypes may then be partly explained
by there being a significant environmental reservoir of VanA enterococci, but no
VanB equivalent. It is likely, however, that other factors will also play a role. It may
be that the predominance ofVanA phenotype is due to the frequent association of the
vanA gene cluster with plasmids and occasionally conjugative transposons that have
facilitated its widespread dissemination. VanB phenotype was long regarded as
being chromosomal, and although it has now been associated with many conjugative
transposons and plasmids, they may not be providing as efficient dissemination as
the vanA-bearing plasmids. Similar reasons have been used to explain the
predominance of TEM-1 (3-lactamase over TEM-2. The use of teicoplanin in
hospitals would also be expected to promote the selection of VanA phenotype over
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VanB, the latter phenotype not displaying teieoplanin resistance. However, the level
of teicoplanin usage is generally far lower than that of vancomycin and so it is
unlikely to be a major factor in the discrepancy between the two phenotypes.
1.9.3.iii Relatedness ofGRE from human and non-human sources
With the controversy surrounding the use and subsequent withdrawal of avoparcin
as a growth-promoting agent in animal livestock and the potential consequences for
both the animal husbandry and pharmaceutical industries, molecular studies are
necessary to determine the relatedness of VanA GRE from human and non-human
sources. However, with such great diversity amongst hospital isolates of GRE,
conclusive evidence for strains common to man and other sources (particularly
animals) is scarce. PFGE and ribotyping are commonly applied, but the horizontal
transfer of resistance genes mediated by both plasmids and transposons leads to
genetically diverse GRE populations. Only in a limited number of cases have
isolates sharing PFGE or ribotype patterns been demonstrated in both humans and
animals or animal-products. In one study, two clinical isolates from separate hospital
patients shared ribotype patterns with porcine isolates (Bates et al., 1994), whilst
another study reported isolates with similar PFGE patterns from humans and minced
meat (Klare et al., 1995b). Identical GRE isolates have also been reported in turkeys
and their farmer (van den Bogaard et al., 1997).
With such heterogeneity amongst GRE isolates pointing to the dissemination of
Tn1546 by plasmid transfer, interest has recently turned to investigating the diversity
of the Tn7545-related elements themselves.
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1.9.4 Diversity of Tn/545-related elements
Whilst the overall structure of the vanA gene cluster is generally conserved, the
genetic organization being as shown in figure 1.3, there is now known to be
considerable diversity amongst the Tn754<5-related elements present in VanA GRE
from both human and non-human sources. Variation within Tn7576-related
elements, which is primarily found in the regions upstream from vanR and
downstream from vanX, is generally attributable to point mutations and the presence
of insertion sequences (IS elements) and deletions, with some studies also taking into
account the integration position of Tn1546 (Handwerger et al., 1995; Jensen et al.,
1998; Palepou et al., 1998; Willems et al., 1999; Woodford et al., 1998). Several IS
elements have now been identified within Tn754<5-related elements, including
IS1542, IS1251, IS1476 and IS727bE-related elements (Darini et al., 1999;
Handwerger et al., 1995; MacKinnon et al., 1997; Willems et al., 1999; Woodford et
al., 1998). Deletion events often accompany these insertions and are frequently
located in the orfl!orf2 region (Palepou et al., 1998; Willems et al., 1999).
Identical transposon types have been identified in VanA GRE isolated from both
human and non-human sources (Jensen et al., 1998; Willems et al., 1999; Woodford
et al., 1998), suggesting a common pool of glycopeptide resistance determinants.
However, the significance of such findings has been questioned, owing to the
potential instability of the variation being described, particularly that attributable to
the presence of IS elements. Often Tn1546 types differ only by one insertion event
and the IS elements responsible are frequently found elsewhere within the
enterococcal genome. Therefore the assigned Tn1546 type can be altered by a single
transposition event. Such Tn1546 instability has been reported, both within the
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clinical setting and during prolonged cold storage ofVanA GRE (Darini et al., 2000;
Woodford et al., 1998).
Thus questions remain over the validity of Tn1546 analysis as an epidemiological
tool. However, it is likely to remain a useful marker, even if it is restricted to 'snap¬
shot' pictures of epidemiology. Interestingly, the restricted geographical distribution
of certain IS elements may be of use as epidemiological markers. In 1995, IS1251
was identified within the vanS-vanH intergenic region of Tn/54(5-related elements in
VanA GRE from the United States (Handwerger et al., 1995). Only recently has this
alteration within the vanS-vanH intergenic region been identified in European GRE
isolates, suggesting recent intercontinental spread (Simonsen et al., 2000).
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Aims of this thesis
• To establish the van genotype of glycopeptide-resistant enterococci in Scottish
hospitals.
• To determine the heterogeneity of nosocomial GRE by PFGE analysis, and to
compare those GRE strains with GSE isolates from hospital and community
sources.
• To study VanA GRE isolates for the ability to transfer vanA-mediated
glycopeptide resistance, and to establish the nature of the element responsible.
• To examine the diversity of Tn/54b-related elements amongst VanA GRE in
Scotland, and to assess any impact the variation is having on the expression of
glycopeptide resistance.
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2.1 Bacterial strains
Glycopeptide-resistant enterococci were collected from eight Scottish hospitals
over a five-year period (1995-1999) following their referral by the hospital's clinical
diagnostic laboratories. In addition, a five-month survey of enterococcal
epidemiology was undertaken, during which time, enterococcal isolates were
collected from the diagnostic laboratories of the Royal Infirmary of Edinburgh (see
section 2.3.1).
Enterococci suspected of being glycopeptide-resistant were subjected to
vancomycin and teicoplanin susceptibility testing (see section 2.3.2) to confirm their
glycopeptide resistance phenotype. Identification of isolates to the species level was
performed by the API20 Strep System (BioMerieux, Marcy-l'Etoile, France)
according to the manufacturer's instructions.
Table 2.1 lists the standard bacterial strains used in the study as control
organisms.
Table 2.1: Standard bacterial strains
Bacterial strain Resistance Reference
E. faecium NCTC 12202 VanA phenotype Uttley et al. (1988)
E.faecalis ATCC 51299 VanB phenotype Swenson et al. (1995)
E. gallinarum NCTC 12359 VanC-1 phenotype Collins et al. (1984)
E. casseliflavus NCTC 12361 VanC-2 phenotype Collins et al. (1984)
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Bacterial strains were stored at -70°C in Brain-Heart Infusion (BHI) broth
supplemented with glycerol to 5% v/v. Subculture of stored strains was performed




Complex media used were BHI broth and agar, Isosensitest agar (ISTA), Mueller-
Hinton agar (MHA) and Kanamycin-Aesculin-Azide agar base (KAA). All were
supplied by Oxoid (Basingstoke, UK), and prepared according to the manufacturer's
instructions. Media were sterilized by autoclaving at 121°C / 15 psi for 15 minutes.
All cultures were prepared in BHI medium unless stated otherwise.
2.2.2 Reagents
All chemicals and reagents were supplied by Sigma-Aldrich Company Ltd.
(Poole, UK) unless otherwise stated.
2.2.3 Antimicrobial agents
Antimicrobial agents used in this study are listed in table 2.2. All were stored at
4°C, with stock solutions freshly prepared as required. Antibiotics were dissolved in
sterile ultra-pure deionized water alone, or in combination with absolute alcohol.
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Table 2.2: Antimicrobial agents












Eli Lilly, Basingstoke, UK
MarionMerrell, Uxbridge, UK
Hoffinan-la-Roche, Basle, Switzerland









All primers were synthesized by Oswel DNA Services Ltd., Southampton. Those
for sequencing were HPLC purified
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2.3 Methods
2.3.1 Survey of enterococcal epidemiology
Whilst the primary objective of this thesis is to assess the diversity of VanA
phenotype GRE in Scotland, it was considered beneficial to study the wider issue of
enterococcal epidemiology, and not simply those isolates displaying glycopeptide
resistance. This enables comparisons to be made between the glycopeptide-resistant
and sensitive enterococcal populations present in hospital and community settings.
To achieve this, a five-month survey of enterococcal epidemiology was
undertaken (January-May, 1998). During this period, enterococcal isolates were
collected from the diagnostic laboratories of the Royal Infirmary ofEdinburgh, both
hospital and general practice isolates. In addition, enterococci were isolated from a
cross-section of faecal samples submitted to the diagnostic laboratories for
investigation. Isolation was achieved with selective media comprising of
kanamycin-aesculin-azide agar base, supplemented with 15mg/L nalidixic acid and
lOmg/L colistin sulphate (Staph/Strep Selective Supplement, Oxoid). Aesculin
hydrolysis by enterococci results in black colouration of the agar, allowing tentative
identification as an Enterococcus. One presumed Enterococcus was taken from each
faecal sample for further investigation.
All enterococcal isolates gathered during this five-month period were screened for
vancomycin resistance with 5pg vancomycin discs (Becton Dickinson & Co.,
Cockeysville, USA). Any isolates tentatively identified as GRE were subjected to
full glycopeptide susceptibility testing and PCR analysis (sections 2.3.2 and 2.3.3).
All isolates were speciated by the API20 Strep System and subjected to PFGE
analysis, as described in section 2.3.5.
64
Chapter 2: Materials and Methods
2.3.2 Antimicrobial susceptibility testing
For routine antimicrobial sensitivity testing, the tests were performed on MHA
plates with minimum inhibitory concentrations (MICs) determined by agar
incorporation of the antimicrobial agents (British Society for Antimicrobial
Chemotherapy Working Party, 1991). Antibiotic stock solutions were prepared
freshly at concentrations permitting the preparation of two-fold dilutions of antibiotic
in MHA. Agar was allowed to cool to 50°C prior to addition of the antibiotic and,
once set, the MIC plates were allowed to dry thoroughly, either at room temperature
or for 15 minutes at 55°C.
Bacterial strains were subcultured from -70°C storage on BHI agar plates prior to
inoculation into BHI broth. Following overnight incubation in an orbital shaker at
37°C, a 100-fold dilution of the overnight culture was made in sterile saline (0.85%
sodium chloride). These diluted cultures were then used to inoculate the MIC plates
with a Denley multi-point inoculator (Denley, Billinghurst, Surrey), resulting in
approximately 104 CFU/spot. After allowing the inocula to dry, plates were
incubated at 37°C for 18-24 hours. TheMIC was defined as the lowest concentration
of antibiotic to inhibit all visible growth. The MIC50 and MIC90 (concentration of
antibiotic required to inhibit 50% and 90% of bacterial strains respectively) were
determined when appropriate.
In an attempt to determine the basis of a media-dependent increase in teicoplanin
resistance associated with Tnl546 genotype (section 6.1), teicoplanin MICs were
later repeated on ISTA supplemented with either pyruvate (O.lmM or O.OlmM final
concentrations) or D,L-lactic acid (0.1% or 0.01% final concentrations). The protocol
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did not vary from that described above, other than the inclusion of pyruvate or lactic
acid within the agar.
2.3.3 Detection of glycopeptide resistance genes by PCR
Determination of the vancomycin and teicoplanin MICs of the strains collected
allowed a prediction to be made as to their glycopeptide resistance phenotype on the
basis of their levels of resistance to the two glycopeptide agents. All isolates
exhibiting high-level resistance to vancomycin and teicoplanin were presumed to be
VanA-type, whilst those displaying only vancomycin-resistance were presumed to be
VanB. These predicted phenotypes were confirmed by PCR detection of the
glycopeptide resistance genes with the vanA- and v<m6-specific primers described by
Dutka-Malen and colleagues. (Dutka-Malen et al., 1995). Primer sequences are
shown in table 2.3.
E. faecium NCTC 12202 and E. faecalis ATCC 51299 were used as vanA and
vanB-positive controls respectively. E. faecalis JH2-2 (Jacob & Hobbs, 1974) was
used as a negative control.
Table 2.3: Primers for detection of vanA and vanB genes
Primer Sequence (5'-3') Coordinates
vanA I (+) GGGAAAACGACAATTGC 7154-71703
vanA2 (-) GTACAATGCGGCCGTTA 7885-7869a
vanB\ ( + ) ATGGGAAGCCGATAGTC 5144-5160b
vanB2 (-) GATTTCGTTCCTCGACC 5778-5762b
a
Coordinates correspond to GenBank accession number M97297
b
Coordinates correspond to GenBank accession number U35369
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Crude DNA template for the PCR reaction was prepared by boiling bacterial cells
(0.8mL overnight culture and 0.2mL sterile deionized water) for 10 minutes in a
boiling water bath. Following centrifugation for 5 minutes to remove debris, 20pL
of supernatant was used as template in the PCR reactions. PCR was performed in
lOOpL volumes containing 40pmol of each obgonucleotide primer, dNTPs to a final
concentration of 500pM, 3mM MgCk and 2 U of Taq DNA polymerase (Advanced
Biotechnologies, Dorking, Surrey) with appropriately diluted manufacturer's reaction
buffer. PCR was performed in a Techne Cyclogene Thermal Cycler (Cambridge)
with the protocol: (i) 94°C for 3 min; (ii) 25 cycles of 94°C for 45s, 45°C for 30s, and
74°C for 90s; and (iii) 74°C for 10 min. PCR products were analysed by
electrophoresis (see section 2.3.4).
2.3.4 Analysis of DNA by agarose gel electrophoresis
PCR products, plasmid extractions and restriction endonuclease digests were
typically electrophoresed on 1.5% agarose gels in TAE buffer (40mM Tris-acetate
pH 8.0; 2mM EDTA). Electrophoresis was performed on horizontal slab gels in the
Bio-Rad Sub-Cell® GT agarose gel electrophoresis system. DNA samples were
mixed with loading buffer (0.25% w/v bromophenol blue; 0.25% w/v xylene cyanol;
30% w/v sucrose) to a ratio of 5:1 prior to loading onto the gel. Samples were
electrophoresed alongside either a 100-bp DNA ladder or GeneRuler™ DNA Ladder
Mix (Helena Biosciences Ltd., UK) or a Lambda/T/mt/III DNA ladder (GibcoBRL,
Life Technologies Ltd., Paisley). The choice ofDNA ladder was dependent on the
size ofDNA fragment being analysed. Electrophoresis was performed at a constant
voltage of 100V until the loading buffer fronts had moved two-thirds of the way
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down the gel. Following electrophoresis, gels were stained in 0.5pg/mL ethidium
bromide and visualized on a UV transilluminator. Photographs were taken with a
Polaroid camera system fitted with an orange filter.
2.3.5 Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) was applied to assess the relatedness of
isolates. Overnight cultures (lOmL) were harvested by centrifugation in a Sorvall
RT6000D bench-top centrifuge (3000rpm; 10 minutes) prior to washing and
resuspension in PIV buffer [1M NaCl, lOmM Tris-HCl (pH 7.6)]. To ensure
reproducibility of results, the cell suspension was standardized with PIV to an optical
density of 1.0 at 610nm in a Perkin-Elmer Lambda 2 spectrophotometer
(Beaconsfield, Bucks.). An equal volume of the standardized cell suspension was
mixed with 1.6% low-melting preparative grade agarose (Bio-Rad Laboratories Ltd.,
Herts) prepared in lysis buffer [6mM Tris-HCl (pH 7.6), 1M NaCl, lOOmM EDTA
(pH 7.5), 0.5% Brij 58, 0.2% deoxycholate and 0.5% sodium lauroyl sarcosine] and
pipetted into plug moulds.
The protocol then followed that described by Miranda and colleagues (Miranda et
al., 1991). Briefly, the cells embedded in the agarose plugs were lysed by overnight
incubation at 37°C in lysis buffer, supplemented with 20pg/mL RNase and lmg/ml
lysozyme. Plugs were then incubated overnight at 50°C in ESP solution [0.5M
EDTA (pH 9.0-9.5), 1% sodium lauroyl sarcosine, and 50pg/mL proteinase K] prior
to washing with TE buffer [lOmM Tris-HCl (pH 7.5), O.lmM EDTA]. At this stage,
plugs could be stored at 4°C in TE buffer.
68
Chapter 2: Materials and Methods
For PFGE analysis, a slice of plug was incubated with 20 U of Smal restriction
endonuclease (Promega UK, Southampton) in a 200pL reaction volume for 6 hours
at 25 °C. The plugs were then washed in TE buffer for 1 hour before being sealed
into the wells of a 1.2% agarose gel prepared in 0.5x TBE buffer (Sigma).
Electrophoresis was performed on a contour-clamped homogeneous electric fields
device (CHEF-DRII; Bio-Rad Laboratories Ltd.). The gel was run for 24 hours at
200V with 5-40 second pulse times. Gels were stained with ethidium bromide
(0.5pg/ml) for 15 minutes, and destained in distilled water (2x15 minutes) prior to
visualization by UV.
2.3.6 Interpretation ofPFGE patterns
2.3.6.i Visual comparison ofPFGE patterns
PFGE patterns were initially compared by eye, and interpreted by the criteria
described by Tenover and colleagues (Tenover et ah, 1995). Using these criteria,
isolates are deemed to be indistinguishable if they have identical PFGE patterns.
Isolates differing by up to three bands are considered to be closely related, with four
to six bands difference suggesting isolates are "possibly related". Isolates are
considered unrelated if they differ by seven or more bands.
Examples of the different PFGE types identified were rerun on the same gel to
overcome difficulties in comparing patterns on different gels.
2.3.6.ii Computer-aided comparison of PFGE patterns
It was latterly decided to assess the diversity of PFGE patterns with the Bio-Rad
Diversity Database software.
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Gel images were introduced into the Diversity Database from the original
Polaroid photographs. Analysis was then performed according to the manufacturer's
guidelines. The results of the comparisons were obtained in two forms: phylogenetic
tree and similarity matrix.
2.3.7 Conjugation by filter mating
The protocol used for filter mating was adapted from that described by Heaton
and Handwerger (Heaton & Handwerger, 1995). VanA E. faecium were mated with
E. faecium GE-1 (Eliopoulos et al., 1982), whilst VanA E. faecalis were mated with
E. faecalis JH2-2 (Jacob & Hobbs, 1974). Both recipients (donated by Dr. N.
Woodford) display resistance to rifampicin (>100mg/L) and fusidic acid (>25mg/L).
Overnight cultures of donors and recipients were diluted 100-fold in fresh broth
and incubated for 2-3 hours. Ten microlitres of donor culture was then mixed with
90pL of recipient culture and the resulting lOOpL dispensed onto a sterile 25mm,
0.2pm pore size filter, previously placed on a BHI agar plate. The cell suspension
was allowed to 'dry' onto the filter prior to incubation at 37°C overnight.
Following incubation for 24 hours, the filter was placed in lOmL BHI broth and
the cells resuspended. Selective plates containing rifampicin (lOOmg/L), fusidic acid
(25mg/L) and vancomycin (lOOmg/L) were inoculated with lOOpL of the mating
mixture and incubated overnight. Control plates were also prepared to ensure the
sensitivity ofdonors to rifampicin and fusidic acid, and the sensitivity of recipients to
vancomycin. After incubation of selective plates for 24 hours they were examined
for the presence of transconjugant colonies. In the absence of colonies, plates were
reincubated for a further 24 hours.
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2.3.8 Curing of plasmid DNA with ethidium bromide
The intercalation of ethidium bromide between base-pairs of DNA inhibits the
functions of both DNA and RNA polymerase. As it preferentially inhibits plasmid
synthesis, it can be used to eliminate ('cure') plasmid DNA from bacterial cells
(Bouanchard et al., 1969).
Ethidium bromide MICs were established for those isolates to be used in plasmid
curing experiments. Ethidium bromide plates for MIC determination ranged in
concentration from 5-70 mg/L. Overnight broth cultures were diluted 100-fold and
used to inoculate fresh BHI broths containing increasing concentrations of ethidium
bromide (2mg/L increments covering the concentration range, MIC ± lOmg/L).
After overnight incubation, the broths were examined for visible growth. The broth
that contained the highest concentration of ethidium bromide and still had visible
growth was plated onto BHI agar plates. After overnight incubation, individual
colonies from this plate were examined for loss of glycopeptide resistance that may
be attributable to loss ofplasmid DNA.
2.3.9 Extraction of plasmid DNA
Several different plasmid extraction protocols were employed in the course of this
study, but the following protocol was employed most widely. Cells were harvested
from lOmL overnight BHI broth cultures by centrifugation and washed in TE buffer
[lOmM Tris, ImM EDTA, pH 8.0]. The protocol then followed that described by
Woodford et al. (1993). Briefly, cells were suspended in lOOpL of suspending
buffer (25% sucrose in TE buffer supplemented with lOmg/mL lysozyme) and
incubated at 37°C for 30 minutes. The cells were lysed by the addition of 200pL
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alkaline-SDS (0.2MNaOH, 1% SDS), and the samples were incubated at 56°C for 1
hour. After addition of 150pL 3M potassium acetate (pH 4.8), the samples were left
on ice for 20 minutes. Following centrifugation for 5 minutes, the precipitated debris
was removed by decanting the supernatant through a double-thickness of medical
gauze (Boots pic., Nottingham, UK) into a fresh tube. An equal volume of phenol-
chloroform-isoamyl alcohol (25:24:1) was added, and samples were centrifuged for 5
minutes. The DNA from 200pL of supernatant was precipitated with 2 volumes of
cold ethanol at room temperature for 2 minutes prior to harvesting by centrifugation.
DNA pellets were allowed to dry prior to resuspension in distilled water
supplemented with lpg ofRNase.
Other plasmid extraction methods employed included the RPM® Spin Midi kit
(BIO 101 Inc., LoJolla, California) and the large-scale plasmid extraction method
described by Heilig et al. (1998). These methods, as with the plasmid extraction
procedure described above, are based on the alkaline lysis method described by
Birnboim(1983).
2.3.10 Detection of plasmids by electrophoresis of 'intact' genomic DNA
Crosa et al. (1994) described a method for the detection of plasmid DNA that is
based on bacterial cell lysis directly in the wells of an agarose gel. Lysis within the
wells ensures the majority of the chromosomal DNA remains intact and thus remains
within the wells of the gel. Less than 0.5% of the total chromosomal DNA should
appear within the gel as a band of linear DNA (Crosa et al., 1994). Plasmid DNA,
however, should migrate freely from the wells of the agarose gel, enabling its
detection.
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As an alternative to lysis within the wells of the gel, plugs previously prepared for
PFGE analysis were electrophoresed unrestricted (i.e. without restriction of genomic
DNA with Smal restriction endonuclease). Plug sections were loaded into the wells
of a horizontal slab gel and electrophoresed for approximately 4 hours at 125V. Gels
were stained and visualized as described previously (section 2.3.4).
2.3.11 Extraction of genomic DNA
High-quality genomic DNA was extracted with guanidium thiocyanate as
described by Pitcher et al. (1989). Briefly, lOmL overnight broth cultures were
harvested by centrifugation and washed in TE buffer prior to resuspension in lOOpL
TE supplemented with 50mg/mL lysozyme. Following incubation at 37°C for 30
minutes, cells were lysed by the addition of 0.5mL GES reagent (5M guanidium
thiocyanate, lOOmM EDTA and 0.5% v/v sarkosyl). Lysates were cooled on ice
prior to the addition of 0.25mL cold (-20°C) 7.5M ammonium acetate. Samples
were held on ice for a further 10 minutes prior to extraction of DNA with
chloroform/isoamylalcohol. DNA was precipitated by the addition of 0.54 volumes
of cold (-20°C) 2-propanol and collected by centrifugation. DNA pellets were
washed in 70% ethanol prior to redissolving in lOOpL of sterile deionized water.
2.3.12 Quantitation ofDNA
Rapid estimation ofDNA concentration was performed by ethidium bromide dot
quantitation as described by Moore and Chory (1998). Lambda/iTwdlll DNA
(GibcoBRL) was used to prepare DNA standards ranging in concentration from 0 to
20pg/mL. DNA to be quantified was mixed with ethidium bromide and spotted onto
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Saran wrap adjacent to the DNA standards. Comparison of fluorescence under UV
illumination of the unknown DNA against the standards provided an estimation of
the DNA concentration of the unknowns.
2.3.13 Design of primers for Tn1546 analysis
Primers used in the analysis of Tn/54b-related elements had either been described
previously or were designed by Primer3 (http://www.genome.wi.mit.edu.cgi-
bin/primer) based on the published sequence of Tn1546 (GenBank accession number
M97297; Arthur et al. (1993, 1995)). Primers used are listed in table 2.4.
2.3.14 PCR analysis of Tn/546-like elements
2.3.14.i Long-range PCR (L-PCR) analysis of Tni54tf-like elements
Tni54b-like elements were amplified with the Expand™ Long Template PCR
System (Boehringer-Mannheim, Mannheim, Germany) according to the
manufacturer's instructions. The PCR system combines Taq DNA polymerase with
the Pwo DNA polymerase that has proof-reading activity. This combination of
polymerases in conjunction with improved buffer and cycle conditions enables PCR
amplification of long DNA fragments.
Tni57<5-IR primer (table 2.4) is specific for both terminal inverted repeats of the
transposon, and thus enables PCR amplification of the entire length of Tn/34d-like
elements. PCR was performed in 50pL reaction volumes containing 250ng genomic
DNA, 30pmol Tnl546-IR primer, 350pM of each dNTP, 1.75mM MgCk (Expand™
PCR buffer 1) and Taq/Pwo enzyme mix (0.75pL). Amplification was performed on
a GeneAmp 9700 PCR system (PE Applied BioSystems, California) with the
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protocol: (i) 94°C for 2 min; (ii) ten cycles of 94°C for 10s, 63°C for 30s and 68°C
for 10 min; (iii) 25 cycles of 94°C for 10s, 63°C for 30s and 68°C for 10 min
(elongation time increased 20s/cycle); and (iv) 68°C for 7 min.
Table 2.4: Primers for the analysis of Tnl546
Primer Sequence Coordinates Reference
Tnl546-IR 5'-GGAAAATGCGGATTTACAACGCTAAG 13-38;
10839-10814









vanX\ 5'-ACTTGGGATAATTTCACCGG 8082-8101 Jensen et al. (1998)









Coordinates are based on the published Tn1546 sequence; Genbank accession number M97297.
Where no reference is listed the primer was designed by Primer3. Primers 1216V-A, -B and -C were
used in the sequencing of the IS72fdf-like element, whilst 1542-A and -B were used in the
sequencing of IS1542. 1216V-D and -E were used to generate an IS1216V-like probe. a Coordinates
correspond to the published sequence of \S1542 (Genbank accession number AF114715; Darini et al.,
1999). b Co-ordinates correspond to the published sequence of the IS72/6F-like element (Genbank
accession number AF093508, Jensen, 1998).
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2.3.14.H Amplification of sequences within Tn1546
Primer pairs internal to the inverted repeats of Tnl546 enabled amplification of
those regions recognized as 'hot-spots' for variation, or those regions previously
identified as harbouring variation by L-PCR and restriction analysis. PCR was
performed according to the protocol described in section 2.3.3, with the exception
that 200-500ng genomic DNA, prepared by guanidium thiocyanate extraction, was
used as template. Primer annealing temperatures were adjusted accordingly. Any
primers that failed to yield the anticipated product were reapplied with the Expand™
Long Template PCR System described above. In such cases, the elongation time was
altered according to the manufacturer's guidelines.
The point mutation at nucleotide position 8234 (G~>T) within the vanX gene,
previously described by Jensen et al. (1998), was screened for by amplification of a
424-bp fragment internal to vanX (primers vanXl and vanXI) and subsequent DdeI
restriction of the amplicon (Palepou et al., 1998).
2.3.15 Restriction analysis PCR amplicons
2.3.15.i Restriction of L-PCR amplicons
To enable comparisons ofTnJ54b-like elements, 0.5pL aliquots of the Tn1546 L-
PCR amplicons were digested with 10 U of Clal or 10 U of BamHl restriction
endonucleases (Promega). Restrictions were performed in 20pL volumes for 4 hours
according to the manufacturer's instructions. Electrophoresis was performed
alongside a GeneRuler™ DNA Ladder Mix (Helena Biosciences Ltd.) and the
restriction fragments were subsequently sized with the BioRad Diversity Database,
Gel Doc software.
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2.3.15.ii Restriction of 'conventional' PCR amplicons
Those PCR amplicons obtained with the PCR protocol described in section 2.3.3
were restricted in 20pL volumes containing lOpL of PCR amplicon and 10 U of
restriction endonuclease according to manufacturer's instructions. The restriction
enzyme used was dependent on the anticipated sequence of the amplicon, based on
the published sequence of Tn1546 (GenBank accession number M97297). Suitable
enzymes were determined with Webcutter v.2.0 (www.firstmarket.com/cutter/cut2.
html).
2.3.16 Automated sequencing of PCR amplicons
PCR products of interest were sequenced to confirm the nature of the variation
present within Tn/576-like elements. Fluorescent automated DNA sequencing with
the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kit and the
ABI Prism 377 DNA Sequencer (Applied Biosystems, California, USA) was
performed by DNASHEF Technologies (c/o Department of Haematology, Royal
Infirmary of Edinburgh). Analysis of sequence data was performed with ABIView
v.1.0 or Chromas v. 1.56 software. The identity of the sequences obtained was
established by electronic submission to the European Bioinformatics Institute
(http ://www2.eblac.uk/fasta3/).
2.3.17 Transfer ofDNA from agarose gel to nylon membrane
For several applications it was desirable to transfer DNA from agarose gels to
nylon membranes to enable hybridization studies. This allowed probing of plasmid
extractions and PFGE gels for the location of the vartA gene cluster, and
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confirmation of the identity ofDNA fragments derived from the restriction analysis
ofTn1546 L-PCR amplicons.
Alkali blotting by downward capillary action was employed. Alkali blotting has
the advantage over Southern blotting that DNA is fixed to positively-charged nylon
membranes during the transfer process. Downward capillary action was considered
more efficient than upward capillary action in the transfer of large DNA fragments
for which overnight transfer was necessary. In the course of upward capillary action
the gel can become crushed, thus reducing the capillary action.
Following electrophoresis ofDNA and visualization by ethidium bromide staining
and UV illumination, gels were prepared for DNA transfer by depurination in 0.25M
HC1 (30 minutes) and denaturation in 0.4M NaOH (30 minutes). Downward
capillary transfer of DNA to a positively-charged nylon membrane (Hybond™-N+,
Amersham Life Sciences Ltd., UK) was then set up according to the protocol
described by Brown (1993) with 0.4M NaOH as transfer buffer. Transfer was
allowed to continue for approximately 18 hours, after which the membrane was
rinsed in 5x SSC (20 x SSC consists of 0.3M sodium citrate, 3M sodium chloride),
wrapped in Saran wrap, and stored at -20°C until use.
2.3.18 Hybridization studies
Membrane-bound DNA prepared as above was probed with non-isotopically
labelled probes and detected by chemiluminescence. Probes were either derived
from PCR products or from oligonucleotide primers.
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2.3.18.i Hybridization studies with probes derived from PCR products
PCR-derived probes were generated with the ECL™ Random Prime Labelling
and Detection System (Amersham Life Sciences Ltd.). Nonamers of random
sequence prime DNA synthesis on a denatured DNA template (in this case,
denatured PCR product) in a reaction catalysed by exonuclease-free Klenow.
Fluorescein-11-dUTP partially replaces dTTP in the labelling reaction, thus
producing a fluorescein labelled probe. Anti-fluorescein-HRP (horseradish
peroxidase) conjugate is applied to the membrane following hybridization, enabling
bound probe to be detected by the presence of bound peroxidase with ECL detection
reagents.
Probe labelling was performed according to the manufacturer's instructions, with
PCR product (purified with the QIAquick PCR Purification kit; Qiagen, Crawley,
UK) as template. Hybridization was performed overnight at 60°C in a Techne
Hybridiser HB-1D with 20mL hybridization buffer, prepared according to the
manufacturer's instructions. Probe concentrations ranged from 5ng/mL to 15ng/mL
depending on the application. Stringency washes, blocking, antibody incubation and
signal generation and detection were performed according to the manufacturer's
instructions. The signal generated is in the form of blue light that was detected on
Hyperfilm™-ECL (Amersham Life Sciences Ltd.). Exposure was performed for 3
hours at 4°C prior to developing the film in an Optimax processor (Jet X-Ray,
London).
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2.3.18.H Hybridization studies with oligonucleotide probes
Fluorescein-labelled oligonucleotides were prepared by the ECL™ 3'-
Oligolabelling and Detection System (Amersham Life Sciences Ltd.). The technique
follows the same principle as that described above (section 2.3.18.i). The
oligonucleotide is fluorescein-labelled through the action of terminal
deoxynucleotidyl transferase that introduces a 3' tail of fluorescein-11-dUTP to the
oligonucleotide.
Hybridization was performed overnight at 42°C in a Techne Hybridiser HB-1D.
Oligonucleotide probe was applied at a concentration of 7.5-10ng/mL in 20mL-
hybridization buffer. Stringency washes, blocking, antibody incubation and signal
generation and detection were performed according to the manufacturer's
instructions. Exposure ofHyperfilm™-ECL and developing of film was performed
as above.
2.3.19 Growth curve analysis of GRE following glycopeptide challenge
In order to assess the response of different VanA GRE to glycopeptide challenge,
log phase cultures were prepared and viable counts were performed at regular
intervals. Cultures were challenged with vancomycin or teicoplanin after one hour,
and viable counts continued at regular intervals for a further 6-7 hours. Colonies
present on the viable count plates after overnight incubation were counted with an
Anderman Colony Counter (Anderman, Kingston-upon-Thames, UK).
Logio[CFU/mL] was plotted against time to enable easy comparison of results.
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2.3.20 Whole cell protein extraction
Cytoplasmic and membrane-associated protein was extracted from bacterial cells
by a modified version of the protocol described by Arthur et al. (1996a). BHI broth
(lOOmL) with or without 8mg/L vancomycin was inoculated with 8mL of overnight
culture and incubated until the optical density at 600nm reached 0.7. Optical density
was determined on a Bio-Rad SmartSpec™ 3000. Once cultures had reached the
desired optical density, bacteria were harvested by centrifugation in a Sorvall RC5B
centrifuge (5000 x g for 15 minutes at 4°C). Cells were then washed in 0.1M
phosphate buffer (pH 7.0) and resuspended in 2.8mL of phosphate buffer
supplemented with 2mg/mL lysozyme. Following incubation at 37°C for one hour,
cells were lysed by sonication in an MSE Soniprep 150 (MSE Instruments, Crawley,
UK). The lysate was centrifuged at 1000 x g for 10 minutes (to remove cell debris)
prior to ultracentrifugation at 100,000 x g for one hour at 4°C in a Sorvall OTD 65B
Ultracentrifuge. The supernatant (SI00) was collected and the pellet (CI00)
resuspended in 2mL of 0.1M phosphate buffer containing 1% Triton X-100.
Protein concentration was estimated by the Bio-Rad Protein Assay on the
SmartSpec™ 3000, with bovine serum albumen as a protein standard.
2.3.21 Enzyme assay for VanX dipeptidase activity
As an indication of glycopeptide resistance gene expression, the dipeptidase
activity of VanX was estimated (with and without induction by vancomycin
challenge) by determining the amount of D-Ala released from D-Ala-D-Ala with D-
amino acid oxidase coupled to peroxidase as indicator reactions. The protocol was
as described by Arthur et al. (1996a). Briefly, reagent A was freshly prepared by
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mixing: 632pL of sterile deionized water, 1029pL of Tris-HCl (50mM), MgCk
(4mM), pH 7.0; 2880pL of disodium pyrophosphate (lOOmM, pH 8.3); 686pL of
flavin adenine dinucleotide sodium salt (0.2mg/mL); 343pL of peroxidase diluted
1000-fold in water (Boehringer Mannheim); 34pL of D-amino acid oxidase
(Boehringer Mannheim); 171 pL of orthodianisidine (5mg/mL) and 225pL of
200mM D-Ala-D-Ala. Reagent A was preheated to 37°C and 525pL was added to
75pL aliquots of S100 extracts, diluted in 0.1M phosphate buffer as required. The
A460 was recorded on a Bio-Rad SmartSpec™ 3000 for one hour, taking readings
every 150 seconds (2.5 minutes).
D,D-dipeptidase specific activity was defined as the number of nmoles of D-Ala
formed per minute per mg of protein present in the extract. To calculate this, the
change in absorbance associated with the complete hydrolysis of known
concentrations of D-Ala was established. The change in absorbance seen in the
VanX enzyme assays could thus be correlated to known concentrations of D-Ala,
thus enabling calculation of the number ofmoles ofD-Ala being formed.
2.3.22 Enzyme assay for VanY carboxypeptidase activity
YanY D,D-carboxypeptidase activity in CI00 extracts was determined as for the
VanX enzyme assays with the following modifications. The pentapeptide L-Ala-y-D-
Glu-L-Lys-D-Ala-D-Ala (Boehringer Mannheim) replaced D-Ala-D-Ala as substrate,
at a final concentration of 0.2ImM. Dilutions of CI00 extracts were performed in
0.1M phosphate buffer (pH 7.0) containing 1% Triton X-100, and Z11SO4 was added
at a final concentration of 5mM.
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For the purposes of this chapter, the enterococcal isolates studied will be assigned
to two distinct groups: 'Nosocomial GRE isolates' and 'Enterococcal epidemiology
study isolates'. 'Nosocomial GRE isolates' refers to those isolates collected from
Scottish hospitals in the course of the five-year study period. These isolates will be
discussed separately from those enterococcal isolates collected during the five-month
study ofenterococcal epidemiology.
3.1 Characterization of the nosocomial GRE isolates
3.1.1 Species identification and van genotyping of nosocomial GRE
Over the five-year period from January 1995 to December 1999, 55 isolates of
GRE were collected from clinical diagnostic laboratories across Scotland,
representing eight different hospitals. As summarized in table 3.1, the majority of
GRE isolated were from the Royal Infirmary ofEdinburgh (RIE), with many of these
being isolated during the course of an outbreak of GRE infection in 1995. The
outbreak, which occurred in the hospital's renal unit, ran from January to September
of that year, during which time 30 GRE were isolated. Whilst four of these isolates
were unavailable for further study, the remaining 26 isolates are amongst the 55
isolates summarized in table 3.1. The remainder of the 55 isolates consist primarily
of sporadic isolates from the RIE and the other hospitals fisted. Relevant details for
all 55 GRE isolates are fisted in tables 3.4 and 3.5 (pages 92 and 93).
All GRE were identified to the species level by the API20 Strep system, and all
were found to be either E.faecium (64%) or E.faecalis (36%).
The clinical laboratories had identified all isolates as vancomycin-resistant at the
time of their isolation. This was subsequently confirmed by vancomycin and
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teicoplanin susceptibility testing, which also enabled identification of the
glycopeptide resistance phenotype. All 55 isolates had glycopeptide resistance
characteristic of either the VanA or VanB phenotype. This was confirmed by PCR
detection of the vanA and vanB resistance genes. Whilst the use of the vanA and
vtmS-specific primers in multiplex PCR has been described (Dutka-Malen et al.,
1995), initial attempts at multiplex PCR foiled. Each isolate was therefore tested for
the vanA and vanB genes, with the primers in two separate PCR reactions. Figure
3.1 shows the PCR amplicons obtained with the vanA and vnnR-specific primers.
Table 3.1: Source and glycopeptide resistance genotypes of nosocomial GRE
isolates
HOSPITAL vanA+ vanB+ vanA/B+ Total
Royal Infirmary ofEdinburgh 22 5 4 31
Western General Hospital,
Edinburgh
1 - - 1
Edinburgh City Hospital 2 - - 2
Borders General Hospital,
Melrose
2 - - 2
Monklands Hospital, Airdrie 2 - - 2
Ninewells Hospital, Dundee 4 - - 4
Western Infirmary, Glasgow 9 1 1 11
Aberdeen Royal Infirmary 1 1 - 2
TOTAL 43 7 5 55
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Figure 3.1: vanA and va«2?-specific PCR
PCR with v<m4-specific primers (A) and v<2«Z?-specific primers (B). Both gels depict PCR reactions
performed on known VanA isolates (lanes 1-4) and VanB isolates (lanes 5 & 6). The vanA amplicon
is 732-bp, whilst the vanB amplicon is 635-bp. The molecular marker (M) is a 100-bp DNA ladder.
The majority of isolates were positive for either vanA or vanB, although five
isolates were positive for both resistance genes. These 'double-positive' isolates
generally displayed the VanA phenotype, although teicoplanin susceptibility varied
between MIC determinations. For the remainder of the thesis, these five isolates will
be referred to as VanA, thus bringing the total number ofVanA isolates to 48.
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Table 3.1 shows the breakdown of resistance phenotypes within the various
hospitals studied, whilst table 3.2 summarizes the levels of resistance detected in the
isolates of different resistance phenotypes. When comparing the breakdown of
glycopeptide resistance phenotypes presented in table 3.1, it should be noted that
isolates collected from Ninewells Hospital, Dundee, and the Western Infirmary,
Glasgow, were collected on the premise that they were VanA isolates. VanB isolates
were not referred for study, and thus the numbers presented from these two hospitals
do not accurately reflect the prevalence of VanA and VanB enterococci in the two
hospitals. The one VanB isolate from Glasgow's Western Infirmary was received in
error.
Table 3.2: Ranges of glycopeptide susceptibilities displayed by VanA, VanB and
'double-positive' (vanA/vanB-positi\e) isolates
Resistance genotype (n) Vancomycin MIC Teicoplanin MIC
range (mg/L) range (mg/L)
vanA+ 43 64- 1024 8-256
vanBT 7 16- 1024 < 1 - 32a
vanA/B+ 5 64 - 512 < 1 - 64b
a One VanB isolate had a teicoplanin MIC of 32mg/L. All other VanB isolates were
teicoplanin sensitive (MIC < 4mg/L). b One vanA/B+ isolate displayed the VanB
phenotype, being susceptible to teicoplanin.
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All vwz/1-positive GRE were later studied for their ability to transfer glycopeptide
resistance (chapter 4). To enable the identification of antibiotic resistance
determinants that were co-transferred with the van genes, a range of antibiotic
sensitivity tests were performed on all VanA isolates. The breakpoints used in the
definition of resistance are shown in table 3.3.





Tetracycline <4 > 16
Erythromycin <0.5 >8
Chloramphenicol <8 >32
Streptomycin > 2000 a
Gentamicin >500 3
a High-level resistance
Erythromycin resistance was exhibited by 88% of the VanA isolates, being
common amongst both E. faecium and E. faecalis. Ampicillin resistance was
encountered more commonly in E. faecium than in E. faecalis (75% versus 19%; P <
0.001). Conversely, tetracycline resistance was more common in E. faecalis than in
E. faecium (94% versus 38%; P < 0.001). Fifty-eight percent of the VanA isolates
displayed high-level streptomycin resistance (HLSR), with 10% displaying high-
level gentamicin resistance (HLGR). All but one of the isolates that displayed
HLGR also displayed high-level resistance to streptomycin. Chloramphenicol
resistance was rarely encountered in the VanA isolates studied.
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Table 3.4 summarizes the site of isolation of the 55 GRE isolates studied. The
preponderance of faecal isolates reflects the routine faecal screening implemented in
April 1995 by the renal unit of the Royal Infirmary of Edinburgh in response to the
GRE outbreak. Twenty of the 26 isolates originating from the renal unit outbreak
were isolated from faecal samples. In addition, the majority of GRE isolates from
Glasgow's Western Infirmary (82%) were faecal samples, being isolated during the
course of a 30-month investigation examining the prevalence ofGRE.
Table 3.4: Sites of GRE isolation
Sites of isolation Number (%)
Faecal 32 (58)
Urine 9 (16)




3.1.2 PFGE analysis of nosocomial GRE isolates
PFGE analysis was performed on all 55 GRE isolates. Figure 3.2 illustrates the
main PFGE types recognized. Interpretation of the results was performed in two
ways: (i) visual comparison of banding patterns and interpretation according to the
criteria described by Tenover et al. (1995), and (ii) comparison with the Bio-Rad
Diversity Database computer software.
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Lane: 1 - RIE-01; 2 - RIE-02; 3 - RIE-03; 4 - RIE-04; 5 - RIE-05; 6 - RIE-06; 7 - RIE-07; 8 - WGH-
01; 9 - RIE-08; 10 -RIE-09; 11 - RIE-10; 12 - BGH-01; 13 - BGH-02; 14 - RIE-11; 15 - RIE-







Lane: 1 - RIE-18; 2 - RIE-19; 3 - ECH-01; 4 - RIE-23; 5 - RIE-24; 6 - RIE-25; 7 - ECH-02; 8 -
RIE-26; 9 - RIE-27; 10 - RIE-29; 11 - MON-01; 12 - MON-02; 13 - R1E-30; 14 - ARI-01; 15
- NIN-01; 16 - NIN-02; 17 - NIN-03; 18 - NIN-04; 19 - GWI-02; 20 - 50-1000 kb DNA
ladder.
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(Figure 3.2 cont.: PFGE analysis of nosocomial GRE isolates)
(c)




3 - GWI-05; 4 - GWI-06;
5 - GWI-07; 6 - GWI-08;
7 - GWI-09; 8 - GWI-10;
9 - GWI-11; 10 - RIE-31;
11 - 50-1000 kb DNA
ladder.
50-kb
3.1.2.i Visual comparison of PFGE patterns
Initial interpretation of PFGE patterns was performed by visual comparison and
adoption of the criteria described by Tenover and colleagues (Tenover et al., 1995).
Tables 3.5 and 3.6 list the relevant details of all 55 GRE isolates, including the
assigned PFGE types, as determined by the visual comparison of restriction patterns.
As outlined in section 3.1.1, 26 of the 55 nosocomial GRE isolates collected over
the five-year period originated from an outbreak in the renal unit of the Royal
Infirmary of Edinburgh in 1995. Visual comparison of the PFGE patterns obtained
from these 26 isolates revealed that a significant proportion of the isolates shared a
common PFGE pattern, and were thus designated the 'outbreak strain'. Nine VanA
E. faecium isolates exhibited identical PFGE restriction patterns (PFGE type A: the
outbreak strain), with a further seven isolates deemed to be closely related to this
group, on the basis that they differed by no more than three bands. These seven
isolates were therefore assigned to PFGE subtypes A1-A7 (table 3.5).
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Table 3.5: Relevant information on GRE isolates from the Royal Infirmary of
Edinburgh
Isolate Species van MIC (mg/L) PFGE
gene VA TE AV~ type
Renal unit isolates
rie-01 fm a 512 16 512 a
rie-02 fm a 1024 32 >512 a
rie-03 fm a 1024 64 >512 a
rie-04 fm a 1024 64 >512 a
rie-05 fm a 1024 64 >512 a,
rie-06 fm a 1024 64 >512 a
rie-07 fm a 1024 32 >512 a
rie-08 fm a 1024 64 >512 a
rie-09 fm a 1024 32 >512 a
rie-10 fm a 256 16 >512 a2
rie-11 fm a 1024 64 512 a
rie-12 fm a 1024 32 >512 a3
rie-13 fm a 1024 32 >512 a4
rie-14 fm a+b 64 <1 8 a5
rie-15 fm a 1024 32 >512 a6
rie-16 fm a 1024 32 512
rie-17 fm b 128 0.5 >512 A7
rie-18 fm a 512 32 >512 b
rie-19 fm a+b 512 32 16 b
rie-21 fs b 16 0.5 16 Ci
rie-22 fs b 64 0.5 16 c2
rie-24 fs a+b 512 64 512 C
rie-25 fs a 64 64 >512 di
rie-26 fs a+b 64 16 256 d2
rie-27 fs a 128 64 >512
rie-28 fs b 1024 32 32
Son-renal unit isolates
rie-20 fs b 64 1 1 c3
rie-23 fs a 1024 32 256 C
rie-29 fs a 128 64 >512 d3
rie-30 fm a 1024 16 nd
rie-31 fs a 64 8 nd
FM - E. faecium; FS - E. faecalis. MIC - Minimum Inhibitory Concentration. VA -
Vancomycin; TE - Teicoplanin; AV - Avoparcin. ND - Not Determined. PFGE types were
assigned on the basis of visual comparison and interpretation according to the criteria
described by Tenover et al. (1995). Where no PFGE type is specified the isolate is unrelated
to any other.
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Table 3.6: Relevant information on GRE isolated from hospitals other than the
Royal Infirmary ofEdinburgh
Isolate Species van MIC (mg/L) PFGE
gene VA TE AV type
Western General Hospital, Edinburgh
wgh-01 fm a 1024 32 >512 a
Borders General Hospital, Melrose
bgh-01 fm a 1024 32 >512 a
bgh-02 fm a 1024 128 >512 a
Edinburgh City Hospital
ech-01 fm a 128 64 64
ech-02 fs a 256 256 >512 d4
Monklands Hospital, Airdrie
mon-ol fm a 512 32 nd
mon-02 fs a 256 128 nd d5
Aberdeen Royal Infirmary
ari-01 fm a 128 64 nd
ari-02 fm b 16 0.5 nd nd
Ninewells Hospital, Dundee
nin-01 fm a 128 64 nd
nin-02 fs a 64 16 nd e
nin-03 fs a 128 16 nd e
nin-04 fs a 64 8 nd
Western Infirmary, Glasgow
gwi-01 fm b 64 0.5 nd
gwi-02 fm a 128 64 nd
gwi-03 fs a 64 8 nd
gwi-04 fm a 512 64 nd
gwi-05 fs a 128 8 nd
gwi-06 fm a 1024 64 nd f
gwi-07 fm a 512 16 nd f
gwi-08 fm a 64 16 nd f,
gwi-09 fm a+b 256 16 nd
gwi-10 fs a 128 8 nd
gwi-11 fs a 64 8 nd
FM - E. faecium; FS - E. faecalis. MIC - Minimum Inhibitory Concentration. VA -
Vancomycin; TE - Teicoplanin; AV - Avoparcin. ND - Not Determined. PFGE types were
assigned on the basis of visual comparison and interpretation according to the criteria
described by Tenover et al. (1995). Where no PFGE type is specified the isolate is unrelated
to any other.
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Interestingly, of the seven isolates assigned to PFGE subtypes A1-A7 (subtypes of
the outbreak strain), one harboured both the vanA and vanB genes, whilst one
harboured solely the vanB gene. However, the isolate harbouring both the vanA and
vanB genes (RIE-14; PFGE subtype A5) exhibited the VanB phenotype, suggesting
that the vanA gene cluster may have been inactive.
The remaining isolates from the renal unit outbreak were deemed to be more
heterogeneous in nature following visual comparison of PFGE patterns, although
small discrete clusters of related isolates were recognized (Table 3.5). Two isolates
of E. faecium (RLE-18 and RIE-19) shared identical PFGE patterns and were
designated PFGE type B. A further two clusters of related isolates were recognized
within the renal unit isolates, being classed as PFGE types C and D. Three isolates
(RIE-21, RIE-22 and RIE-24) were deemed to be closely related to one another, and
were assigned to PFGE type C and subtypes Ci and C2. Two further isolates (RIE-25
and RIE-26) were also deemed to be closely related to one another and were assigned
to PFGE types Di and D2.
PFGE analysis of isolates from outwith the renal unit outbreak revealed a
predominantly polyclonal collection of GRE. However, some non-renal unit isolates
were found to be related to isolates originating from the renal unit outbreak. Most
notably, three VanA E. faecium isolates, two from the Borders General Hospital,
Melrose, and one from Edinburgh's Western General Hospital, displayed identical
PFGE patterns to the outbreak strain (PFGE type A) identified within the renal unit
of the Royal Infirmary of Edinburgh (table 3.6). A further five non-renal unit
isolates showed varying degrees of similarity to renal unit isolates by PFGE analysis.
Isolate RIE-23 from the medical ward of the Royal Infirmary of Edinburgh had an
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identical PFGE pattern to RIE-24 from the renal unit (PFGE type C), whilst RIE-20
from the transplant ward was closely related (table 3.5). Finally, three non-renal unit
isolates were deemed to be 'possibly related' to RIE-25 and RIE-26 from the renal
unit. These three isolates (designated PFGE types D3-D5) included one isolate from
Edinburgh City Hospital and one fromMonkland's Hospital, Airdrie (table 3.6).
Two VanA E. faecalis isolates from Dundee's Ninewells Hospital shared an
identical PFGE pattern (type H), whilst three VanA E. faecium isolates from
Glasgow's Western Infirmary were closely related to one another (PFGE type J and
subtype Ji). PFGE types H and J were distinct from each other, and from those
PFGE types discussed above. All other GRE isolates studied by PFGE had unique
PFGE patterns and were deemed to be unrelated to any other isolates.
3.1.2.ii Computer-aided comparison of PFGE patterns
Latterly it was decided to re-evaluate the similarity between PFGE patterns with
the Bio-Rad Diversity Database software. The criteria defined by Tenover et al. are
"intended to be used ... to examine relatively small sets of isolates (typically < 30)
related to putative outbreaks of disease" (Tenover et al., 1995). Whilst these criteria
could thus be applied to the group of isolates comprising the renal unit outbreak in
1995, they were not ideally suited to the study of the complete set of isolates. The
issue ofPFGE interpretationwill be addressed in the discussion (chapter 7).
The gel images introduced into the Diversity Database were taken from the
original Polaroid photographs. This, however, had a disadvantage, as the gels were
not initially run with a view to the computer-aided comparison being made. Ideally,
the gels should be run with at least two DNA ladders flanking the samples, and
preferably one further DNA ladder situated in the middle of the gel.
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Diversity Database analysis was performed on the three gel photographs depicted
in figure 3.2. Samples do not electrophorese uniformly across the width of a gel, and
thus a sample in the first lane of a gel will seldom be directly comparable to a DNA
ladder in the last lane of a gel. It was therefore anticipated that isolates deemed to be
related by visual comparison ofPFGE patterns would fail to be recognized as related
by the computer software, which is dependent on the calculated size of the DNA
fragments being compared.
This did indeed prove to be the case, and was particularly evident in the analysis
of the outbreak strain (PFGE type A) depicted in figure 3.2a. Rather than the one
outbreak strain (as had been recognized by visual comparison of the PFGE patterns),
the phylogenetic tree obtained through Diversity Database analysis suggested several
small clusters of related isolates. The nine isolates that were judged to be identical
by eye, ranged in similarity from 56% to 96% when analysed by the Diversity
Database, and the seven isolates deemed to be closely related were shown to have
57% to 86% similarity with the PFGE type A strain. The phylogenetic tree obtained
through analysis of figure 3.2a is shown in appendix A.
Similar findings were obtained with analysis of those gels depicted in figure 3.2b
and 3.2c. Whilst the Diversity Database identified RIE-23 and RIE-24 as being
'identical' (89% similarity), it failed to detect identity between isolates RIE-18 and
RIE-19 (63% similarity). GWI-06 and GWI-07, previously identified as having
identical PFGE patterns, were calculated as 88% similar, with the closely related
isolate GWI-08 showing 77% similarity (see appendices B and C).
All isolates deemed to be unrelated to any other isolates by visual comparison of
PFGE patterns were confirmed as such by Diversity Database analysis, with
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similarity typically under 50%. The only exception to this was with isolates GWI-05
and RIE-31 (figure 3.2c), previously considered unrelated. Diversity Database
analysis calculated the two isolates to have 65% similarity. Whilst such percentage
similarity would ordinarily indicate that the strains were unrelated, it was thought
this may be significant, given the variation seen in percentage similarity of 'identical'
strains.
3.2 Characterizaton of isolates from five-month epidemiology survey
3.2.1 Species identification and van genotyping of isolates
During the course of the five-month survey of enterococcal epidemiology, 94
isolates were collected from the diagnostic laboratories of the Royal Infirmary of
Edinburgh. Of these 94 isolates, 49 were hospital isolates and 26 general practice
isolates. The remaining 19 isolates were obtained through the routine screening of
faecal samples.
Figure 3.3 demonstrates the proportion of isolates belonging to different species,
as determined with the API20 Strep system. As anticipated, E. faecalis was the
predominant species, with E.faecium accounting for the majority ofthe remainder.
The API20 Strep system identified five isolates as E. casseliflavus and one as E.
avium; all six isolates being obtained from the routine screening of faecal samples.
Attempts were made to amplify the E. casseliflavus species-specific vanCl/3 gene
from those five isolates identified as E. casseliflavus, with the primers described by
Dutka-Malen et al. (1995). PCR analysis failed to demonstrate the presence of the
vanC2!3 gene, thus casting doubt over the API identification.
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According to API20 Strep system identification
All isolates were screened for vancomycin resistance with a 5|_tg vancomycin disc.
Of the 94 isolates, two were identified as being glycopeptide-resistant. Glycopeptide
susceptibility testing suggested both isolates, one E. faecalis and one E. faecium,
were VanA phenotype, and this was subsequently confirmed by PCR detection of the
vanA gene. Both isolates were general practice isolates from different individuals
residing in the Penicuik area, situated to the south ofEdinburgh.
3.2.2 PFGE analysis of enterococcal isolates
All 94 isolates collected during the five-month period were analysed by PFGE and
the resulting patterns interpreted according to the criteria described by Tenover et al.
(1995), as outlined previously.
Within the 94 isolates, ten clusters of related isolates were identified, designated
PFGE types I-X so as to avoid confusion with those PFGE types recognized
previously. The largest cluster (PFGE type I) consisted of nine E. faecium isolates,
whilst the remaining clusters consisted ofE. faecalis isolates. Table 3.7 summarizes
the ten clusters of related isolates.
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I 9 RIE, ECH, General practice
II 7 RIE
m 4 RIE, General practice
IV 4 General practice
V 3 RIE
VI 2 RIE, General practice
VII 2 ECH, General practice
VIII 2 RIE, General practice
IX 2 SMMP, General practice
X 2 SLTU, RIE
RIE - Royal Infirmary of Edinburgh; ECH - Edinburgh City Hospital; SMMP - Simpson's Memorial
Maternity Hospital; SLTU - Scottish Liver Transplant Unit a Number of isolates of each PFGE type,
including sub-types.
Whilst PFGE types II, V and X consisted solely of nosocomial isolates, and PFGE
type IV consisted solely of general practice isolates, many of the PFGE types
included both nosocomial and general practice isolates, suggesting strains that were
common to both the community and hospital settings. All the isolates represented in
table 3.7 are glycopeptide-sensitive. The two VanA general practice isolates
identified in the course of the study were unique by PFGE, as were all remaining
isolates. Amongst the isolates represented in table 3.7 are two of the isolates
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identified as E. casseliflavus by API20 Strep identification. One such isolate was of
PFGE type I and thus appeared to be a misidentified E. faecium, whilst the other was
ofPFGE type VII and was therefore thought to be an E.faecalis isolate.
The PFGE patterns exhibited by the 94 isolates were compared to the PFGE
patterns displayed by the nosocomial GRE described previously. The two VanA
GRE from general practice specimens were unrelated to nosocomial GRE. However,
PFGE types I and II appeared related to the previously identified PFGE types B and
D that were described in section 3.1.2. Representative isolates were re-examined by
PFGE so they could be viewed together on the same gel (figure 3.4).




Lanes: 1 - PFGE type B (RIE-18); 2 - PFGE
type I; 3 - PFGE type D3 (RIE-29); 4 - PFGE
type II; 5 - 50-1000 kb DNA ladder
As shown in figure 3.4, PFGE types I and II, displayed by glycopeptide-sensitive
enterococci, were closely related to PFGE types B and D, respectively, that were
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displayed by glycopeptide-resistant enterococci. The glycopeptide-sensitive
enterococci belonging to PFGE types I and II appeared to be widespread within the
Royal Infirmary of Edinburgh, being isolated from many different locations within
the hospital. Amongst the wards from which PFGE types I and II were isolated were
the renal unit and GI/Liver wards. The same wards harboured GRE isolates ofPFGE
types B and D, these isolates being identified two to three years earlier than the
glycopeptide-sensitive organisms.
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Chapter 4: Results
Transferability and location of Tnl546
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4.1 Transferability of Tn1546
The 48 nosocomial GRE isolates identified as harbouring Tn1546 were used as
donor cells in filter mating experiments with a suitable recipient cell. All E. faecium
isolates were mated with E. faecium GE-1, whilst all E. faecalis isolates were mated
with E. faecalis JH2-2. Both recipients are glycopeptide-sensitive, but resistant to
rifampicin and fusidic acid, thus allowing selection of glycopeptide-resistant
transconjugants on suitable selective media.
Thirty-eight of the 48 vanA-positive GRE isolates (81%) successfully transferred
glycopeptide resistance. All transconjugants displayed VanA phenotype resistance,
including the transconjugant derived from RIE-14 (vanA/B+; VanB phenotype). One
transconjugant colony was picked from each successful mating, sub-cultured and
stored at -70°C to enable further study. One transconjugant (arising from donor
GWI-06) was lost during storage. The remaining 37 transconjugants were screened
for co-transfer of resistance determinants. Erythromycin, chloramphenicol,
ampicillin, tetracycline, streptomycin and gentamicin susceptibility tests were
performed on all donors and transconjugants. The results of these susceptibility tests
are summarized in table 4.1.
The two recipients used in the conjugation experiments were found to be sensitive
to all agents tested, with the exception of E. faecium GE-1, which displayed
tetracycline resistance (MIC 32mg/L). This prevented the identification of
tetracycline resistance gene transfer from E. faecium isolates. Ten of the 37
transconjugants (27%) had acquired erythromycin resistance in addition to
glycopeptide resistance, whilst chloramphenicol resistance, HLSR and HLGR were
only rarely co-transferred. No transfer ofampicillin resistance was detected.
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Table 4.1: Details of VanA donor strains and resulting transconjugants




ARB-01 RIE-01 FM Em, Amp, HLSR
ARB-02 RIE-02 FM HLSR
ARB-03 RIE-03 FM Em, Amp, Tet, HLSR
ARB-04 RIE-04 FM Em, Amp, Tet, HLSR
ARB-05 RIE-05 FM Em, Amp, HLSR
ARB-06 RIE-06 FM Em, Amp, HLSR
ARB-07 RIE-07 FM Em, Amp, HLSR
ARB-08 WGH-01 FM Amp, HLSR
ARB-09 RIE-08 FM Em, Amp, Tet, HLSR
ARB-10 RIE-09 FM Em, Amp, Tet, HLSR
ARB-11 RIE-10 FM Em, Amp, Tet, HLSR
ARB-12 BGH-01 FM Em, Amp, HLSR
ARB-13 BGH-02 FM Em, Amp, HLSR
ARB-14 RIE-11 FM Em, Amp, HLSR
ARB-15 RIE-12 FM Em, Amp
ARB-16 RIE-13 FM Em, Amp, Tet, HLSR
ARB-17 RIE-14 FM Em, Amp, Tet, HLSR
ARB-18 RIE-15 FM Em, Amp, Tet, HLSR
ARB-19 RIE-16 FM Em, Amp, HLSR
ARB-20 RIE-18 FM Em, Amp, HLSR Em
ARB-21 RIE-19 FM Em, HLSR Em, HLSR
ARB-22 ECH-01 FM -
ARB-23 RIE-23 FS Em, Amp, Tet, HLSR Tet
ARB-24 RIE-24 FS Em, Amp, HLSR Tet
ARB-25 ECH-02 FS Em, Tet, HLSR Em, HLSR
ARB-26 RIE-27 FS Em, Amp, Tet, HLSR Tet
ARB-27 RIE-29 FS Em, Tet, HLSR, HLGR Tet, HLGR
ARB-28 MON-01 FM Amp, Tet
ARB-29 ARI-01 FM Em, Tet
ARB-30 RTE-30 FM Em, Amp, Tet, HLSR
ARB-31 NIN-03 FS Em, Tet Em
ARB-32 NIN-04 FS Em, Tet Em
ARB-33 GWI-07 FM Em, Amp Em
ARB-34 GWI-08 FM Em Em
ARB-35 GWI-10 FS Em, Tet Em
ARB-36 GWI-11 FS Em, Tet Em
ARB-37 RIE-31 FS Em, Cm, Tet, HLSR Em, Cm, Tet, HLSR
FM - E. faecium; FS - E. faecalis. a Resistance profile following erythromycin (Em), ampicillin
(Amp), chloramphenicol (Cm), tetracycline (Tet), streptomycin and gentamicin susceptibility testing.
HLSR & HLGR - High-level resistance to streptomycin and gentamicin respectively. Co-transferred
resistance determinants are in addition to glycopeptide resistance. The co-transfer of tetracycline
resistance from E. faecium isolates could not be detected due to the tetracycline resistance in E.
faecium GE-1.
104
Chapter 4: Results - Transferability & Location ofTn1546
The co-transfer of tetracycline resistance from E. faecalis isolates was detected,
and it is thought likely that similar transfer from E. faecium isolates would have been
witnessed, had a suitable recipient been used. Alternatively, the presence of
tetracycline resistance determinants (e.g. tetM) within E. faecium transconjugants
could have been detected by probing. It was noticeable that many E. faecium
transconjugants had a tetracycline MIC 4- to 8-fold higher than that of the recipient.
This may reflect the transfer of tetracycline resistance from the donor.
4.2 Analysis of plasmid DNA in donors and transconjugants
4.2.1 Extraction of plasmid DNA
Repeated attempts were made at extracting plasmid DNA from both the VanA
GRE isolates and their corresponding transconjugants. Attempts with the RPM Spin
Midi kit (BIO 101 Inc.) and the large-scale plasmid extraction method described by
Heilig et al. (1998) were unsuccessful, failing to yield any plasmid DNA.
Potential plasmid DNA was, however, extracted by the technique described by
Woodford et al. (1993), and so the technique was applied to a range of isolates,
chosen so that many different PFGE types would be represented. Figure 4.1
(overleaf) shows the result ofthe plasmid extraction.
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Figure 4.1: Plasmid extractions performed according to the protocol
described by Woodford et al. (1993)




Lane: 1 - RIE-01; 2 - RIE-02; 3 - RIE-09; 4 - RIE-13; 5 - RIE-15; 6 - RIE-16; 7 - R1E-18;
8 - R1E-19; 9 - ECH-01; 10 - RIE-23; 11 - RIE-24; 12 - RIE-25; 13 - ECH-02; 14 -
R1E-27; 15 - RIE-29; 16 - DNA ladder (XHindlII)
As shown in figure 4.1, isolates deemed to be related by PFGE analysis gave rise
to comparable bands following the plasmid extraction. Lanes 1-5 depict isolates of
PFGE type A and related sub-types. Lanes 7 and 8 depict isolates that were identical
by PFGE, as do lanes 10 and 11. The gel shown in figure 4.1 was subjected to alkali
blotting, and the resulting membrane-bound DNA was probed for the presence of the
vanA gene. The probe was generated from v<m4-specific PCR product derived from
primers vanAl and vanA2 (table 2.3, page 66). The results of the vanA probing are
illustrated in figure 4.2.
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Figure 4.2: vaft4-probing of plasmid extraction depicted in figure 4.1.
23-kb
4-kb
Lane: 1 - RIE-01; 2 - RIE-02; 3 - RIE-09; 4 - RIE-13; 5 - RIE-15; 6 - RIE-16; 7 - RIE-18;
8 - RJE-19; 9 - ECH-01; 10 - RIE-23; 11 - RIE-24; 12 - R1E-25; 13 - ECH-02; 14 -
RIE-27; 15 - RIE-29. Molecular sizes indicated on figure 4.2 were estimated from
the XHindl 11 ladder that was run alongside samples (figure 4.1)
None of the presumed plasmid bands evident in figure 4.1 hybridized with the
vanA probe. Indeed, many of the bands were recognizable as 'clear' bands amidst
the high background signal present in many of the lanes, confirming that they were
negative for vanA. Instead, all isolates, with the exception of ECH-02 (lane 13), had
a common vanA-hybridizing band that was approximately 23-kb in size. This vanA-
positive band was faint when compared with other bands present on the gel depicted
in figure 4.1. Subsequent vanA -probing of the PFGE gels depicted in figure 3.2
revealed variation in the size of vanA -positive fragments present in some of those
isolates depicted in figure 4.1 (see section 4.4.3). The contrasting picture illustrated
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in figures 4.1 and 4.2, with a common vanA-positive band in all isolates, suggested
that this band of 'plasmid' DNA was fragmented DNA, either chromosomal in
nature, or from a large plasmid that had not survived the extraction procedure.
The same plasmid extraction protocol was applied to a selection of
transconjugants and to the plasmid-free recipients used in the conjugation
experiments. These attempts were unsuccessful, frequently yielding bands that were
common to both the transconjugants and recipients (figure 4.3). These bands were
most likely to be fragmented chromosomal DNA. Heavy chromosomal
contamination was evident within the wells of the gel, and the results of EcoRl
restriction of the plasmid extractions were consistent with a chromosomal restriction.
Further attempts at plasmid extractions failed to yield plasmid DNA, including an
alternative plasmid extraction method, specifically designed for the extraction of
large plasmids (Crosa et al., 1994)
Figure 4.3: Plasmid extraction performed on transconjugants and recipients
1 2 3 4 5 6 7 8
Lane: 1 - ARB-01; 2 - ARB-16; 3 - E. faecium GE-1; 4 - DNA ladder (XHindlU); 5 - DNA
ladder (XHindlII); 6 - ARB-25; 7 - ARB-27; 8 - E.faecalis JH2-2.
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4.2.2 Ethidium bromide curing of plasmid DNA
Ethidium bromide MICs were established for all 48 VanA isolates and
transconjugants. E. faecium isolates were inhibited by ethidium bromide
concentrations ranging from 60 to 70mg/L, whilst the MIC for E. faecalis isolates
was typically less than lOmg/L.
Plasmid curing was performed on those isolates depicted in figure 4.1. Following
overnight incubation in varying ethidium bromide concentrations, the highest
concentration permitting visible growth was spread inoculated on a BHIA plate and
the resulting colonies were screened for the loss of glycopeptide resistance. No loss
of resistance was detected. Likewise, no loss of glycopeptide resistance occurred
when plasmid curing was performed on a selection of transconjugant strains.
4.3 Detection of plasmids by electrophoresis of'intact' genomic DNA
An alternative approach for the identification of plasmid DNA was adopted in
view of the lack of success experienced with plasmid extractions. It was anticipated
that electrophoresis of unrestricted PFGE plugs would enable the identification of
plasmid DNA which would be free to migrate from the wells of a gel, as opposed to
chromosomal DNA which would remain within the wells.
PFGE plugs were prepared for all 38 VanA donor strains that successfully
transferred glycopeptide resistance and for the transconjugants arising from these
donors. Plugs were also prepared for the two recipients used in the conjugation
experiments. All donor strains were electrophoresed adjacent to their transconjugant.
The resulting gels are depicted in figure 4.4.
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Figure 4.4: Electrophoresis of'intact' genomic DNA of donors and
transconjugants
Lane: 1 - RIE-01; 2 - ARB-01; 3 - RIE-02; 4 -
ARB-02; 5 - RIE-03; 6 - ARB-03; 7 - RIE-04;
8 - ARB-04; 9 - R1E-05; 10 - ARB-05; 11 -
RIE-06; 12 - ARB-06; 13 - RIE-07; 14 - ARB-
07; 15 - WGH-01; 16 - ARB-08; 17 - RIE-08;
18 - ARB-09; 19 - Super-coiled DNA ladder;
20 - XHindlll DNA ladder
8-kb super-coiled DNA linear DNA
Lane: 1 - RIE-09; 2 - ARB-10; 3 - RIE-10; 4 -
ARB-11; 5 - BGH-01; 6 - ARB-12; 7 - BGH-
02; 8 - ARB-13; 9 - RIE-11; 10-ARB-14; 11 -
RIE-12; 12 - ARB-15; 13 - RIE-13; 14 - ARB-
16; 15 - RIE-14; 16 - ARB-17; 17 - RIE-15; 18
- ARB-18; 19 - Super-coiled DNA ladder; 20 -
XHindlll DNA ladder
8-kb super-coiled DNA 23-kb linear DNA
In figure 4.4 (a-e), lane numbers for all
gels run from left to right.
Lane: 1 - RIE-16; 2 - ARB-19; 3 - RIE-18; 4 -
ARB-20; 5 - RIE-19; 6 - ARB-21; 7 - ECH-01;
8 - ARB-22; 9 - RIE-23; 10 - ARB-23; 11 -
RIE-24; 12 - ARB-24; 13 - ECH-02; 14 - ARB-
25; 15 - RIE-27; 16 - ARB-26; 17 - RIE-29; 18
- ARB-27; 19 - Super-coiled DNA ladder; 20 -
XHindlll DNA ladder
8-kb super-coiled DNA 23-kb linear DNA
Lane: 1 - MON-01; 2 - ARB-28; 3 - ARI-01; 4
- ARB-29; 5 - RIE-30; 6 - ARB-30; 7 - ECH-
01; 8 - ARB-22; 9 - NIN-03; 10-ARB-31; 11 -
NIN-04; 12 - ARB-32; 13 - GWI-06; 14 -
ARB-38; 15 - GWI-07; 16 - ARB-33; 17 -
GWI-08; 18 - ARB-34; 19 - Super-coiled DNA
ladder; 20 - XHindlll DNA ladder
8-kb super-coiled DNA 23-kb linear DNA
Lane: 1 - GWI-10; 2 - ARB-35; 3 - GWI-11; 4
- ARB-36; 5 - RIE-31; 6 - ARB-37; 7 - E.
faecium GE-1; 8 - E. faecalis JH2-2; 9 - Super-
coiled DNA ladder; 10 - XHindlU DNA ladder
8-kb super-coiled DNA
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The vast majority of strains (GRE donor strains and transconjugants) yielded a
band of DNA equivalent to approximately 8-kb super-coiled DNA or 23-kb linear
DNA, with this band occasionally replaced by a double band. All GRE isolates and
transconjugants showed considerable DNA present within the wells of the gels. This
was presumed to be chromosomal DNA. All gels were transferred to nylon
membranes to enable probing for Tn1546 sequences. A vanR probe was used,
generated from vanR-specific PCR product obtained with the vanR-f and vanR-r
primers (table 2.4, page 75).
Figure 4.5 shows the result of vanR-probing of the gel depicted in figure 4.4(a).
As was typically the case for the other gels, probe hybridized to both DNA within the
wells of the gel, and to the band equating to 23-kb linear DNA. All GRE donor
strains and transconjugants were shown to be vanR-positive, with probe either
hybridizing to the wells, bands within the gel, or both. The recipient strains (E.
faecium GE-1 and E.faecalis JH2-2) did not hybridize with the vanR probe.
Figure 4.5: vanif-probing of'intact' genomic DNA
Lane: 1 - RIE-01; 2 - ARB-01; 3 - RIE-02; 4 - ARB-02; 5 - R1E-03; 6 - ARB-03; 7 - R1E-04; 8 -
ARB-04; 9 - RIE-05; 10 - ARB-05; 11 - RIE-06; 12 - ARB-06; 13 - RIE-07; 14 - ARB-07;
15-WGH-01; 16-ARB-08; 17-RIE-08; 18-ARB-09
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Given that Tn1546 is 10.8-kb in length, the predominant band identified as being
v<mR-positive (equating to 8-kb super-coiled DNA) was too small to be an intact
plasmid harbouring the van gene cluster. It was likely, therefore, that this band had
the same origin as the -positive fragments seen in the plasmid extractions, being
linear, fragmented DNA, either chromosomal or plasmid in nature.
4.4 Probing ofS>nal-restricted PFGE gels for Tn1546
All 48 VanA GRE isolates were analysed by PFGE, as described in section 3.1.2.
The three PFGE gels, depicted in figure 3.2, were transferred to nylon membrane to
facilitate probing for vanA. Likewise, the 37 transconjugants arising from
conjugation experiments, listed in table 4.1, were subjected to PFGE analysis. This
enabled identification of DNA fragments that were present within the
transconjugants, but not within the recipients from which they were derived. It also
facilitated vanA probing of the transconjugants to determine the location ofTnl546.
Figures 4.6 and 4.7 on the following pages show the PFGE gels of the
transconjugants.
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Lane: 1 - ARB-01; 2 - ARB-02; 3 - ARB-03; 4 - ARB-04; 5 - ARB-05; 6 - ARB-06; 7 - ARB-07;
8 - ARB-08; 9 - ARB-09; 10-ARB-10; 11-ARB-ll; 12 - ARB-12; 13 - ARB-13; 14 - E.





Lane: 1 - ARB-14; 2 - ARB-15; 3 - ARB-16; 4 - ARB-17; 5 - ARB-18; 6 - ARB-19; 7 - ARB-20;
8 - ARB-21; 9 - ARB-22; 10 - ARB-29; 11 - ARB-30; 12 - ARB-33; 13 - ARB-34; 14 - E.
faecium GE-1; 15 - DNA ladder (50 - 1000 kb)
The white arrow in figures (a) and (b) indicate the position of the additional DNA
fragment (see section 4.4.1).
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Lane: 1 - ARB-23; 2 - ARB-24; 3 - ARB-25; 4 - ARB-26; 5 - ARB-27; (Lane 6 included in error);
7 - ARB-31; 8 - ARB-32; 9 - ARB-35; 10 - ARB-36; 11 - ARB-37; 12 - E. faecalis JH2-2;
13 - DNA ladder (50 - 1000 kb).
The white arrows indicate the positions of additional fragments (section 4.4.1).
4.4.1 PFGE analysis of transconjugants
As shown in figure 4.6, all E. faecium transconjugants, with the exception of
ARB-33 and ARB-34 (derived from GWI-07 and GWI-08 respectively), displayed
an additional DNA fragment within their PFGE pattern when compared with the
PFGE pattern of E. faecium GE-1. This fragment was estimated at 115-kb in all
transconjugants, with the exception of ARB-19, in which it appeared approximately
5-kb smaller. This suggested the presence of a common transferable genetic element
in the majority ofVanA E. faecium isolates from Edinburgh.
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To establish if the same 115-kb fragment was present in the donor strains, a
selection of donors and transconjugants were run alongside one another. Donor
strains were chosen to include diverse strains (according to PFGE analysis), but all
donor strains chosen gave rise to a transconjugant with the 115-kb additional
fragment. As shown in figure 4.8, all donors studied had a DNA fragment within
their PFGE pattern that matched the additional fragment seen in their transconjugant.






Lane: 1 - DNA ladder (50 - 1000 kb); 2 - RIE-03; 3 - ARB-03; 4 - RIE-04; 5 - ARB-04; 6 - E.
faecium GE-1; 7 - RIE-18; 8 - ARB-20; 9 - RIE-19; 10 - ARB-21; 11 - E.faecium GE-1; 12
- ARI-01; 13 - RIE-30; 14 - DNA ladder (50 - 1000 kb).
The white arrows indicate the positions of the additional DNA fragments seen in
transconjugants.
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PFGE analysis of E. faecalis transconjugants (figure 4.7) showed only three to
have clearly visible additional fragments when compared to the recipient strain, E.
faecalis JH2-2. Transconjugant ARB-23 displayed an additional fragment of
approximately 45-kb, ARB-25 had a fragment of approximately 75-kb, whilst ARB-
27 had an additional fragment estimated at approximatelyl72-kb. No other E.
faecalis transconjugants displayed additional fragments within their PFGE patterns,
although small-scale variation in the sizes of'existing' fragments (those also present
within the E. faecalis JH2-2 recipient) could not be ruled out.
4.4.2 Probing of transconjugant PFGE gels for Tn1546
The three gels depicted in figures 4.6 and 4.7 were probed for the presence of the
vanA gene. All transconjugants that displayed an additional DNA fragment by PFGE
analysis, as outlined in the previous section, yielded a single vanA-hybridizing
fragment following probing of the PFGE gels. However, in all but one
transconjugant, the size of the vanA-positive fragment did not match the size of the
additional fragment that was seen in the PFGE pattern. Figure 4.9 shows the result
of probing the gel depicted in figure 4.6(a) for the presence of the vanA gene. A
common vanA-positive fragment was present in all transconjugants. The fragment
was approximately 45-kb, some 70-kb smaller than the additional DNA fragment
that was seen in the PFGE pattern ofthe transconjugants.
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Figure 4.9: va/tA-probing of the transconjugant PFGE gel
depicted in figure 4.6(a)
Lane: 1 - ARB-01; 2 - ARB-02; 3 - ARB-03; 4 - ARB-04; 5 - ARB-05; 6 - ARB-06; 7 - ARB-07;
8 - ARB-08; 9 - ARB-09; 10-ARB-10; 11 -ARB-11; 12-ARB-12; 13-ARB-13.
The sizes indicated were estimated from the DNA ladder shown in figure 4.6(a)
The only transconjugant to have a vanA-positive fragment of a size matching that
of the additional fragment seen in its PFGE pattern was ARB-23. Both the additional
and the va«A-positive fragments were estimated to be approximately 45-kb in size.
Of the 11 transconjugants that did not display an additional DNA fragment in their
PFGE pattern, two yielded a vrm/1-positive fragment upon probing of the PFGE gel.
Transconjugants ARB-24 and ARB-26 had a vanA-positive DNA fragment of
approximately 38-kb and 53-kb respectively. Fragments in this size range were
poorly resolved on the PFGE gels and so any small-scale variation in the sizes of
such fragments would not have been detected. The results of the vanA-probing of
transconjugant PFGE gels are summarized in table 4.2, alongside the results of
probing the VanA donor strains, discussed in section 4.4.3.
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Table 4.2: Summary of the results of va/tA-probing and PFGE analysis of
transconjugants and VanA donor strains
vanA-positive fragment in vaw/l-positive fragment in Size of any additional
donor PFGE transconjugant PFGE fragment in transconjugant
Donor Size (kb) Transconjugant Size (kb) PFGE (kb)
RIE-01 45 ARB-01 45 115
RIE-02 45 ARB-02 45 115
RIE-03 45 ARB-03 45 115
RIE-04 45 ARB-04 45 115
RIE-05 45 ARB-05 45 115
RIE-06 - ARB-06 45 115
RIE-07 - ARB-07 45 115
WGH-01 45 ARB-08 45 115
RIE-08 45 ARB-09 45 115
RIE-09 45 ARB-10 45 115
RIE-10 45 ARB-11 45 115
BGH-01 - ARB-12 45 115
BGH-02 - ARB-13 45 115
RIE-11 - ARB-14 45 115
RIE-12 - ARB-15 45 115
RIE-13 45 ARB-16 45 115
RIE-14 - ARB-17 45 115
RIE-15 45 ARB-18 45 115
RIE-16 45 ARB-19 137 110
RIE-18 60 ARB-20 68 115
RIE-19 60 ARB-21 68 115
ECH-01 - ARB-22 45 115
RIE-23 38 ARB-23 45 45
RIE-24 38 ARB-24 31 -
ECH-02 115 ARB-25 160 75
RIE-27 38 ARB-26 53 -
RIE-29 38 ARB-27 31 172
MON-Ol - ARB-28 - -
ARI-01 - ARB-29 45 115
RIE-30 38 ARB-30 45 115
NIN-03 - ARB-31 - -
NIN-04 - ARB-32 - -
GWI-07 - ARB-33 - -
GWI-08 - ARB-34 - -
GWI-10 - ARB-35 - -
GWI-11 - ARB-36 - -
RIE-31 - ARB-37 - -
denotes that no vanA positive fragment was detected, or that no additional PFGE fragment was
visible.
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4.4.3 Probing of donor PFGE gels for Tnl546
The three gels depicted in figure 3.2 were probed for the presence of the vanA
gene, with typical hybridization results shown in figure 4.10 (overleaf). The PFGE
gel depicted in figure 3.2(a) was run with a different DNA ladder from all the other
gels. The ladder used (Saccharomyces cerevisiae DNA ladder) was not ideally
suited for sizing of low molecular weight DNA fragments, as the smallest fragment
in the DNA ladder is 225-kb. The size of the vanA-positive fragments detected from
probing of this gel was estimated from a later gel, which was run with representatives
of the isolates depicted in figure 3.2(a) alongside a suitable DNA ladder.
The results obtained from the vanA-probing of all gels are summarized in table
4.2. In brief, the majority of isolates belonging to the outbreak strain (PFGE type A)
had a common -positive fragment of approximately 45-kb. For many of these
isolates, the signal generated by the vanA hybridization was very weak, and so
members of the outbreak strain that did not appear to have a 45-kb fragment
harbouring the vanA gene may simply have gone undetected. Isolates RIE-18 and
RIE-19, identical by PFGE analysis, had a common vanA-positive fragment
estimated as being 60-kb in size, whilst a group of clonally diverse isolates had a
common vanA-positive band ofapproximately 38-kb (figure 4.10).
Table 4.2 only summarizes the van/l-probing results of those GRE isolates that
successfully transferred glycopeptide resistance during conjugation. However,
probing was performed on all VanA GRE isolates, including the ten isolates that
failed to yield transconjugants. Of these ten isolates, three yielded a van/1-positive
fragment upon hybridization. Two of these isolates (RIE-25 and RIE-26) were
amongst the group of isolates displaying a vanA-positive fragment of approximately
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38-kb depicted in figure 4.10. The remaining isolate, GWI-09, was found to have a
vanA-positive fragment that was estimated at 204-kb.
Figure 4.10: vanA-probing of the VanA donor PFGE gel
depicted in figure 3.2(b)
Lane: 1 - RIE-18; 2 - RIE-19; 3 - ECH-01; 4 - RIE-23; 5 - RIE-24; 6 - R1E-25; 7 - ECH-02; 8 -
RIE-26; 9 - RIE-27; 10 - RIE-29; 11 - MON-01; 12 - MON-02; 13 - RIE-30; 14 - ARI-01;
15 - NIN-01; 16 - NIN-02; 17 - NIN-03; 18 - NIN-04; 19 - GWI-02. The sizes indicated
were estimated from the DNA ladder shown in figure 3.2(b).
Analysis of the results presented in table 4.2 showed occasional disparity between
the sizes of vawzl-positive fragments that were seen in the VanA donor strains and
those seen in the resulting transconjugants. In some cases, this may have been due to
inaccurate sizing of the vanA -positive bands. As well as a visual estimation of band
sizes, estimations were made using the Diversity Database software described
previously, and thus the estimations were prone to the same difficulties that were
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encountered when using Diversity Database to compare PFGE patterns. A single
DNA ladder run in the last lane of a gel did not necessarily reflect the sizes of all
DNA fragments in all lanes across the gel, owing to variation between lanes. It is
therefore possible that when vanA-positive fragment sizes in donors and
transconjugants differ only slightly, they may indeed be the same fragment. For
example, isolates RIE-18 and RIE-19 both showed a 60-kb vanA-positive fragment,
whilst their transconjugants (ARB-20 and ARB-21) had 68-kb vanA-positive
fragments. In PFGE gels, there is insignificant difference in the migration distances
ofDNA fragments that differ by only 8-kb.
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Prior to the application of long-range PCR (L-PCR) to amplify the entire length of
Tn1546, shorter regions of the transposon were amplified by 'conventional' PCR to
assess the diversity of the VanA elements within certain regions. Three different
regions were examined: the vanS-vanH, vanX-vanY and orf2-vanR intergenic
regions. These regions were chosen because variation, attributable to insertion and
deletion events, had been described previously in all three regions. Sections 5.1 - 5.7
describe the PCR analysis performed on the 48 nosocomial VanA GRE. PCR
analysis of the two VanA isolates from general practice specimens that were isolated
during the course of the five-month epidemiology survey is discussed in brief in
section 5.8.
5.1 PCR analysis of the vanS-vanH intergenic region
Handwerger et al. described a novel IS element, designated IS1251, within the
vanS-vanH intergenic region ofVanA enterococci isolated in the northeastern United
States (Handwerger et al., 1995). To screen for such variation within the VanA
transposons of Scottish GRE, a 364-bp fragment, spanning the intergenic region, was
amplified with the vanS-f and vanH-x primers listed in table 2.4.
All VanA GRE yielded a PCR amplicon of the anticipated size, as shown in figure
5.1. Restriction analysis of amplicons was performed with Sspl restriction
endonuclease, which cuts the prototype sequence once, generating two fragments
(123-bp and 241-bp). All amplicons gave rise to the anticipated fragments upon
restriction analysis, consistent with no insertion or deletion events within the vanS-
vanH intergenic region.
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Figure 5.1: PCR analysis of the vanS-vanH intergenic region
Lane: 1 - RIE-01; 2 - RIE-03; 3 - RIE-05; 4 - RIE-06; 5 - RIE-07; 6 - RIE-18; 7 - ECH-01; 8 - RIE-
23; 9 - RIE-30; 10 - 100-bp DNA ladder
5.2 PCR analysis of the vanX-vanY intergenic region
Arthur et al. (1993) and Miele et al. (1995) both identified significant variation
within the vanX-vanY intergenic region of certain Tn754d-related elements, although
the nature of this variation was not established. Subsequently, many studies have
shown that this variation is common and is most often attributable to the presence of
IS727d-related insertion sequences. Often these insertions are accompanied by
small-scale deletions. Primers vanX-i and vanY-r (table 2.4) were used to amplify
the vanX-vanY intergenic region to detect any insertions or deletions present within
the region.
Initially, few VanA isolates yielded any PCR amplicons, with those few yielding a
prototype sized amplicon of 691-bp. Further success was achieved following
optimization of the 'conventional' PCR protocol. However, it was not until L-PCR
was adopted that all VanA isolates yielded a vanX-vanY PCR amplicon. Figure 5.2
shows the results of vanX-vanY PCR on a selection of VanA isolates. PCR
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amplicons were either of the prototype size (691-bp) or in the region of 1500 base
pairs. This increased amplicon size suggested the presence of an insertion of
approximately 800 base pairs.
Initial restriction analysis was performed with Xbal restriction endonuclease,
which cuts the prototype vanX-vanY amplicon once, generating fragments of 559 and
132-bp. Those amplicons of the prototype size yielded the anticipated restriction
fragments upon Xbal restriction. All amplicons that were estimated to be
approximately 1500-bp in size gave rise to a 132-bp fragment and a single fragment
ofapproximately 1400-bp following Xbal restriction analysis.
Figure 5.2: PCR analysis of the vanX-vanY intergenic region
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Lane: 1 - BGH-01; 2 - BGH-02; 3 - ECH-01 (prototype amplicon); 4 - RIE-23; 5 - RIE-25; 6 - ECH-
02; 7 - RIE-27; 8 - R1E-29; 9 - MON-01; 10 - MON-02; 11 - RIE-30; 12 - RIE-05; 13 - RIE-
12; 14 - RIE-13; 15 - RIE-16; 16 - RIE-18; 17 - Negative control (E. faecalis ATCC 51299);
18 - Negative control (no template DNA); 19 - 100-bp DNA ladder.
As shown in figure 5.2, there appeared to be slight variation within the sizes of the
amplicons that harboured the putative insertion. Further restriction analysis was
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performed with Mnll restriction endonuclease, a frequent cutter that would enable
more detailed comparisons to be made. Mnll cuts the prototype vanX-vanY amplicon
four times, generating five fragments of 259, 184, 108, 96 and 44-bp. Figure 5.3
shows a selection of vanX-vanYamplicons following restriction with Mnll.
Figure 5.3: Mnll restriction analysis of vanX-vanY PCR products
600-bp 600-bp
Lane: 1 - 100-bp DNA ladder; 2 - RIE-05; 3 - BGH-01; 4 - RIE-18; 5 - ECH-01; 6 - RIE-23; 7 - RIE-
25; 8 - RIE-29; 9 - MON-01; 10 - MON-02; 11 - RIE-30; 12 - GWI-07; 13 - GW1-06; 14 - 100-
bp DNA ladder.
As shown in figure 5.3, Mnll restriction showed three distinct restriction patterns.
Lane 5 (ECH-01) showed the prototype Mnll restriction pattern, consistent with no
insertion or deletion events. Four of the five anticipated fragments were visible, with
only the 44-bp fragment undetectable. A non-prototype restriction pattern
(designated type 1) was evident in lanes 9, 10, 12 and 13. A different restriction
pattern (designated type 2) was seen in lanes 2-4, 6-8 and 11. Mnll restriction of the
remaining non-prototype amplicons showed that all conformed to one of these two
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non-prototype restriction profiles. Interestingly, the type 2 restriction profile of the
vanX-vanY amplicon was found only in isolates from Edinburgh and the Borders
(isolates with the three-letter prefix RIE, ECH, WGH or BGH). Of the 31 vanA-
positive GRE from the Edinburgh/Borders region, 28 had a non-prototype vanX-vanY
intergenic region of Til1546. Twenty-six of these 28 displayed a type 2 MnlI
restriction profile, with the remaining two VanA elements displaying a type 1
restriction pattern. Only five of the 17 VanA GRE from outwith the
Edinburgh/Borders region displayed a non-prototype vanX-vanY intergenic region.
All five were shown to be type 1 by MnK restriction analysis.
Two non-prototype vanX-vanY amplicons were fully sequenced, one belonging to
the type 1 MnlI restriction group, the other to the type 2 restriction group. Initial
sequencing was performed using the vanX-f and vanY-r primers that were used in the
original PCR. On the basis of the partial sequence obtained, additional primers were
designed to enable sequencing of the entire amplicon (primers 1216V-A, 1216V-B
and 1216V-C; table 2.4). Sequencing showed that both amplicons harboured the
same insertion sequence, showing greater than 99% homology to the IS1216V-like
element described by Jensen (GenBank accession number AF093508; Jensen, 1998).
The IS element is 809-bp in length and had inserted at nucleotide position 8839
(TnJ546 co-ordinates) in both isolates sequenced. Insertion generated an 8-bp target
site duplication. The sequence of both products was consistent with the IS1216V-
like element being orientated so that transcription/translation occured in the opposite
direction to that of the flanking genes.
The reason for the differing Mnli restriction patterns of the two amplicons was
ascertained as being a 93-bp deletion (nucleotides 8747-8839; Tn1546 co-ordinates)
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that had occurred immediately upstream of the IS727(5F-like insertion point in the
type 2 vanX-vanY amplicons. The deletion was within the vanX-vanY intergenic
region and did not infringe on either the vanXor vanYgene sequences.
5.3 PCR analysis of the or/2-vanR intergenic region
The first description of variation within the orf2-vanR intergenic region was made
by Woodford et al., who identified the novel insertion sequence IS1542 (Woodford
et al., 1998). All VanA GRE were thus examined for this, or other, insertions within
the orf2-vanR region.
PCR was performed with primers vanR-f and vanR-r (table 2.4), designed to
amplify an 859-bp fragment from within the or/2-vanR intergenic region to the vanS
gene. Typical results from the orf2-vanR PCR are shown in figure 5.4.
Figure 5.4: PCR analysis of the orf2-vanR intergenic region
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Lane: 1 - ECH-01; 2 - RIE-27; 3 - RIE-29; 4 - MON-Ol; 5 - MON-02; 6 - RIE-31; 7 - NIN-01; 8 -
NIN-02; 9 - NIN-03; 10 - NIN-04; 11 - GWI-02; 12 - GWI-03; 13 - 100-bp DNA ladder.
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Two amplicon sizes were seen, as shown in figure 5.4. Of the 48 VanA GRE
isolates, 15 yielded the anticipated amplicon size (859-bp). The remaining 33
isolates yielded an amplicon over 2-kb in size, consistent with an insertion of at least
1.2-kb. Interestingly, these 33 GRE isolates were the same 33 isolates previously
identified as harbouring the IS727<5F-like element within the vanX-vanY intergenic
region. The orf2-vanR amplicons were subjected to restriction analysis with Vspl
restriction endonuclease. Vspl should cut the prototype amplicon once, generating
two fragments of 557 and 302-bp. This is shown in figure 5.5 (lanes 4-7), alongside
the results of Vspl restriction of three non-prototype amplicons (lanes 1-3).





Lane: 1 - GWI-06; 2 - GWI-07; 3 - GWI-08; 4 - GWI-09; 5 - GWI-10; 6 - GWI-11; 7 - RIE-31; 8 -
GeneRuler DNA ladder mix (MBI Fermentas).
All non-prototype orf2-vanR amplicons yielded the same Vspl restriction profile,
displaying three bands of approximately 300, 250 and 1700-bp (lanes 1-3, figure
5.5). The insertion within the orf2-vanR region thus appeared to be the same in all
isolates harbouring a non-prototype Tn1546 element.
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The amplicon of two non-prototype VanA isolates was sequenced to confirm the
nature of the insertion. Initial sequencing was performed with the vanR-f and vanR-r
primers. Whilst the sequence obtained from the vanR-r primer was solely that of the
vanR gene, sequencing from the vanR-f primer yielded approximately 350 bases
matching the published sequence ofIS/542 (GenBank accession number AF114715;
Darini et al., 1999). Based on the published sequence of IS1542 and of Tn1546, two
additional primers were designed (1542-A and 1542-B; table 2.4) to enable complete
sequencing of the insert region. Sequencing confirmed the orf2-vanR insert within
the 33 VanA isolates as being IS1542, displaying 100% identity with the published
sequence of IS1542. The IS element was inserted at Tn1546 nucleotide position
3932, the same position described by Woodford et al. (1998). As with the IS1216V-
like element within the vanX-vanY intergenic region, IS/542 was orientated so that
transcription/translation occurs in the opposite direction to that of the flanking genes.
5.4 L-PCR analysis of Tn/54d-related elements
As discussed in the previous sections, PCR analysis of specific regions within
Tn1546 had highlighted two IS elements within the majority of Tn/545-related
elements: IS/542 within the orf2-vanR intergenic region, and an IS/2/dF-like
element within the vanX-vanY intergenic region. At this point it was decided to
apply L-PCR with primer Tn/546-IR (table 2.4) to amplify the entire length of the
VanA transposoa Initial attempts were generally unsuccessful, with few isolates
yielding any PCR product. Those isolates that did yield PCR product were amongst
the 15 isolates in which no variation from the prototype Tn/545 had been found by
previous PCR analysis. None of the 33 isolates previously identified as harbouring
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IS1542 and IS/2/dL-like insertions within their VanA transposon yielded L-PCR
product with the Ynl546-IR primer. This raised the question of whether these non-
prototype VanA elements had deletions within their 5' region, perhaps to compensate
for the insertions elsewhere. If such deletions removed the left-hand inverted repeat,
then one primer-annealing site would be lost.
To assess the Tn/57b-related elements for the presence of the left- and right-hand
inverted repeats (IRl and IRr respectively), the TniJ^d-IR primer was applied in
PCR reactions with either the vanR-r primer (to amplify nucleotides 13-4699), or the
vanX-iprimer (to amplify nucleotides 8448-10839).
5.4.1 L-PCR analysis of the v<wlV-IRr region
All isolates studied yielded a PCR amplicon with the Tn/54<5-IR and vanX-f
primers. The anticipated amplicon from a prototype Tnl546 element is 2391-bp.
The variation in the size of the L-PCR amplicons, as shown in figure 5.6, was
consistent with the previous findings on variation within the vanX-vanY intergenic
region. The presence of the IS/27bL-like insertion increases the amplicon size to
approximately 3.2-kb.
All v<3/iY-IRr L-PCR amplicons were analysed by Hinjl restriction to establish if
the non-essential vanY and vanZ genes contained any insertions or deletions. Table
5.1 shows the predicted Hinjl restriction fragments on the basis of (i) the known
variation within the vanX-vanY intergenic region, and (ii) the published sequence of
the vanY and vanZ genes (Genbank accession number M97297; Arthur et al., 1993;
Arthur et al., 1995).
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Figure 5.6: L-PCR analysis of the vohX-IRr region
Lane: 1 - RIE-03; 2 - WGH-01; 3 - BGH-01; 4 - BGH-02; 5 - RIE-14; 6 - RIE-18; 7 - RIE-19; 8 -
ECH-01; 9 - RIE-25; 10 - ECH-02; 11 - RIE-26; 12 - RIE-27; 13 - RIE-29; 14 - MON-01; 15 -
RIE-30; 16 - GWI-08; 17 - NIN-01; 18 - GeneRuler DNA ladder mix (MBI Fermentas).
Table 5.1: Anticipated Hinfl restriction fragments of vanX-IRR L-PCR
amplicons
Anticipated Hinfl restriction fragments
Prototype vo«lY-IRr sequence 552, 1242, 261 & 337-bp
raraX-lRR harbouring IS727(51/-like 362, 665, 248, 1242, 261 & 337-bp
insertion
va«X-IRR harbouring IS727bT-like 455, 655, 248, 1242, 261 & 337-bp
insertion and 93-bp deletion
When the Hinfl restrictions were electrophoresed, the 337 and 362-bp fragments
and the 248 and 261-bp fragments could not be distinguished from each other. The
presence of the 665-bp fragment was indicative of the IS7276F-like element, whilst
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the 455-bp fragment identified those amplicons which did not have the 93-bp
deletion at the point of IS727dF-like insertion. Representative Hinjl restrictions are
shown in figure 5.7. Lane 9 showed the Hinjl restriction typical of a prototype vanX-
IRr sequence. The remaining lanes showed the Hinjl restriction of amplicons
harbouring the IS727(5L-like element, with the 93-bp deletion (lanes 1-4, 6 and 7),
and without the deletion (lanes 5, 8, 10 and 11).




Lane: 1 - RIE-11; 2 - RIE-12; 3 - RIE-13; 4 - RIE-15; 5 - RIE-16; 6 - RIE-23; 7 - RIE-24; 8 - MON-
02; 9 - ARI-01; 10 - GW1-07; 11 - GWI-08; 12 - GeneRuler DNA ladder mix (MBI Fermentas)
All isolates yielded the anticipated Hinjl restriction, and were thus confirmed as
having the previously assigned vanX-vanY intergenic region, as well as intact vanY
and vanZ genes.
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5.4.2 PCR analysis of the 5' (orfl/or/2) region of Tnl546
5.4.2.i PCR analysis internal to orfl
In contrast to the success of the wwiAT-IRr L-PCR, no isolates harbouring non-
prototype Tn7546-related elements yielded a PCR product when studied by lRL-vanR
L-PCR. This supported the idea that perhaps the left-hand inverted repeat was absent
in many, ifnot all, of the non-prototype VanA transposons.
To examine for large-scale deletions within orfl, attempts were made to amplify a
692-bp fragment internal to orfl with primers orfl-f and orfl-r (table 2.4). Of the 48
VanA GRE isolates, only five gave a non-prototype orfl amplicon. These five
isolates (MON-Ol, MON-02, GWI-06, GWI-07 and GWI-08) all yielded a band of
approximately 1.5-kb; all, but GWI-06, also yielded a prototype amplicon (692-bp).
Restriction analysis of all orfl amplicons was performed with the BsuRl restriction
endonuclease. The prototype amplicon is cut twice by BsuRl, generating fragments
of 243, 129 and 320-bp. All amplicons of the prototype size yielded the anticipated
restriction fragments. The 1.5-kb amplicon obtained from the five isolates fisted
above was inconsistent in its BsuRl restriction profile. Three of the five isolates
(MON-Ol, GWI-07 and GWI-08) yielded two non-prototype fragments of
approximately 600 and 900-bp following BsuRl restriction, whilst the 1.5-kb
amplicon ofMON-02 was not cut by BsuRl. No restriction pattern was visible for
isolate GWI-06 due to the low yield of PCR amplicon. A selection of BsuRl
restrictions is shown in figure 5.8.
If the 1.5-kb amplicon obtained from the five isolates fisted above is a genuine
PCR product, representing DNA between nucleotides 906 and 1597 (Tnl546 co¬
ordinates; GenBank accession number M97297), it is interesting to note that the size
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is consistent with there being an insertion of approximately 808-bp, thus matching
the size of IS/27dF-like elements. However, if such an insertion were responsible
for the 1.5-kb amplicon, it would not be expected to simply yield two fragments
upon BsuRl restriction.





Lane: 1 - GWI-02; 2 - GWI-03; 3 - GWI-04; 4 - GWI-05; 5 - GWI-06; 6 - GWI-07; 7 - GWI-08; 8 -
GWI-09; 9 - GWI-10; 10 - GWI-11; 11 - RIE-31; 100-bp DNA ladder.
5.4.2.ii L-PCR analysis of the orfl-vanR region
The majority of isolates yielded a prototype 692-bp orfl amplicon. This
suggested that if deletion events within non-prototype Tn1546 elements had removed
the IRl, such deletions were restricted to the first 905-bp of the transposon. The
PCR internal to orfl did not, however, give any indication of insertion or deletion
events within the remainder oforfl (nucleotides 1598-3041) and within orf2.
L-PCR was thus employed with the orfl-f primer in combination with the vanR-r
primer to amplify the region from nucleotides 906-4699. The anticipated amplicon
135
Chapter 5: Results - Diversity ofTn/54<5-related elements
size from the orfl-vanR L-PCR is approximately 3.8-kb for those prototype Tn1546
elements, and approximately 5.1-kb for those harbouring IS1542 within the orf2-
vanR intergenic region.
Seven of the 48 isolates failed to yield an orfl-vanR L-PCR amplicon, including
isolates MON-Ol and MON-02 that had previously shown non-prototype orfl
amplicons. With the exception of isolates GWI-06 and GWI-07, all remaining VanA
isolates yielded the anticipated L-PCR amplicon size, consistent with the presence or
absence of IS1542 as determined previously. All amplicons were subjected to
restriction analysis with Vspl restriction endonuclease. Vspl cuts the prototype orfl -
vanR sequence four times, generating five fragments of 757, 352, 1400, 982 and 303-
bp in length. The IS1542 insertion introduces another Vspl cut site, thus giving rise
to six fragments following Vspl restriction. All isolates that had yielded a PCR
amplicon of the prototype size (3.8-kb) yielded the appropriate restriction fragments
following Vspl restriction (lanes 14-19, figure 5.9). This was consistent with there
being no variation between nucleotides 906 and 4699. Those isolates previously
identified as harbouring the IS1542 insertion (lanes 1-13, figure 5.9) showed no
further variation (in the form of insertions and deletions) from the prototype
sequence between nucleotides 906 and 4699. Thus the majority of isolates (39 of the
48) had no apparent insertions or deletions within nucleotides 906-3041 of orfl, or
within the orf2 gene. Interestingly, this group of 39 isolates included GWI-08, which
had yielded two orfl amplicons, one ofwhich was approximately 800-bp larger than
anticipated (section 5.4.2.i). This potential variation within orfl was not detected by
the orfl-vanR L-PCR.
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Lane: 1 - RIE-12; 2 - RIE-13; 3 - RIE-15; 4 - RIERIE-16; 5 - RIE-18; 6 - RIE-19; 7 - RIE-25; 8 -
ECH-02; 9 - RIE-26; 10 - RIE-27; 11 - RIE-29; 12 - RIE-30; 13 - RIE-01; 14 - NIN-01; 15 -
NIN-02; 16 - NIN-03; 17 - NIN-04; 18 - GWI-02; 19 - GW1-03; 20 - GeneRuler DNA ladder
mix (MBI Fermentas)
GWI-06 and GWI-07 had also yielded orfl amplicons of approximately 1.5-kb,
some 800-bp larger than anticipated. L-PCR analysis of the orfl-vanR region of
these two isolates yielded two amplicons. One amplicon was consistent in size with
the prototype Tn1546 sequence (lacking the IS1542 insertion), whilst the other
amplicon appeared to be consistent with the presence of IS1542. Restriction analysis
yielded multiple fragments, some of which fitted neither the pattern anticipated from
restriction of the prototype amplicon, nor of the amplicon harbouring IS1542. The
explanation for this result is not known. Both GWI-06 and GWI-07 had previously
been identified as having IS1542 within the orfl-vanR intergenic region by PCR and
restriction analysis.
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5.4.3 L-PCR analysis of the full-length Tni546-related elements
Much of the above PCR analysis on the Tn/54(5-related elements was performed
on the same genomic DNA extractions that were stored at -20°C. Some of those
isolates that failed to yield orfl-vanR L-PCR amplicon were isolates that had
previously been studied by L-PCR without failures. L-PCR requires template DNA
that is relatively 'fresh', and thus it was decided to repeat the genomic extractions, so
as to enable further L-PCR analysis of the VanA elements. The VanA isolates,
having been stored at 4°C, were sub-cultured onto selective media prior to the
genomic extractions. Initial attempts at full-length L-PCR with Tn754b-IR primer
on the new genomic extractions yielded amplicon from the majority of isolates
tested. L-PCR was repeated on the remaining isolates. The majority of isolates (43
of 48) yielded an amplicon of an appropriate size (>10-kb). Some size variation
within the amplicons was seen, as shown in figure 5.10. This variation in size
appeared to be consistent with the variation previously identified within the majority
ofVanA elements.
Figure 5.10: L-PCR of Tn/546-related elements with Tn75</6-IR primer
Lane: 1 - GeneRuler DNA ladder mix; 2 - RIE-16; 3 - RIE-18; 4 - RIE-19; 5 - ECH-01; 6 - RIE-23; 7
- RIE-24; 8 - RIE-25; 9 - ECH-02; 10 - R1E-26; 11 - RIE-27; 12 - RIE-29; 13 - MON-01; 14 -
MON-02; 15 - ARI-01; 16 - RIE-30; 17 - NIN-01; 18 - NIN-02; 19 - Negative control (no
template DNA); 20 - GeneRuler DNA ladder mix.
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5.5 Restriction analysis of full-length Tn/546-related PCR amplicons
Clal restriction analysis was performed on the 43 Tn1546 L-PCR amplicons.
Prior to restriction analysis, the sizes of Clal restriction fragments were predicted on
the basis of the known variation within the Tn/546-related elements. As shown in
figure 5.11 (following page), Clal cuts the prototype Tn1546 element in three places,
generating four fragments. Both IS1542 and the IS727dF-like element introduce an
additional Clal cut site, thus generating six fragments, assuming no further variation
is present elsewhere within the transposon.
Figure 5.12 shows the Clal restriction of prototype Tnl546 elements, confirming
14 of the 48 isolates harboured a prototype VanA transposon, designated TnJ546
type A. A further nine transposon types (B-K) were identified on the basis of their
Clal restriction profile. The yield of non-prototype L-PCR amplicon was extremely
variable and so their Clal restriction patterns (shown in figure 5.13) were not all
readily visible. To enable easier comparison of Tnl546 types, figure 5.14 is a
diagrammatic representation of the different Clal restriction patterns that were
identified amongst the 48 isolates studied.
Figure 5.12: Clal restriction analysis of prototype Tn1546 elements
Lane: 1 - ECH-01; 2 - ARI-01; 3 - NIN-01; 4 - NIN-02; 5 - NIN-03; 6 - NIN-04; 7 - GWI-02; 8 -
GWI-03; 9 - GWI-04; 10 - GWI-05; 11 - GWI-09; 12 - GWI-10; 13 - GWI-11; 14 - RIE-31; 15
- GeneRuler DNA ladder mix.
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Lane: 1 - GeneRuler DNA ladder mix; 2 - RIE-01; 3 - RIE-02; 4 - RIE-03; 5 - RIE-04; 6 - RIE-05; 7 -
RIE-06; 8 - RIE-07; 9 - WGH-01; 10 - RIE-08; 11 - RIE-09; 12 - RIE-10; 13 - BGH-02; 14 -
RIE-11; 15 - RIE-16; 16 - RIE-18; 17 - RIE-19; 18 - RIE-23; 19 - RIE-24; 20 - GeneRuler
DNA ladder mix.
Lane: 21 - GeneRuler DNA ladder mix; 22 - RIE-25; 23 - ECH-02; 24 - RIE-26; 25 - R1E-27; 26 -
RIE-29; 27 - MON-01; 28 - MON-02; 29 - ARI-01; 30 - RIE-30; 31 - NIN-01; 32 - NIN-02; 33
- NIN-03; 34 - N1N-04; 35 - GeneRuler DNA ladder mix.
None of the isolates previously identified as harbouring the IS1542 and IS1216V-
like insertions displayed the Clal restriction profile predicted in figure 5.11, thus
indicating that all isolates had variation elsewhere within the VanA transposon. The
bands depicted in yellow in figure 5.14 (on following page) are those that were not
predicted and thus represent further variation. Table 5.2 lists those isolates
displaying each of the Tnl546 types identified in figure 5.14.
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Figure 5.14: Diagrammatic representation of Tnl546 types A-K on the basis of
their Clal restriction profiles
A B C DE FGH J k.
3000—
500—
GcncRulcr DNA ladder mix
Table 5.2: VanA isolates harbouring the Tn1546 types defined in figure 5.14.
Tn1546 type Number Isolates
A 14 ECH-01, ARI-01, NIN-01, NIN-02, NIN-03, NIN-04, GWI-02,
GWI-03, GWI-04, GWI-05, GW1-09, GWI-10, GWI-11, RIE-31
B 14 RIE-01, RIE-02, RIE-05, RIE-06, RIE-07, WGH-01, R1E-09,
RIE-10, BGH-02, RIE-18, RIE-19, RIE-23, RIE-24, RIE-30




G 2 MON-Ol, MON-02
H 1 GWI-07
J 2 GWI-06, GWI-08
K 1 RIE-16
Tnl546 type A is the prototype transposon
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Thirty-nine of the 48 VanA isolates are listed in table 5.2. The remaining nine
isolates could not be assigned to a Tn1546 type on the basis of their Clal restriction
profile. Five of these isolates (BGH-01, RIE-12, REE-13, RIE-14 and RIE-15) failed
to yield an L-PCR amplicon despite repeated attempts. The remaining isolates (RIE-
04, RIE-26, RIE-27 and RIE-29) yielded non-prototype L-PCR amplicon, but the
yield ofL-PCR product was too low to permit restriction analysis.
Of the VanA isolates that harboured a non-prototype Tn75A5-related element,
approximately half harboured a type B transposon. The Clal restriction profile of the
type B transposon varied from the predicted profile (based on the known IS1542 and
IS727<5F-like insertions) solely on the size of the 3419-bp fragment of the orfUorfi.
region (figure 5.11). The 3419-bp fragment was replaced by a fragment
approximately 4150-bp in size, suggesting a possible insertion within the orfllorf2
region. On the basis of previous PCR results, this putative insertion was thought to
be within the first 905-bp of the VanA transposon. Tnl546 type F, displayed by only
one isolate (ECH-02), had the same variation within the 3419-bp fragment as that
seen in the type B transposon. The only difference between the transposon types B
and F was the 93-bp deletion within the vanX-vanY intergenic region of the type B
transposons.
Variation of transposon type K from the predicted Clal restriction profile was also
due to variation within the orfl/orf2 region, altering the size of the 3419-bp
fragment. The restriction profile of transposon type K was the same as that for the
type F transposon, with the exception of an additional band ofapproximately 500-bp.
Transposon type C also varied from the predicted Clal restriction profile solely by
the size of the 3419-bp fragment. However, the fragment appeared only marginally
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larger than predicted, at just over 3.5-kb. This increase in size was too small to be
caused by the presence of an intact insertion sequence alone, and may have reflected
the insertion of an IS element followed by a large-scale deletion of a size
approximately 100-bp less than that of the IS element.
Earlier PCR analysis performed on isolates MON-Ol and MON-02 suggested a
possible insertion within the orfl gene (see section 5.4.2.i), but no L-PCR amplicon
was obtained from either isolate with the orfl-HvanR-x primers. These results
suggested possible variation within the orfl/orf2 region, and Clal analysis of the
Tn1546 L-PCR amplicons of both isolates supported this suggestion. The isolates
(assigned to Tn1546 type G) both appeared to have substantial deletions within the
orfl/orf2 region. Their Clal restriction profiles were missing both the 3419 and 645-
bp fragments, which correspond to the orfllorf2 region. Instead, fragments of
approximately 2500 and 500-bp were apparent, suggesting a deletion of
approximately 1-kb. The size of this deletion may have been larger than this if it had
followed the insertion ofan IS element (see section 5.6).
The three VanA isolates from Glasgow's Western Infirmary identified as
harbouring non-prototype VanA elements (GWI-06, GWI-07 and GWI-08) also
appeared to have substantial deletions within the orflIorfl region. Like isolates
MON-Ol and MON-02, these three Glasgow isolates yielded an unexpected orfl
amplicon, albeit in addition to the prototype orfl amplicon (section 5.4.2.i). In
addition, results from the orfl-f/vanR-r L-PCR on these three isolates were
inconsistent with other PCR analysis performed previously. The Clal restriction
profiles of the Tn1546 elements of the three isolates (types H and J) were both
missing the 3419-bp fragment corresponding to orfl/orfl and the 645-bp fragment
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generated by the additional Clal site that is introduced by IS1542. In the place of
these two bands, Tn1546 type H (GWI-07) had three fragments of approximately
700, 500 and 300-bp. These three fragments combined amount to approximately 2.5-
kb less than the two missing fragments. Tn1546 type J (GWI-06 and GWI-08)
showed the same 700-bp fragment that was seen in type H, although the 500 and
300-bp fragments were missing. However, the 700-bp fragment of type J was very
faint, so it is possible that the 500 and 300-bp fragments have simply gone
undetected. The significance of these findings in relation to the previous PCR
analysis performed on these three isolates is unclear. There certainly appears to be
significant variation within the orfllorf2 region. It may be that some of this variation
arose during cold storage of the isolates, after the initial PCR analysis was
performed.
It is certainly thought that isolate RIE-25, displaying Tn1546 type E, underwent
Tn1546 variation during cold storage. As in other non-prototype Tn1546 elements,
the anticipated 3419-bp fragment was absent. However, also missing from Tn1546
type E were the 645 and 805-bp fragments, indicative of the previously identified
IS1542 and IS72fdF-like insertions respectively. No attempts were made to
ascertain the nature of this variation.
Finally, Tn1546 type D, harboured by isolate RIE-11, appeared to have variation
located outwith the orfllorfl region other than that identified by earlier PCR
analysis. In addition to an alteration within the 3419-bp orfllorf2 fragment, the
predicted 3647-bp fragment also appeared to be altered. The two bands were,
instead, just under and just over 4-kb in size. It was unclear which fragment
corresponded to which region of the transposon. Both the 645-bp and the 2009-bp
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fragments that were predicted (figure 5.11) were unaffected by the variation, and the
isolate had previously yielded a prototype amplicon from the vanS-vanH intergenic
region. If such variation was indeed present, it either suggested that the isolate had
undergone variation during cold storage, perhaps within the vanS-vanH intergenic
region, or alternatively that the vanS gene may have been disrupted by an insertion.
5.6 Hybridization analysis of Tn1546 types A-J
Clal and BamHl restrictions were performed with representatives ofTn1546 types
A-J. Tnl546 type K was not recognized until later, and was thus not included. The
restrictions were electrophoresed and transferred to nylon membranes to facilitate
probing.
5.6.1 Probing ofClal restrictions for the vanA gene
As a way of confirming that all L-PCR amplicons obtained with Tnl546-IR
primer were, indeed, Tnf5¥d-derived, the Clal restrictions were probed for the
presence of the vanA gene. A common fragment was found to be van/1-positive in
all Tnl546 types studied, the fragment estimated as being 2-kb in size. This
corresponded to the 2009-bp fragment within the vanHAX genes that is obtained by
Clal restriction analysis (figure 5.11). All L-PCR amplicons were thus Tn1546-
derived.
5.6.2 Probing of Clal restrictions for the inverted repeat (IR)
To try and identify those Clal restriction fragments corresponding to the extreme
5' and 3' ends of the transposon, thus containing the left and right-hand inverted
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repeats, the Tn7545-IR primer was fluorescein-labelled and used as an
oligonucleotide probe. The same membrane that was probed for the vanA gene was
probed for the inverted repeat. As shown in figure 5.11, a prototype Tn1546 element
would be expected to have IR-positive fragments of 3419 and 2455-bp following
Clal restriction. Those Tn/544-related elements that harbour the IS7276T-like
insertion within the vanX-vanY intergenic region should have a 2375-bp fragment
containing the right-hand inverted repeat. The size of the fragment harbouring the
left-hand inverted repeat would be expected to vary according to the nature of the
variation within the orfllorf2 region. The results of the IR-probing are shown in
figure 5.15.
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In an attempt to compensate for the low yield of L-PCR amplicon obtained from
many of the isolates, the amount of amplicon restricted, and subsequently
electrophoresed, was higher than that which would normally be used. It was thought
that this 'over-loading' of lanes was responsible for some spurious IR-hybridizing
bands that are evident in figure 5.15.
The prototype Tn1546 element in figure 5.15 (type A) showed IR-positive
fragments corresponding to Clal restriction fragments of 3419 and 2455-bp as
anticipated. Other IR-positive fragments visible in the restriction of the type A
transposon did not match with any restriction fragments of that transposon, and were
probably caused by overloading of lanes and perhaps spillage from neighbouring
wells when loading samples into the gel.
With the exception of Tn1546 type E, all other non-prototype Tn1546 types
showed an IR-positive fragment corresponding to the anticipated Clal restriction
fragment of 2375-bp, which contains the right-hand inverted repeat. Unexpectedly,
however, no other IR-positive fragments were seen in Tn1546 types B, C, D, F and
G. Tnl546 types H and J both showed other IR-positive fragments besides the 2375-
bp fragment. Both the 500 and 300-bp fragment seen in the Clal restriction of
Tn1546 type H (figure 5.14) appeared to be IR-positive. It was suggested previously
that the lack of 500 and 300-bp fragments in Tnl546 type J might simply be due to
them being undetected. In support of this theory, Tn1546 type J showed an IR-
positive fragment of 500-bp. However, given that overflow from the well of lane 8
(Tn1546 type H) may account for the IR-positive 500-bp fragment seen in lane 7
(Til1546 type A), the 500-bp IR-positive fragment seen in Tnl546 type J may have a
similar source.
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Finally, the previous suggestion that isolate RIE-25, displaying Tn1546 type E,
had undergone considerable alteration within the Tn1546 element during cold
storage was supported by the results of IR-probing. As shown in figure 5.15, the
only IR-positive fragments corresponded to the 700 and 500-bp fragments seen
within the Clal restriction profile (figure 5.14). Despite the Clal restriction yielding
a fragment apparently matching the predicted 2375-bp fragment, consistent with the
vanYZ region at the 3' end of the transposon, this fragment did not hybridize with the
IR probe.
The failure of many Tn1546 types to yield two IR-positive fragments may be
explained by the left-hand inverted repeat having undergone alteration. This may
also partly explain the difficulties experienced in L-PCR with the Tni57<5-IR primer.
Clearly, however, the inverted repeat must be present in some form, otherwise no L-
PCR amplicon would have been obtained. Decreasing the stringency of the
hybridization process failed to identify any other IR-positive fragments. An
alternative, and perhaps more plausible, explanation for the single IR-positive
fragment is that an inverted duplication of the 3' end ofTnl546 has replaced part of
orfl. This possibility is discussed in section 7.4.
5.6.3 Probing ofBamHl restrictions for the IS/2/6K-Iike element
Given the unknown nature of the variation within the orfllorf2 region of the
majority of the Tni54b-related elements identified, it was decided to probe this
region for the presence of an IS727dF-like element, like that seen in the vanX-vanY
intergenic region. An IS/2i5F-like probe was generated from the PCR product
obtained with primers 1216V-D and 1216V-E (table 2.4). Tn/54<5-related elements
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(representing types A-J) were Zfr/mM-restricted. BamHl was chosen as it cuts the
Tnl546 element once within the vanA gene, and thus separates the known IS1216V-
like element within the vanX-vanY intergenic region from the unknown variation
within the orfl/orf2 region. Figure 5.16 shows the result of the BamHl restriction,
with the result of the IS72/(5F-probing shown in figure 5.17.
Figure 5.16: BamHl restriction analysis oiTn!546 types A-J
DNA ladder is the GeneRuler DNA ladder mix.
Figure 5.17: IS/2/6K-like probing of restricted Tn1546 types A-J
BCDEFG A H J
For approximate sizes of IS/2/dF-positive fragments, refer to figure 5.16.
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Again, over-loading of the lanes to compensate for low PCR yield led to
'dirty' hybridization results. Neither of the fragments generated by the BamHl
restriction of the prototype Tn1546 element hybridized with the IS727(5E-like probe.
However, all non-prototype Tn1546 elements had two fragments which hybridized
with the probe for the IS 727 <5E-like insertion sequence. These results indicated that
an IS element related to the IS727<5F-like element was present within the 5' region of
Tn1546 types B-J. It should be noted, however, that the CM restriction of Tn1546
types B, C, F and perhaps J only had one fragment of altered size, rather than
additional fragments. The IS727<5F'-like insertion identified within the vanX-vanY
intergenic region has a CM cut site, and so if this element was present in its entirety
within the orfUorf2 region of these transposons, it would be expected to introduce an
additional CM cut site and thus yield an additional fragment following CM
restriction.
5.7 Screening of the vanX gene for a point mutation at position 8234
A point mutation at nucleotide position 8234 (G->T) within the vanX gene has
been associated primarily with porcine isolates of VanA GRE, being relatively
uncommon amongst VanA GRE isolated from humans and poultry (Jensen et al.,
1998).
The 48 nosocomial GRE isolates were screened for the presence of the point
mutation by amplification of a 424-bp fragment internal to the vanX gene and
subsequent DdeI restriction analysis. DdeI restriction of the prototype amplicon is
expected to give rise to three fragments, whilst the point mutation at nucleotide
position 8234 eliminates a DdeI cut site, thus resulting in only two fragments.
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All 48 isolates yielded three fragments upon DdeI restriction, consistent with none
of the isolates harbouring the point mutation.
5.8 PCR analysis of the Tn1546 elements of the two general practice VanA GRE
The two VanA isolates identified during the course of the five-month survey of
enterococcal epidemiology were subjected to limited PCR analysis of their VanA
transposons. The orf2-vanR and the vanX-vanY intergenic regions were examined by
PCR, as described in sections 5.2 and 5.3.
One of the general practice isolates yielded prototype amplicons from the two
regions studied, whilst the other gave rise to amplicons consistent with the presence
of IS/542 and IS/2/bF-like elements within the orf2-vanR and vanX-vanY regions
respectively. Restriction analysis confirmed these insertions, with the vanX-vanY
restriction consistent with a deletion adjacent to the point of IS/2/bF-like insertion.
This suggested that the transposon types prevalent amongst nosocomial VanA
isolates in Edinburgh can also be found in community isolates.
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Large-scale alterations within the orfltorfl region of Tni5¥b-related elements
will clearly disrupt the transposase and resolvase functions, which together facilitate
the transposition of the transposon. The impact of variation elsewhere within the
transposon is, however, less clear. Whilst insertions and/or deletions within genes
will clearly disrupt the function of that gene, such variation within intergenic regions
may or may not affect the expression of the downstream genes. The resistance
phenotypes expressed by the VanA GRE, with and without the Tn1546 insertions
described in the previous chapter, were compared to assess any impact of Tn1546
variation.
6.1 Correlation between Tn1546 genotype and teicoplanin susceptibility
Those isolates harbouring Tn75¥b-related elements with IS1542 and IS727bF-like
insertions upstream of vanR and vanY respectively were found to have increased
levels of teicoplanin resistance when compared with those isolates harbouring
prototype Tn1546 elements. Vancomycin resistance levels were unaltered.
Teicoplanin resistance levels conferred by non-prototype elements were clearly
greater than those conferred by prototype elements (PO.OOl) when susceptibility
tests were performed on brain-heart infusion media. The same phenomenon was
apparent when susceptibility tests were performed on Iso-Sensitest agar (PO.OOl).
The difference between prototype and non-prototype elements was less apparent on
Mueller-Hinton agar (0.05<P0.1). The MIC results are summarized in table 6.1.
Appendix D shows results of susceptibility testing on the three different media of
isolates harbouring prototype and non-prototype Tn1546 elements.
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The fact that the prototype Tn1546 elements conferred comparable levels of
teicoplanin resistance when tested on the three different media indicated that the
elevated resistance seen in the non-prototype VanA isolates was not solely due to the
differences in the media used (table 6.1).
Table 6.1: Summary of teicoplanin MIC data for VanA isolates with prototype
and non-prototype Tn1546 elements
Prototype Tn1546 (n=15) Non-prototype Tn1546 a (n=33)
Media MIC50 MIC90 Range MIC5o MIC90 Range
ISTA 8 32 4-32 64 128 16-128
MHA 16 64 4-64 32 64 16-128
BHIA 16 32 8-32 256 512 32 - 1024
MIC50, MIC90 and MIC range expressed in mg/L. a Non-prototype Tn1546 elements defined as
having IS1542 and IS727<5C-like insertions within the orf2-vanR and vanX-vanY intergenic regions
respectively.
The basis for glycopeptide resistance is the substitution ofD-alanine for D-lactate,
which is synthesized from pyruvate. It was considered possible, therefore, that if
BHI media was significantly richer in either pyruvate or lactic acid than the other
two media used in the sensitivity testing, it may explain the results shown in table
6.1. Sensitivity testing was therefore repeated on Isosensitest agar supplemented
with varying levels of either pyruvate (sodium pyruvate) or lactate (D,L-lactic acid).
The addition of neither component made any impact on the level of teicoplanin
resistance. A summary ofthese results is shown in appendix E.
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6.2 Identification of a hybrid promoter formed by IS/542 insertion
Attention turned to the two IS elements present within the non-prototype Tn1546-
related elements in an attempt to identify features that may influence the expression
of the van genes.
The IS/2/<5F-like insertion within the vanX-vanY intergenic region was initially
thought to be the most likely cause for the elevation in teicoplanin resistance.
Teicoplanin resistance is known to be conferred by the vanZ gene, and so if the
IS72/<5F-like insertion introduced any feature that may enhance expression of the
downstream genes, it would have a direct effect on vanZ. Examination of the
sequence of the modified vanX-vanY region did not reveal any feature likely to
enhance gene expression. Indeed, given that the vanY and vanZ genes are most
likely co-transcribed with vanHAX, it is more likely that the presence of the
IS/2/6F-like insertion within the intergenic region would hinder, rather than
enhance, expression of the downstream genes.
However, similar examination of the IS/542 insertion region identified a hybrid
promoter that was formed by the insertion of IS/542. The -10 TATAAT box that
forms part of the native vanR promoter (nucleotides 3926-3931) was duplicated as
part of the 8-bp target site duplication generated by IS1542 insertion at nucleotide
position 3932. This duplicated -10 box formed a promoter sequence in conjunction
with an outwardly-directed -35 box, which is present within the inverted repeat of
IS/542. The hybrid promoter sequence is illustrated in figure 6.1.
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Figure 3. Sequences of the proposed vanR promoter regions. A. vanR promoter region present in the
prototype orfl-vanR sequence, as proposed by Holman et al. (1994). B. The hybrid vanR promoter
generated by IS1542 insertion at nucleotide 3932. The -10 and -35 regions are labelled and
highlighted in bold, with the distance between these regions also indicated. The 8-bp target site
duplication generated by IS/542 insertion is indicated by the broken box spanning figures A and B.
The start of the vanR gene is indicated (ATG; nucleotides 3976-3978), as is the start of IS/542
(reverse orientation relative to vanR) in figure B, with the IS/542 DNA underlined.
6.3 Growth curve analysis of VanA GRE following glycopeptide challenge
The insertion of ISJ542 introduces over 1.3-kb of additional DNA between the
native vanR promoter and the start of the vanR gene. As the vanRS genes encode the
two-component regulatory system that is ordinarily responsible for the expression of
the downstream resistance genes in response to glycopeptide challenge, it was
thought possible that the additional DNA may interfere with this inducible resistance
gene expression mediated by VanR and VanS. Growth curve analysis was thus
performed to determine if glycopeptide resistance was still induced by glycopeptide
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challenge, or if it was expressed constitutively, perhaps from the hybrid promoter
described in section 6.2.
Figure 6.2 shows the results of growth curve analysis that was performed on a
variety of VanA GRE, some harbouring prototype lnl546 elements, and some
harbouring non-prototype elements containing the ISJ542 insertion.
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Each line represents a different VanA isolate. Those isolates depicted in blue have non-prototype
Tn1546 elements, harbouring the IS/542 insertion. Those depicted in red have prototype Tn/54<5
elements. Vancomycin was added to cultures to a final concentration of 8mg/L after 60 minutes.
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Growth curve analysis showed that the growth rate of all isolates at least slowed
upon glycopeptide challenge and, in some cases, growth stopped completely.
Generally, growth resumed two to three hours after glycopeptide challenge. This
trend is consistent with inducible glycopeptide resistance, for if expression of
resistance was constitutive, the rate of growth would be expected to be maintained
upon glycopeptide challenge. As shown in figure 6.2, there were no consistent
differences in the rate of response to glycopeptide challenge between those isolates
with prototype Tn1546 elements, and those with non-prototype elements.
6.4 D,D-dipeptidase activities of prototype and non-prototype Tn1546 elements
As a measure of van resistance gene expression, VanX and VanY enzyme assays
were performed on a selection of VanA isolates with and without exposure to
glycopeptides. Isolates were selected so as to include those with prototype Tn1546
elements and those with non-prototype elements that include the hybrid promoter
formed by IS1542 insertion. VanY enzyme assays were unsuccessful, failing to
demonstrate any VanY activity in isolates harbouring either prototype or non-
prototype Tn1546 elements. The reason for this is unknown. The VanX assay was,
however, successful and the results, expressed as nmoles ofD-Ala formed per minute
per milligram protein, are shown in table 6.2.
VanX activity conferred by prototype and non-prototype Tn1546 elements was
comparable when expression was induced by glycopeptide exposure (table 6.2).
However, discounting isolate RIE-29, VanX activity conferred by non-prototype
Tn1546 elements without induction was on average 10-fold greater than that
conferred by prototype Tn1546 elements in the absence of induction (table 6.2). It
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was thought likely that this moderate-level constitutive expression of vanX in non-
prototype Tn1546 elements was attributable to the hybrid promoter formed by
IS1542 insertion.
Table 6.2: VanX activity conferred by prototype and non-prototyype Tn1546
elements with and without induction
Isolate
VanX Dd>-dipeptidase specific activity a















a VanX activities are expressed as nanomoles of D-Ala formed per minute, per milligram protein
(nmol min"1 mg"1). Non-prototype Tnl546 elements are defined as those harbouring the hybrid
promoter generated by IS1542 insertion within the orf2-vanR intergenic region.
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The VanX assay clearly demonstrated that the normal induction system was still
active, and thus presumably expression from the native vanR promoter was
unaffected by the IS1542 insertion. The moderate-level constitutive expression of
the van genes from the hybrid promoter seemed to supplement, rather than replace,
the expression from the native vanR promoter.
A notable exception to the trend discussed above was seen in isolate RIE-29
which, despite harbouring a non-prototype Tn1546 element with the IS1542
insertion, had a VanX activity only marginally greater than that of isolates
harbouring prototype Tn1546 elements. The orf2-vanR intergenic region of isolate
RIE-29 was sequenced and the presence of the hybrid promoter was confirmed, with
no sequence variation from that shown in figure 6.1. The reason for the lower than
anticipated VanX activity in the absence of induction is unclear.
It is interesting to note that isolate RIE-19, used in the VanX dipeptidase enzyme
assays, was one of the isolates that was identified by PCR as harbouring both the
vanA and vanB genes. Assuming that the vanB gene was indicative of an intact vanB
gene cluster within RIE-19, it would be anticipated that vancomycin challenge would
induce both the VanX and VanXB enzymes. This would be expected to result in
RIE-19 exhibiting higher levels of VanX dipeptidase activity than those isolates
harbouring the vanA gene cluster alone. As shown in table 6.2, this is not the case.






During the last decade, GRE have emerged as a significant cause of nosocomial
infection and colonization in both Europe and the USA, having previously been
regarded as a low-grade pathogen. The propensity of enterococci, and in particular E.
faecium, to acquire antibiotic resistance determinants has undoubtedly been a major
factor in their emergence as nosocomial pathogens. Whilst in the USA GRE are solely
a nosocomial pathogen, their epidemiology in Europe is complex, with GRE readily
isolated from a variety of non-hospital sources. A multifaceted approach is required in
any attempt to gain an understanding of their epidemiology.
The interest in the epidemiology of GRE was heightened by the controversy
surrounding the use, and eventual withdrawal, of avoparcin as a growth-promoting
agent in animal livestock production. This controversy and the potential implications
for both the animal husbandry and pharmaceutical industries following avoparcin's
withdrawal, have resulted in many studies addressing the degree of relatedness of
VanA GRE from human and non-human sources.
The application of conventional techniques, such as ribotyping and PFGE, in the
study ofGRE typically reveals a very heterogeneous population within hospitals, unless
isolates are associated with a defined outbreak. With such diversity amongst GRE from
human sources, conclusive evidence for strains that are common to man and other
sources (particularly animals) is scarce. The diversity of GRE isolates points to the
dissemination of VanA resistance by the transfer of plasmids and transposons. Thus
interest has turned to investigating the diversity Of the Tn1546 elements themselves.
In the course of this study, 55 isolates of GRE were collected from eight hospitals
across Scotland. To gain an understanding of their epidemiology, and to enable
comparison of the VanA elements prevalent in Scotland, the 55 isolates were studied by
PFGE and all VanA isolates were examined for diversity within their Tn754<5-related
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elements. In addition, all VanA isolates were examined for their ability to transfer
glycopeptide resistance, and attempts were made to ascertain the nature of transferable
elements mediating glycopeptide resistance gene transfer.
7.1 The composition of the GRE isolates studied
The composition of the 55 GRE isolates was consistent with previous published
findings. Whilst the majority of cases of enterococcal infection are caused by E.
faecalis, E. faecium is the predominant species in collections of multi-drug resistant
enterococci. Thus a collection of enterococcal isolates gathered on the premise that
they are glycopeptide-resistant will not reflect the true prevalence ofE. faecalis against
E. faecium. For example, of 105 clinical GRE collected from 31 hospitals in the United
States, 78% were identified as E. faecium (Clark et al., 1993). Similarly, of 116 GRE
isolated from six US hospitals, 92% were E. faecium (Bopp et al., 1999). In this study
64% of GRE isolates were E. faecium, with the remainder being E. faecalis. This was
in contrast to the collection of glycopeptide-sensitive enterococci (GSE) that was
established during the five-month survey of enterococcal epidemiology. Seventy-five
percent of the GSE isolates were E. faecalis. The predominance ofE. faecalis in cases
ofenterococcal infection may reflect the fact that E. faecalis is inherently more virulent
than E. faecium. However, potential virulence determinants within E. faecium are
currently the focus ofmuch attention and it is likely that such virulence factors will be
identified. It is also likely that the multi-drug resistant nature ofE. faecium becomes a
virulence factor, particularly in infections of immuno-compromised patients
undergoing aggressive antibacterial therapy.
All isolates were identified to the species level by the API20 Strep system of
biochemical tests. All nosocomial GRE isolates were identified as either E. faecium or
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E. faecalis, with the identification showing strong certainty on the basis of the API
profile. Whilst the majority ofGSE isolates were also identified with certainty as either
E. faecium or E. faecalis by the API20 Strep system, five isolates were misidentified as
E. casseliflavus. The five isolates failed to yield the vawC2/3-specific PCR products
that would confirm the API identification. Subsequent PFGE analysis of the isolates
suggested one of the five to be an E. faecium, with another an E. faecalis. The
problems associated with the identification of non-classical enterococcal species are
well documented (Devriese et al., 1993). Commercially available kits, including the
API20 Strep system, are recognized as being unreliable in the identification of
enterococcal species other than E. faecalis (Miranda et al., 1991; Morrison et al.,
1997). Whilst the misidentification of an E. faecium isolate may not, therefore, be
regarded as unusual, the API20 Strep system would be expected to correctly speciate an
E. faecalis isolate. If, as suggested, at least one of the misidentified isolates was an E.
faecalis, it may reflect errors in either the set-up or the interpretation of the API strip.
However, it may be significant that the five misidentified isolates were not clinical
isolates, but were obtained from the screening of faecal samples. It is likely that the
identity of the five isolates could have been resolved by PCR analysis with the species-
specific primers described by Dutka-Malen et al. (1995).
The proportion of VanA and VanB isolates within the 55 GRE studied was in
accordance with published findings. Typically, the VanA phenotype is the most
commonly encountered glycopeptide resistance phenotype (Morrison et al., 1997; Bopp
et al., 1999). In this study, 78% of the GRE isolates were vanA genotype, 13% were
vanB genotype, and the remaining isolates were found to harbour both the vanA and
vanB genes. Enterococcal isolates in which the vanA and vanB gene clusters coexist
have only rarely been described (Woodford et al., 1997b). It should be noted that there
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are exceptions to the 'rule' of VanA predominance. In some hospitals, studies have
identified the predominant resistance phenotype to be VanB (Taylor et al., 1999;
Nelson et al., 2000). This includes Glasgow's Western Infirmary, from which 11
VanA GRE were collected in the course of this study (Nelson et al., 2000). Such
findings highlight the fact that, whilst interhospital spread of GRE certainly occurs,
GRE appear to have emerged independently at different hospitals and thus hospitals can
have quite distinct GRE populations and epidemiology.
The levels of vancomycin and teicoplanin resistance displayed by VanA and VanB
phenotype enterococci were generally consistent with the typical range of sensitivities
that would be expected. The one exception to this was a VanB isolate that displayed
teicoplanin resistance (MIC 32mg/L). The teicoplanin resistance of this isolate (RIE-
28) was not investigated further, although it is likely to have arisen through the
constitutive expression of the vanB gene cluster, as described by Hayden et al. (1993).
Teicoplanin sensitivity of VanB enterococci is caused by the failure of teicoplanin to
induce vanB gene expression (Evers & Courvalin, 1996). Constitutive expression of
the genes renders VanB strains resistant to teicoplanin.
Avoparcin MICs were ascertained for many of the VanA and VanB isolates. The
results clearly demonstrate the cross-resistance between the glycopeptide agents. More
notable, however, is that the VanB isolates display avoparcin resistance, albeit at
variable levels. Thus whilst the VanB resistance mechanism is not induced by
teicoplanin, it is induced by avoparcin. The apparent lack ofVanB GRE in animals and
environmental sources does not, therefore, stem from the failure of avoparcin to select
for VanB enterococci.
The results of sensitivity testing of non-glycopeptide antibiotics on the VanA GRE,
performed primarily to identify co-transferred resistance determinants, were generally
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consistent with anticipated results. Once again, however, it should be noted that the
collection ofGRE isolates does not reflect a typical collection of enterococcal isolates.
Isolates collected solely on the basis of their glycopeptide resistance are more likely to
be multi-drug resistant than would otherwise be the case if the enterococcal collection
were not specifically glycopeptide-resistant. This is illustrated by comparing the
studies described by Klare et al. (1999) and Leach et al. (2000), which looked at
antibiotic susceptibilities of a collection of enterococcal isolates and a collection of
GRE isolates respectively. Resistance rates were significantly higher amongst the GRE
isolates. In general, the resistance rates described in this study were consistent with
what would be expected of a collection ofGRE isolates, although rates were lower than
those described by Leach et al. (2000). The isolates studied by Leach and colleagues
were, however, solely vancomycin-resistant E. faecium, whereas the GRE collection in
this study included both E. faecium and E.faecalis.
In this study, as anticipated, ampicillin resistance was significantly more common in
E. faecium than in E. faecalis. Conversely, tetracycline sensitivity tests performed on
the VanA isolates showed a significantly higher prevalence of tetracycline resistance in
E. faecalis isolates than in E. faecium. High-level resistance to streptomycin was
detected in 58% of the GRE isolates, being more common amongst E. faecium isolates
than E. faecalis (69% versus 50%). Only five of the 48 isolates displayed HLGR, with
four of the five also displaying high-level resistance to streptomycin. Although several
new aminoglycoside phosphotransferase enzymes conferring gentamicin resistance
have been identified (Chow, 2000), HLGR is most frequently associated with the
production of a bifimctional enzyme that confers resistance to all clinically-available
aminoglycosides, with the exception of streptomycin (Ferretti et al., 1986). However,
the streptomycin adenyltransferase enzyme is often produced by HLGR strains in
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addition to the bifunctional enzyme that confers gentamicin resistance, thus rendering
the strain resistant to all aminoglycosides (Gray & Pedler, 1992). The four isolates that
display high-level resistance to both gentamicin and streptomycin may possess this
combination ofaminoglycoside-modifying enzymes.
The five-month survey of enterococcal epidemiology was performed primarily to
ascertain the degree of diversity amongst clinical enterococcal isolates that did not
necessarily display glycopeptide resistance, and to look for any relationships between
GRE and GSE. The two isolates that were identified as VanA GRE were both from
general practice specimens - no GRE were detected through the routine screening of
faecal samples. It should be noted, however, that the method used for the selection of
enterococci from faecal samples was not selective for GRE, and thus the fact that no
GRE were detected does not mean that none were present. The media used for the
routine screening of faecal samples was a modified version of that used by Nelson et al.
(2000) for the selection of GRE. Vancomycin was omitted from the media, as the
primary objective was the isolation of enterococci and not specifically GRE. The
likelihood that GRE would go undetected was further increased by the fact that only
one suspected enterococcal colony was picked for further study from each faecal
sample. In this way, the epidemiology survey was looking at a cross-section of the
enterococcal population, rather than being a comprehensive study. It certainly cannot
be used to draw any conclusions on the carriage rate of GRE, not least because the
number of faecal samples screened was low.
7.2 PFGE analysis and interpretation
All isolates collected in the course ofthis study were analysed by PFGE to assess the
degree of clonality within the GRE population and the sensitive enterococcal isolates.
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Interpretation of the PFGE patterns was performed according to the criteria described
by Tenover et al. (1995). These criteria are intended for use in clinical hospital
laboratories when examining relatively small sets of isolates (typically no more than
30) which are related to putative outbreaks of disease. Accordingly, although perfectly
suited to the investigation of the renal unit outbreak within the Royal Infirmary of
Edinburgh, the criteria are less-well suited for interpreting the PFGE patterns of the 94
GSE isolates collected during the five-month epidemiology study.
The interpretation criteria are based on the number of fragment differences that
would be expected within PFGE patterns that had undergone a defined number of
"genetic events". These genetic events are defined as point mutations that result in the
creation, or loss, of restriction sites, and insertions or deletions ofDNA. PFGE patterns
that differ by two or three fragments are deemed to be closely related on the basis that
the fragment differences have arisen through a single genetic event. Two genetic
events, according to Tenover et al., would be expected to result in four to six fragment
differences and would be interpreted as being possibly related. PFGE patterns with
fewer than 50% of fragments in common are considered unrelated, indicative of three
or more genetic events that result in seven or more fragment differences. Tenover et al.
propose that these criteria are reliable if PFGE resolves at least ten distinct fragments.
The basis of the criteria is a simplified account of variation within the bacterial
genome. Whilst the rationale behind the number of fragment differences that can be
expected following a defined number of genetic events appears sound, there is
considerable debate over the number of fragment differences that can be expected from
clonal isolates.
A point mutation that leads to the creation of an additional restriction site would,
according to Tenover et al., result in a three-fragment difference, as might insertion of a
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large mobile genetic element (200-300 kb) into the chromosome. In both cases, the
resulting PFGE patterns would be classed as closely related to the original pattern,
although the two resulting strains differ significantly in their degree of relatedness to
the original strain. In addition, transfer of vancomycin resistance associated with large
chromosomal elements can markedly alter the biochemical properties of the recipient
strain (McAshan et al., 1999). Thus while the number of fragment differences may be
small, phenotypic properties of a strain can alter significantly. Whilst many studies
report that phenotypic characteristics are not a reliable indicator of clonality (Miranda
et al., 1991), such conclusions are based on the assumption that PFGE analysis and,
more importantly, interpretation of the PFGE patterns, is a reliable indicator of
clonality.
Whilst doubts exist over the relatedness of isolates that differ by up to three
fragments, one study has suggested that isolates of a single strain can differ by up to
seven fragments (Morrison et al., 1999). Morrison et al. analysed 30 isolates of
vancomycin-resistant E. faecium by PFGE, ribotyping, plasmid profile analysis,
biotyping, pyrolysis mass spectrometry (PyMS) and antibiogram analysis. Despite
PFGE analysis showing one cluster of isolates to differ by up to seven fragments, the
isolates were grouped together by ribotyping, plasmid profile analysis, biotyping and
PyMS. These results, combined with the geographical and temporal association of the
isolates, led Morrison et al. to conclude that these isolates represented a single strain.
Thus whilst PFGE is considered the gold standard for bacterial typing, the issue of
PFGE interpretation is very much unresolved. High degrees of polymorphism within
the PFGE banding patterns of vancomycin-resistant E. faecium strains has been
described (Morrison et al., 1997), suggesting that genetic events occur frequently in
this species, or in certain strains of the species. It is recognized that different bacterial
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species vary in the degree ofpolymorphism that they exhibit (Struelens et al., 1996). It
is likely, therefore, that even if criteria such as those defined by Tenover et al. (1995)
were widely accepted, they could not be universally applied to all bacterial species.
Studies assessing the clonality ofGRE isolates by PFGE have, in the past, employed
many different criteria in the interpretation of patterns. Whilst many have considered
isolates differing by no more than three PFGE fragments to be clonal (Murray et al.,
1991; Chadwick et al., 1996; Descheemaeker et al., 1999), other studies have deemed
that isolates differing by three PFGE fragments are unrelated (Sader et al., 1994).
Given the apparently high degree of genomic polymorphism amongst E. faecium
isolates (Morrison et al., 1997), it is unsurprising that Sader et al. (1994) identified
"great genomic variability" when ruling that three fragment differences indicated
unrelatedness. The criteria defined by Tenover and colleagues provide some degree of
uniformity in the interpretation of PFGE patterns, allowing easier comparison of the
conclusions reached by different epidemiology studies. It is then for the individual to
decide if they accept the full conclusions drawn from such interpretation, or whether
they discount those isolates that differ by 'X' number of fragments. The criteria also
have the advantage that they do not require any computer software in their
interpretation and thus are easily understandable and accessible. The advantages and
disadvantages of computer-aided comparisons ofPFGE patterns will be discussed later.
The main problem encountered in the interpretation of PFGE patterns in this study
was that the majority of isolates had one or more clusters of low molecular weight
DNA fragments (< 100-kb) that were not adequately resolved by the running conditions
employed (5-40 second pulse times). To enable these low molecular weight fragments
to be resolved, without sacrificing the resolution of the high molecular weight
fragments, would have required each isolate to be analysed by PFGE twice, by two
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different sets of pulse parameters. Such an approach has been successfully applied by
Morrison et al. (1999) and Miranda et al. (1991). Morrison and colleagues employed
linear ramped pulse times of 1 to 10 and 10 to 40 seconds for the separation of
fragments below and above 145-kb respectively, with a run time of 40 hours. Miranda
et al. described good resolution of high molecular weight fragments (200 to 500-kb)
with pulse times ranging from 5 to 35 seconds, whilst resolution of low molecular
weight fragments was achieved by decreasing the pulse times to a fixed five-second
interval (Miranda et al., 1991). Miranda et al. also demonstrated that isolates, which
had identical high molecular weight fragments, proved to be identical when comparing
low molecular weight fragments that were resolved with different running parameters.
At the most, analysis of the low molecular weight fragments revealed only one or two
fragment differences. Thus if variation in low molecular weight fragments went
undetected due to inadequate resolution, the 'worst-case' scenario is that isolates would
be classed as identical when, according to the criteria defined by Tenover et al. (1995),
they ought to be classed as closely related. The inadequate resolution of low molecular
weight PFGE fragments in this study is therefore unlikely to have had a significant
impact when assessing the clonality of the isolates. In retrospect, however, it would
have been beneficial to employ running parameters such as those described by Miranda
et al. (1991) or Morrison et al. (1999) for the PFGE analysis of transconjugants. The
potential for variation within low molecular weight fragments to go undetected was
clearly demonstrated by the combination of PFGE analysis and va»yf-probing
performed on transconjugant strains. Transconjugants ARB-24 and ARB-26 did not
have any apparent fragment differences in their PFGE patterns when compared to the
recipient strain, E. faecalis JH2-2. Despite this, both transconjugants were identified as
harbouring the vanA gene within low molecular weight DNA fragments, indicating that
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some degree of variation had occurred. The sizes of the fragments that were found to
be vtf7^4-positive (38 and 53-kb) were within the range ofpoorly resolved fragments.
Given the temporal association of the isolates originating from the outbreak within
the renal unit of the Royal Infirmary ofEdinburgh, and the rapid intermixing ofpatients
that occurred within the unit (Brown et al., 1998), it was unsurprising that an outbreak
strain was identified. The recognition of an outbreak strain, and the cross-infection that
it implies, is a common finding of studies investigating similar clusters of GRE
infection (Handwerger et al., 1993; Woodford et al., 1993; Chadwick et al., 1996),
although the nature of the outbreak strain varies between studies. Chadwick et al.
(1996) described an outbreak comprised primarily of VanB E. faecium, whilst
Woodford et al. (1993) described cross-infection with a single strain of VanA E.
faecalis. In this study, the outbreak strain was a VanA E. faecium. Ofnote was the fact
that the outbreak strain that was identified within the renal unit of the Royal Infirmary
of Edinburgh was not restricted to that hospital. A further three VanA E. faecium
isolates were identified that displayed the PFGE pattern of the outbreak strain; two
isolates from the Borders General Hospital, Melrose, and one isolate from Edinburgh's
Western General Hospital. Such interhospital spread has been described previously,
usually occurring between hospitals in close geographic proximity that may share
patients and staff (Murray et al., 1991; Sader et al., 1994; Chadwick et al., 1996). It is
possible that the movement of patients between hospitals in the Edinburgh/Borders
region has facilitated interhospital spread. The movement of hospital staffmay also be
implicated in the interhospital spread, although no screening of staff was performed
during the course of the outbreak. In retrospect, it would have been of interest to
compare the PFGE pattern of the outbreak strain (PFGE type A) with representatives of
the five epidemic strains ofglycopeptide-resistant E. faecium identified to date.
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Discounting the outbreak strain, PFGE analysis of the 55 nosocomial GRE isolates
revealed a largely heterogeneous population, consistent with the well-documented
polyclonal nature of GRE. No other isolates from different hospitals shared identical
PFGE patterns, although one isolate from the Edinburgh City Flospital and one from
Monkland's Hospital, Airdrie, were deemed to be possibly related to two isolates from
the Royal Infirmary of Edinburgh. Isolates from different areas of the Royal Infirmary
of Edinburgh also showed varying degrees of similarity, from identical to possibly
related, suggesting the spread of GRE strains between different wards. Small clusters
of related isolates were identified within Glasgow's Western Infirmary and Dundee's
Ninewells Hospital. The clusters were distinct from each other and from those PFGE
types identified elsewhere. It is not known whether the isolates from Glasgow and
Dundee were associated with any identified outbreak, or whether there was any
epidemiological link between the sources ofthe isolates within each hospital.
When studying the data presented in table 3.4, it is notable that there is often
variation in the van genotype of isolates that belong to the same PFGE type or related
subtypes. In one such example, the situation appears to mirror that described by
Woodford et al. (1997b), where the genotype of an E. faecium strain changed from
vanB to vanA through an intermediate isolate that contained both genes on distinct
plasmids. In this study, isolates RIE-14 and RIE-17 were closely related to the renal
unit outbreak strain (PFGE type A) which was vanA genotype. RIE-14, isolated in May
1995, harbours both the vanA and vanB genes, whereas RIE-17, isolated one month
later, contained only vanB. It is possible, therefore, that RIE-14 (PFGE type As) was
an intermediate isolate between the outbreak strain (PFGE type A) and isolate RIE-17
(PFGE type A7). The situation is not as 'clear-cut' as that described by Woodford et al.
(1997b), as the isolates described here were not identical by PFGE. Isolates RIE-18
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(vanA-positive) and RIE-19 (vanA/vanB-positive) were, however, identical by PFGE.
RIE-19 was isolated one month after RIE-18, and appears to have arisen through the
acquisition of vanB by a strain identical to RIE-18. These findings clearly indicate that
isolates are in an environment containing GRE of different genotypes, and that
resistance gene transfer is occurring in vivo.
PFGE analysis of the 94 enterococcal isolates collected in the course of the five-
month epidemiology survey again identified a largely polyclonal collection of isolates.
Whilst ten distinct PFGE types were identified within the 94 isolates, the majority of
these types consisted of only two or three isolates. PFGE analysis of this collection of
isolates did raise a number of interesting points. Firstly, at least one of the PFGE types
(type II) appeared to represent a GSE strain that was endemic within the Royal
Infirmary of Edinburgh. All seven isolates belonging to PFGE type II came from the
Royal Infirmary, with six of these being isolated from different wards within the
hospital. Endemic strains of enterococci have been described previously (Patterson et
al., 1991). Secondly, many PFGE types are common to isolates from both hospitalized
patients and general practice patients, suggesting that the same enterococcal strains that
are present in the community are the cause of infection and colonization within
hospitals.
Perhaps the most noticeable result from the PFGE analysis of these GSE isolates is
the identification of GSE strains that are closely related to strains of GRE identified
some two to three years previously, in the course of the renal unit outbreak. Whilst the
two VanA GRE that were isolated from general practice specimens were unique by
PFGE, the two predominant PFGE types amongst the GSE isolates (types I and II) were
identified as being closely related to PFGE types B and D identified within GRE
isolates. Given that the GRE isolates were isolated two to three years prior to the
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closely related GSE isolates, and that no related GRE have been isolated since, the most
likely explanation for this finding is that some of the GRE isolates responsible for the
outbreak in 1995 have since lost their glycopeptide resistance determinant. This may
have occurred in response to the decrease in vancomycin usage that was implemented
in an attempt to control the GRE outbreak and prevent any subsequent outbreak.
Rather than the GRE isolates converting to GSE and then becoming endemic within the
hospital, it may be that the same GSE strains were endemic around the time of the
outbreak in 1995, and that some organisms acquired, albeit temporarily, glycopeptide
resistance. No GSE isolates from around the time ofthe GRE outbreak were studied by
PFGE, so this suggestion cannot be confirmed either way. If these PFGE findings are
typical, and reflect the loss of glycopeptide resistance determinants by GRE, they
would suggest that the GRE population within the Royal Infirmary of Edinburgh is
extremely dynamic.
A consistent finding of the PFGE analysis ofboth the nosocomial GRE and the GSE
isolates is the inability to determine the relatedness of enterococcal isolates on the basis
of their phenotypic characteristics. This is highlighted in appendix F, which lists the
API profile, antibiotic resistance profile and PFGE type of the 26 isolates that
comprised the renal unit outbreak. Within PFGE types, both the API profile and the
antibiotic resistance profile is seen to vary. Likewise, isolates with the same API
profile were deemed to be unrelated by PFGE analysis. Similar findings have been
reported previously (Miranda et al., 1991). Appendix F also lists the Tnl546 type that
was assigned (where applicable) on the basis of the Clal restriction profile. Tn1546
type is also seen to vary within PFGE types, and isolates unrelated by PFGE are shown
to share Tn1546 types. The issue ofTn1546 variation is discussed later.
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In the latter stages of this study, it was decided to readdress the issue of PFGE
interpretation and employ the Bio-Rad Gel Documentation system and Diversity
Database software for the comparison ofPFGE patterns. The primary objective of this
reanalysis of PFGE patterns was to identify the advantages and disadvantages of using
such a system for PFGE interpretation, rather than to identify PFGE types that had
previously gone undetected, or to discount PFGE types that had been mistakenly
identified.
The most striking observation arising from the use of the Diversity Database
software was the extreme sensitivity of this type of analysis to any inconsistencies
across the gel. Duplicate samples run in the first and last lanes of the same gel will
seldom show equal migration rates for the restriction fragments. Owing to time
constraints at the time Diversity Database analysis was undertaken, the PFGE gels were
not rerun. Instead of the gel image being digitized directly from the gel, images were
digitized from the original Polaroid photographs that were used for the original visual
comparison of PFGE patterns. These gels were only run with one molecular weight
ladder and, as such, proved poor subjects for Diversity Database analysis. Isolates that
were deemed to be identical by visual comparison ofPFGE patterns had widely ranging
percentage similarities according to Diversity Database analysis.
For this type of computer-aided analysis to be successful, the PFGE gels themselves
must be extremely clear and should contain multiple molecular weight ladders so as to
compensate for variable migration rates across the width of the gel. Another problem
that was encountered with Diversity Database analysis was that, following the detection
of the bands by the computer, it was always necessary to delete bands that had been
wrongly detected due to high background, add bands that had not been detected, and, in
some cases, alter the precise location of the detected bands. It was often necessary to
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add bands that were part of a cluster of two or three bands that, whilst visible by eye,
had only been detected as a single, or perhaps a double band by the computer. Whilst
this problem was exacerbated by digitizing a Polaroid image that was two to three times
smaller than the actual gel, the same problem was encountered when analysis was
performed from PFGE gels themselves. The gel depicted in figure 3.4 was run late in
the study and was digitized so as to assess the reliability of band detection from an
actual gel. Several bands that were visible by eye were not resolved by computerized
detection of the bands. The adjustments that were therefore required following band
detection mean that the visual component of PFGE analysis cannot be removed
entirely, and thus any bias due to the user's own visual interpretation cannot be
avoided.
It is unclear whether other researchers have experienced difficulty in the computer
analysis of PFGE patterns. Descheemaeker et al. (1999) analysed 132 glycopeptide-
resistant E. faecium isolates by PFGE, and performed both visual and computerized
(GelCompar software, Applied Maths) comparison of the PFGE patterns. Whilst
Descheemaeker and colleagues make no mention of any difficulties encountered with
GelCompar analysis, they state that "visual and computerized analysis of all Smal
patterns obtained revealed 81 clones when three or fewer band differences was used as
the criterion to define a different clone". The criteria defined by Tenover and
colleagues (1995) were cited, and it thus appears the interpretation of the PFGE
patterns was primarily performed by visual comparison, and not using the GelCompar
software.
Despite the problems encountered with the computer-aided comparison of PFGE
patterns in this study, it is likely to be a useful tool for PFGE analysis, providing that
the running conditions of gels, and the layout of samples within gels, are optimized.
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Assuming that such optimization successfully overcomes the problems discussed
above, Diversity Database analysis would be expected to be far superior to visual
comparison and interpretation of large sets of isolates. In this study, the visual
comparison ofpatterns and interpretation according to the criteria described by Tenover
and colleagues was certainly adequate for the analysis of the nosocomial GRE isolates
from the renal unit outbreak in 1995. However, it is thought that the five-month survey
of enterococcal epidemiology would have benefited from the use of the Diversity
Database software for the comparison of the PFGE patterns.
7.3 Transferability of VanA glycopeptide resistance
Thirty-eight of the 48 -positive nosocomial GRE in this study successfully
transferred glycopeptide resistance to a sensitive recipient of the same species. The
transfer frequency was not determined. Although altering the conjugation conditions
may have had an impact on the transferability of glycopeptide resistance, the potential
for transfer from the ten remaining isolates was not investigated further.
Resistance determinants identified as having been co-transferred with glycopeptide
resistance include high-level gentamicin resistance and resistance to MLSb antibiotics
(Leclercq et al., 1989; Heaton & Handwerger, 1995; Woodford et al., 1995a). In this
study, the most frequently co-transferred resistance traits were erythromycin resistance
and tetracycline resistance, with chloramphenicol resistance and high-level resistance to
streptomycin and gentamicin rarely being co-transferred. It should be noted, however,
that no attempts were made to ascertain whether co-transferred resistance determinants
identified in this study were genetically linked to the van gene cluster. Co-transferred
determinants may have been located on different plasmids or mobile chromosomal
elements. No ampicillin resistance transfer was detected, suggesting that none of the
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isolates studied harboured transferable resistance to P-lactams, mediated either by p-
lactamases or PBP5. The gene encoding PBP5 has been identified as being linked to
transferable vancomycin resistance in some VanB enterococci (Carias et al., 1998). As
discussed in the introduction, P-lactamase-producing enterococci are often no more
resistant at the inoculum used for sensitivity testing than non-P-lactamase-producers,
and thus may go undetected (Murray, 1992). However, the E.faecium GE-1 strain used
as recipient in conjugation experiments is hypersusceptible to P-lactam antibiotics
(Eliopoulos et al., 1982). Therefore, if P-lactamase-mediated resistance had been
transferred, it is anticipated that it would have been detectable as an increase in
ampicillin resistance. The co-transfer of resistance determinants occurred more
frequently from E. faecalis than from E. faecium. The apparent absence of any co-
transferred determinants from the majority of E. faecium isolates may reflect the fact
that many appear to share the same transferable genetic element, as concluded from the
results of PFGE analysis and vanA hybridization studies. The exact nature of this
transferable element, discussed below, could not be ascertained.
Despite the ready transfer of glycopeptide resistance from the majority of VanA
GRE isolates, no vow^-positive plasmid DNA was extracted from any of the isolates
used in plasmid extractions. Many extractions failed to yield any plasmid DNA, with
the only band (usually a poorly defined, broad band) equating to approximately 23-kb
linear DNA. A similar band was sometimes obtained from plasmid extractions that
were performed on plasmid-free recipients, and this suggested that the band was
perhaps fragmented chromosomal DNA. Whilst an alternative possibility was that the
fragmented DNA was plasmid DNA, the plasmid being too large to be extracted intact
by the plasmid extraction protocol employed, the failure to cure strains of plasmid
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DNA, and thus glycopeptide resistance, suggested this was not the case. However, the
sensitivity of the curing experiments cannot be estimated as viable counts of the
exposed cultures were not performed. The failure to cure plasmid DNA may, therefore,
reflect low sensitivity rather than the absence of plasmid DNA. Whilst it had been
hoped that electrophoresis of 'intact' genomic DNA (unrestricted PFGE plugs) would
enable the identification of plasmid DNA, the technique also yielded a common
Tn/54d-positive band ofapproximately 23-kb linear DNA.
The combination of PFGE analysis and vanA hybridization studies of the pulsed-
field gels suggested that the majority of VanA E. faecium isolates possess a common
genetic element that is responsible for the transfer of glycopeptide resistance. The size
of this element, based on the size of vanA-positive fragments within donors and
transconjugants, and the size of the additional DNA fragments seen in transconjugants,
was estimated at approximately 160-kb. Despite the inability to extract intact plasmid
DNA and the unsuccessful attempts at plasmid curing with ethidium bromide, the
combined results of PFGE and vanA-probing suggest that this 160-kb element is,
indeed, a plasmid. The fact that the size of the wmzl-positive fragments in donors
matched the size of those in transconjugants is inconsistent with a mobile element that
is integrated into the chromosome, unless the vanA gene cluster was internal to the
mobile element, and flanked by Smal restriction sites. When Handwerger and Skoble
(1995) identified a chromosomal mobile element carrying the vanA gene cluster, the
size of vanA-positive fragments in transconjugants differed from that seen in the donor
strain. The presence of a 160-kb plasmid is further supported by the fact that the
majority ofE. faecium transconjugants have a common additional DNA fragment (115-
kb) that is matched by a DNA fragment within the PFGE pattern of the donor strains.
Again, this common band size between donors and transconjugants is inconsistent with
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the mobile element being integrated into the chromosome. The most likely scenario,
therefore, is that of a 160-kb plasmid, which is cut twice by Smal, generating two
fragments: a 45-kb fragment containing Tnl546, and a 115-kb fragment. It is
interesting to note that none of the transconjugants exhibiting the combination of the
45-kb vanA-positive fragment and the 115-kb fragment displayed any co-transferred
resistance determinants. This suggests that the common mobile element only harbours
the van gene cluster and no other resistance determinants.
At least two assumptions have been made in the interpretation of the PFGE and
vanA-probing studies discussed above. Firstly, it was assumed that the 45-kb fragment
shown to be vanA-positive, and the 115-kb fragment evident in transconjugants, are
part of the same mobile genetic element. This assumption was made primarily on the
basis of the close association between the two fragments (table 4.2). The second
assumption made was that the 115-kb additional fragment seen in the transconjugants is
the same fragment as the 'matching' fragment identified in the donor strains. If either
of these assumptions were incorrectly made, it would cast doubt on the proposed 160-
kb plasmid.
A technique employed by Quintiliani and Courvalin (1994) may have helped to
resolve this issue. In the course of identifying v<m8-containing chromosomal
insertions, they employed zero integrated-field electrophoresis (ZIFE). Agarose plugs
were prepared as for PFGE analysis and digested overnight with Sfil. This resulted in
only six DNA fragments that were clearly resolved by ZIFE. This technique enabled
easy identification of any additional DNA that may have integrated into the
chromosome, as only six fragments were being compared, as opposed to the 15-20
fragments that are generated by Smal restriction.
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Assuming the identification of a 160-kb plasmid is correct, the consistent
identification of vanA within the 45-kb fragment may be explained by the findings of
Tn1546 analysis that identified substantial alterations within the orfl/orf2 region of the
majority of transposons. Such alterations would disrupt the activities of the transposase
and/or resolvase enzymes and thus prevent the movement of the Tn75A5-related
element within the genetic element in which it is located.
It seems likely that the apparent lack of success in extracting plasmid DNA was due
to the inability to extract the large plasmid intact, rather than the actual absence of any
plasmid DNA. The reason for the failed attempts at plasmid curing with ethidium
bromide is unknown, as is the reason for the inability to identify plasmid DNA by the
electrophoresis of 'intact' genomic DNA. The plasmid extraction technique that was
applied in this study has been used to identify gentamicin resistance plasmids in
enterococci (Woodford et al., 1993). The plasmids identified ranged in size from 53 to
80-kb. Typically, vanA or v<mB-bearing plasmids range in size from 26 to 60-kb
(Leclercq et al., 1988, 1989; Clark et al., 1993; Handwerger et al., 1995; Heaton &
Handwerger, 1995; Woodford et al., 1995b). However, Werner et al. (1999) used a
modified plasmid extraction protocol, based on that described by Woodford et al.
(1993) and used in this study, to successfully extract large conjugative vanA plasmids
ranging from 125-kb to 200-kb. The modifications to the protocol included doubling
the length of lysozyme treatment, and performing ethanol precipitation of DNA
overnight. Gentle handling of samples was employed throughout. Such modifications
may have helped in the isolation of the 160-kb plasmid in this study. Assuming the
genetic element identified here is a plasmid, it appears to be amongst the largest vanA-
bearing plasmids identified to date.
183
Chapter 7: Discussion
7.4 Tn1546 diversity and the impact of variation on glycopeptide resistance
Different studies examining the diversity of Tn754b-related elements have, in
general, identified similar forms of variation within the VanA elements, although the
prevalence of these non-prototype elements varies significantly between studies. For
example, Woodford et al. (1998) described a very heterogeneous set of Tn757d-related
elements within 106 VanA GRE studied. Whilst 19% of isolates harboured a prototype
Tn1546 element, the remaining isolates harboured non-prototype elements with various
insertions and deletions within the orfllorf2 region and the orf2-vanR and vanX-vanY
intergenic regions. Twenty-three distinct types of non-prototype Tn754d-related
elements were identified. The findings of Willems et al. (1999) were in accordance
with those of Woodford and colleagues. Willems et al. described Tn1546 diversity
amongst 97 VanA GRE. Twenty-one percent of isolates harboured a prototype Tn1546
element, whilst the remaining isolates harboured various non-prototype elements
disrupted by insertions and deletions.
In contrast, Descheemaeker et al. (1999) reported a remarkably conserved set of
Tn1546 elements in 132 VanA E. faecium studied. Over 80% of the strains studied
harboured one of two transposon types, one being the prototype element, and the other
differing only in the loss of a DdeI restriction site through the previously described
point mutation at nucleotide position 8234. Only nine of the 132 isolates were
identified as containing Tn/546-related elements harbouring IS elements in the
orflIorf2 region, or within the orf2-vanR or vanX-vanY intergenic regions.
The results presented in this thesis are generally more consistent with the findings of
Woodford et al. (1998) and Willems et al. (1999) than with Descheemaeker et al.
(1999). Indeed, the predominant non-prototype Tn1546 element identified in this study
(type B) appears not too dissimilar to the predominant Tn1546 type (type H) that was
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identified by Woodford et al. (1998). The two types harbour IS1542 and lS1216V-hke
insertions within the orf2-vanR and vanX-vanY intergenic regions respectively. Tn1546
type H, identified by Woodford et al., was the most common Tni5¥<5-related element
identified in human enterococcal isolates. It was rarely observed in enterococci from
other sources.
Twenty-nine percent of the VanA isolates in this study were identified as harbouring
a prototype Tn1546 element. The remaining isolates harboured non-prototype Tn1546-
related elements that contained IS1542 within the orf2-vanR intergenic region and at
least two copies of an IS72/bF-like element. Despite the majority of isolates
harbouring non-prototype Tn1546 elements, marked by insertions and deletions, there
is a remarkable degree of uniformity in these non-prototype elements. All non-
prototype Tn1546 elements contain both IS1542 within the orf2-vanR intergenic region
and the IS72/bT-like element within the vanX-vanY intergenic region. The majority of
non-prototype elements are distinguished from one another solely on the basis of
variation within the orfl/orf2 region. In contrast, the non-prototype Tn1546 elements
identified by Woodford et al. (1998), and subsequently characterized by Palepou et al.
(1998), were more heterogeneous in nature. The same insertions were identified within
the orf2-vanR and vanX-vanY intergenic regions, but the insertions occurred separately
in some Tn/54<5-related elements, as well as together in other elements.
The IS1542 and ISi2i6T-like elements have both previously been described at the
same nucleotide positions within Ynl546 as those described here (nucleotides 3932 and
8839 respectively) (Woodford et al., 1998; Descheemaeker et al., 1999; Willems et al.,
1999). The fact that the IS1542 and IS727<5F-like elements frequently, if not
exclusively, occur at the same positions within Tn7546-related elements suggests that
both elements have some degree of specificity for a target sequence. Specific
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consensus target sequences are involved in the transposition of several IS elements,
with specificity arising from the recognition of a specific target sequence, a structural
or functional feature of the DNA, or a combination of these factors (Galas & Chandler,
1989). IS1216V and related elements have been identified at various positions within
Tn1546 (Descheemaeker et al., 1999; Willems et al., 1999), however, comparison of
sequences around these published insertion sites failed to identify any specific
consensus sequence. This suggests that if specificity does exist for IS72/<5F-like
insertion, it is a structural or functional feature of the DNA. No similar comparison of
IS1542 insertion sites was possible, as it has only been identified at nucleotide position
3932.
As witnessed in this study, small-scale deletions have often been identified adjacent
to the point of IS12J6V insertion within the vanX-vanY intergenic region (Willems et
al., 1999). IS elements are known to induce alterations within the surrounding DNA
(Galas & Chandler, 1989). Many IS elements have been identified as inducing
deletions, increasing the deletion frequency by 30- to 2000-fold. Such deletions
typically terminate precisely at one end of the IS element, as seen in the isolates in this
study that harboured an ISi2/bF-like insertion with an adjacent 93-bp deletion within
the vanX-vanY intergenic region.
It is interesting to speculate that whilst IS1542 and ISi2/<5T-like elements may
differ in their abilities to induce deletions, the apparent absence of deletions
immediately adjacent to the point of IS1542 insertion may reflect the nature of the
surrounding DNA. IS72idC-like elements frequently insert at nucleotide position 8839
within the vanX-vanY intergenic region, some 200-bp downstream from the end of the
vanX gene. Thus sizeable deletions upstream from the point of insertion can take place
without affecting glycopeptide resistance. Deletions downstream of the insertion point
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would, at most, disrupt the function of the non-essential accessory genes. Conversely,
deletions either upstream or downstream from the point of ISf542 insertion (nucleotide
position 3932) would be expected to disrupt the expression of glycopeptide resistance.
The insertion site is located just 44-bp upstream from the start of the vanR gene, thus a
deletion within this region would disrupt the expression of the VanRS two-component
regulatory system. Any deletion upstream of the insertion point would remove the
native vanR promoter that runs from nucleotide 3899 to 3931. The results of the VanX
enzyme assays following induction suggest that the native vanR promoter is still active
despite the insertion of IS1542. Thus if the promoter was deleted by an IS1542-
induced deletion, it is likely that the expression of glycopeptide resistance would at
least be decreased, and perhaps lost altogether. If the insertion of IS/542 does, on
occasion, induce deletions, it would therefore be likely that they would go undetected.
Such deletions would result in glycopeptide sensitivity, and so there would be no
reason to examine for a Tn/54d-related element.
A prominent feature of the majority of Tn/54d-related elements identified in this
study is substantial rearrangement within the 5' region of the transposon that
corresponds to the orfllorf2 genes, encoding the transposase and resolvase enzymes.
Other studies have reported similar findings, with the variation usually attributable to
the insertion of IS/2/5F and/or ISi-like elements with accompanying deletions. The
combination of IS1216V and a truncated IS5-like element within the 5' region of
Tn1546 was first identified by Handwerger and Skoble (1995), and appears to arise
through sequential insertion of the IS elements. This combination of IS elements,
associated with the loss of the first 120-bp of the transposon, has since been identified
in other studies (Jensen et al., 1998; Palepou et al., 1998; Willems et al., 1999). The
two IS elements have also been identified separately within the orfltorfl region.
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Willems et al. (1999) describe IS1216V in various positions within the orfl and orf2
genes, whilst the most common Tn1546 type identified by Woodford et al. (1998)
contained an ISJ-like/or/7 complex, but lacked the ISf2idk7ISJ-like complex (Palepou
et al., 1998). The majority of Tn754<5-related elements identified in this study as
having variation within the 5' region appear to have any insertions and deletions
restricted to the first 905-bp of the transposon, and all non-prototype transposons
appear to have at least one copy of an ISi275F-like element within the 5' region. The
IS5-like element described above was not screened for.
Five isolates in this study failed to yield an L-PCR amplicon with the Tni54<5-IR
primer alone. Interestingly, these five isolates were clonally related to one another,
belonging to PFGE type A and closely related subtypes. The five isolates may have
undergone variation within the orfl region that has removed the left inverted repeat.
The failure of L-PCR, associated with such Tn1546 alterations, has been described
previously (Palepou et al., 1998).
It was proposed that Tn1546 type D, identified in this study in isolate RIE-11, may
harbour an IS element within the vanS gene. This proposal was on the basis that the
Clal restriction fragment corresponding to the region from IS1542 (within the orf2-
vanR intergenic region) to vanH is larger than anticipated. The isolate was previously
identified as having a prototype vanS-vanH intergenic region. Darini et al. (1999b)
described a VanA E.faecium isolate with an IS1216V insertion within the 3' end of the
vanS gene. Whilst IS1216V insertion at the position described by Darini et al. would
most likely have been detected by PCR with the vanS-f and vanH-r primers used in this
study, it is possible that a similar insertion has occurred elsewhere within the vanS
gene. Disruption of the vanS gene does not affect glycopeptide resistance (Arthur et
al., 1992c). It is thought likely that VanR-dependent transcription in the absence of
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VanS may proceed through cross-talk with other two-component regulatory systems
encoded by the host chromosome.
Perhaps the main question arising from the PCR analysis of the Tn75¥d-related
elements is why L-PCR with Tnl546-IK primer alone and in combination with the
vanR-r primer, failed to yield any product from non-prototype VanA elements until the
latter stages of the study. And why, despite the eventual success of the L-PCR with
Tn/54(5-IR primer alone, the results of IR-probing experiments suggested that the
majority of TnfJ^d-related elements contain only one Txvl546-\R primer-annealing
site.
In theory, the failure of L-PCR with the TniJ^d-IR primer in conjunction with the
vanR-x primer may be explained by the unmatched nature of the primers. The two
primers differ significantly in their length and melting-temperatures. However, the
Tni5¥<5-IR primer was successfully applied with the vanX-f primer to confirm the
integrity of the 3' end of the Tn/546-related elements. The vanX-f and vanR-x primers
are comparable in their length and melting-temperatures, and so given that L-PCR with
the Tnf5¥6-IR and vanX-f primers was successful, it seems unlikely that the failure of
TxU546-lR/vanR-x L-PCR can be solely attributable to the use of an unsuitable primer
combination.
Whether the paradox of the successful Txil546-IR. L-PCR, but only one apparent
Tnl546-YR annealing site, reflects variation within the left-hand inverted repeat would
require sequencing to confirm. Sequencing would need to be performed from a site
within the Tni54d-related element, going back towards the left-hand inverted repeat.
Such an approach is complicated by the fact that the sequence downstream of the
inverted repeat is not known, given the uncertain nature of the variation within the
orfUorf2 region. It may be that conditions within the L-PCR reaction were better able
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to compensate for degeneracy within the primer-annealing site than the oligonucleotide
probing conditions with the Tn75-/6-IR primer. However, initial hybridization
conditions in IR-probing experiments were not particularly stringent, and lowering the
stringency further did not result in the identification ofmore IR-positive fragments.
An alternative explanation for the single IR-positive fragment seen in many of the
non-prototype Tn]546 elements is that an inverted duplication of the 3' end of Tn1546
has replaced part of orfl. Darini et al. (2000) reported such a phenomenon within the
Tn1546 element of a VanA GRE stored at 4°C for a prolonged period. The genetic
organization of the resulting Tn/546-related element is shown in figure 7.1.
Figure 7.1: Genetic organization of a Tn75</6-related element arising from
inverted duplication of the 3' end of Tn1546
<•<: :<: > <-!•: :>: :> •: >: :> :><: >z>>
IR vanZ vanY 1216V orfl 1542 vanR vanS vanH vaiiA vanX 1216V van Y vanZ IR
1216V and 1542 represent the IS727dF-like and IS/542 elements respectively. IR indicates a terminal
inverted repeat. The orfl gene is truncated due to the inverted duplication.
Figure adapted from Darini et al., 2000
As shown in figure 5.11 (pagel40), the IS727bF-like element contains a single Clal
restriction site. Thus, in a situation like that shown in figure 7.1, Clal restriction will
yield two identical fragments, one from the 5' end of the transposon and one from the
3' end. Both fragments will be IR-positive (both containing the right-hand inverted
repeat) but will appear as a single fragment following gel electrophoresis.
Confirmation of such an arrangement could be achieved by BamHl restriction of
Tn754b-related elements and probing for either the vanY or vanZ genes. The non-
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prototype Tn75-76-related elements identified in this study cannot be exactly like the
transposon depicted in figure 7.1, as L-PCR analysis confirmed the integrity of orf2 and
most of orfl (from nucleotide position 906) in the majority of isolates. However, the
inverted duplication may have replaced a section oforfl restricted to the first 905-bp.
An interesting observation from the results of Tn1546 analysis is that certain types
of variation appear restricted in their geographical distribution. The deletion
immediately adjacent to the point of insertion of the IS 727 (5F-like element within the
vanX-vanY intergenic region is only seen in VanA GRE from the Edinburgh/Borders
region Ofthe 28 VanA GRE from the Edinburgh/Borders region that harboured a non-
prototype Tn754b-related element, 26 had the 93-bp deletion adjacent to the point of
insertion. Whilst only five VanA isolates from outwith the Edinburgh/Borders region
harboured non-prototype Tn7J7<5-related elements, none of these isolates had the
deletion adjacent to the point of IS7276F-like insertion This suggests that different
areas of Scotland have differing Tnl546 profiles, although more isolates, particularly
from outwith the Edinburgh/Borders region, would need to be studied in order to
confirm this.
Comparing the results presented here with those of similar studies highlighted a
further possible example of varying geographical distribution of Tnl546 types. The
insertion of IS1542 within the orf2-vanR intergenic region was first described by
Woodford et al. who identified the element in 37 of the 106 VanA isolates studied
(Woodford et al., 1998). Thirty-four of the 50 VanA isolates in this study (including
the two VanA general practice isolates) were found to harbour Tn7J46-related elements
with the 1S1542 insertion. In comparison, three similar studies in continental Europe,
which have between them looked at over 260 VanA GRE, have only identified one
isolate from outwith the UK that harbours what is presumably IS7542 within the or/2-
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vanR intergenic region (Jensen et al., 1998; Descheemaeker et al., 1999; Willems et al.,
1999). Descheemaeker et al. (1999) described one isolate of human origin with an
"IS2J<5-like element at position 3932 in the orf2-vanR intergenic region". Limited
geographical distribution of certain IS elements within Till546 has been described
previously. 1S1251 was identified within the vanS-vanH intergenic region of VanA
GRE from the United States (Handwerger et al., 1995). Only recently has the same
variation within the vanS-vanH intergenic region been identified in European isolates
(Simonsen et al., 2000), suggesting recent intercontinental spread. How certain IS
elements can become established within, and restricted to, a certain geographical area is
unclear, but such restricted IS element distribution may be of use as an epidemiological
marker.
A major issue concerning the use of Tn1546 diversity as an epidemiological marker
is the potential instability of Tn1546 variation. Distinct Till546 types may differ by
only one insertion event, and the IS elements responsible are frequently found
elsewhere within the enterococcal genome. Tnl546 types can thus be altered by a
single transposition event. Till546 instability has been described previously, both
within the clinical setting and during prolonged cold storage of the GRE isolates
(Woodford et al., 1998; Darini et al., 2000). To examine Tn1546 stability, Woodford
et al. studied the VanA elements of 12 isolates of the epidemic strain EVREM-3. Six
distinct types ofTill546 were recognized within the 12 isolates. In addition, the VanA
elements varied within three isolates from various stages of a prolonged outbreak on a
single hospital unit, suggesting that the VanA element may have undergone some
alteration during the outbreak. The results presented in this thesis suggest similar
Tn1546 instability in clonal isolates. Within PFGE type A (and closely related
subtypes), three distinct Tn/54<5-related elements were seen, differing from each other
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primarily within the orfllorf2 region. In addition, Tn1546 instability during cold
storage of isolates was apparent, being exemplified by isolate RIE-25 (Tn1546 type E).
The nature of the alteration that had occurred was not ascertained, although it appears
to have been a structural change of the 3' region, associated with the presence of
IS1216V within the vanX-vanY intergenic region. Some IS elements are known to
induce alterations within surrounding DNA, including inversions (Galas & Chandler,
1989). Darini et al. (2000) describe an inverted copy of the IS1216V-vanY-vanZ-
inverted repeat block from the 3' end of a Tn754b-related element replacing the first
3417 nucleotides of the transposon, the alteration taking place during cold storage of
the isolate.
These findings do cast doubt over the validity of Tn1546 diversity as an
epidemiological marker. However, such analysis is still likely to be of use in localized
studies, perhaps in conjunction with other techniques. In this study this is perhaps best
illustrated by isolate RIE-30 which, although isolated in the Royal Infirmary of
Edinburgh, was thought to have originated in the United States. RIE-30 was isolated in
December 1997 from a patient, ordinarily resident in the Edinburgh area, who was
transferred to the Royal Infirmary ofEdinburgh following intensive care treatment in a
hospital in the US. Upon arrival at the Royal Infirmary, the patient was found to be
both MRSA and GRE-positive, and it was assumed that both had been acquired during
hospital treatment in the United States. However, studies showed that whilst the GRE
isolate was unique by PFGE analysis, it harboured a Tn/57(5-related element identical
to those predominating in Edinburgh hospitals (Tnl546 type B). The time-scale of
isolation made it unlikely that the GRE isolate was acquired by the patient following
transfer to the Royal Infirmary. It seems likely, therefore, that the isolate was not
actually acquired whilst in the US, but was of an endogenous origin, having been
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acquired previously either from a community source or during a previous hospital stay
in the Edinburgh region. Further studies support this hypothesis, suggesting that the
160-kb genetic element that carries Tn.1546 in the majority of nosocomial VanA E.
faecium in Edinburgh is also present in isolate RIE-30. The possibility that the same
Tn754<5-related elements prevalent amongst nosocomial GRE are also present in the
community setting was also suggested by the limited PCR analysis performed on the
two VanA GRE isolates from general practice specimens. One of these isolates was
found to harbour a Tn/54<5-related element with IS1542 and \S1216V-We insertions.
IS elements can have both positive and negative effects on the expression of
downstream genes. In general, IS elements are expected to exert a strong polar effect
on the downstream genes, with the simplest explanation being that the inserted
elements carry internal transcription terminators (Galas & Chandler, 1989). Thus it
could be expected that the expression of the vanY and vanZ genes, most likely co-
transcribed with the vanHAX genes situated upstream, would be disrupted by the
insertion of IS727<5E-like elements within the vanX-vanY intergenic region. This is
inconsistent, however, with the results of this study which showed that the level of
teicoplanin resistance is elevated, rather than lowered, in those isolates harbouring non-
prototype Tn/5¥d-related elements. The VanY enzyme assays were unable to establish
whether vanYwas still expressed. However, Willems et al. (1999) describe a deletion
within the vanY gene that was associated with reduced resistance to teicoplanin. They
proposed that the vanY deletion affects the transcription of the vanZ gene that is known
to confer teicoplanin resistance. Therefore, with disruption of the vanYZ genes being
associated with a decrease in teicoplanin resistance, it seems unlikely that the IS1216V-
like insertion is exerting any negative effect on the downstream genes.
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Activation of downstream genes has been observed for several IS elements, and is
generally due either to the presence of outwardly-directed promoters within the
element, or to the formation of new promoters (hybrid promoters) upon insertion. The
latter scenario is that displayed by IS1542 insertion within the orf2-vanR intergenic
region. IS1542 is just one ofmany IS elements that have potential outwardly-directed
-35 regions within their inverted repeat, and thus have the potential to form hybrid
promoters in conjunction with a -10 region situated just downstream of the insertion
site (Galas & Chandler, 1989). Transcription of antibiotic resistance genes from IS-
generated hybrid promoters has been described previously (Galas & Chandler, 1989),
although not within the van gene cluster. Whilst the results presented in this thesis are
the first description of an IS-generated hybrid promoter leading to expression of the van
genes, the potential for this to happen was first illustrated by Handwerger et al. (1995).
They described the IS1251 element within the vanS-vanH intergenic region and
identified a perfect -35 promoter consensus region (TTGACA) within the right inverted
repeat of the IS element. However, the orientation of the IS element was such that any
hybrid promoter would be formed at the 3' end of the vanS gene, in the opposite
direction to which the genes are transcribed. As the inverted repeats of IS1251 are
imperfect, no -35 region is present in the left inverted repeat that may have had the
potential to form a hybrid promoter upstream ofvanH. Examination of the sequence of
the ISi2ibF-like insertion within the vanX-vanY intergenic region failed to identify any
hybrid promoter that may have enhanced the expression of the vanY and vanZ genes.
Another possible explanation that was considered for the apparent association
between IS elements and an elevated resistance to teicoplanin was that the IS elements
(either IS1542 or the ISi27bF-like element) harboured a P-VanR binding site that
would enhance the expression of the downstream van resistance genes. Holman et al.
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(1994) identified a 12-bp sequence that was present in one copy at the vanR promoter
and in two copies at the vanH promoter. The sequence was located within the P-VanR
footprinted regions of the two promoters and was thus proposed as serving as a
consensus recognition site for P-VanR binding. Examination of the sequences of the
IS1542 and ISi2MF-like elements failed to identify any 12-bp sequence displaying
homology to that described by Holman et al.. Gel mobility shift experiments and
DNasel footprinting would be required to confirm this either way. It is, however,
unlikely that if the IS elements did harbour such a P-VanR binding site, that it would
have any effect on downstream gene expression, as the P-VanR binding site would
probably need to be associated with a promoter sequence.
The results presented in this thesis, therefore, suggest that IS1542, and not the
IS727bF-like element, exerts an effect on the downstream genes, by means of a hybrid
promoter that leads to constitutive expression of the downstream genes, albeit at a
lower level than that seen following induction. Figure 7.2 compares the sequence of
the native vanR promoter, the hybrid promoter and the consensus sequence of the
Escherichia coli 070 promoter.
Figure 7.2: Comparison of the native vanR, hybrid, and Escherichia coli (J70
promoter sequences
Native vanR promoter: TTATGT (21-bp) TATAAT
Hybrid promoter: TTTACA (20-bp) TATAAT
Escherichia coli <r7o promoter: TTGACA (17-bp) TATAAT
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The sequence of the hybrid promoter matches that of the Escherichia coli 0-70
promoter more closely than the native vanR promoter and may, therefore, be considered
to be a stronger promoter. However, direct comparison of the two promoters (native
vanR and hybrid) on the basis of their sequences is not actually possible, due to the
influence ofP-VanR binding. When the vanR promoter was identified, it was initially
proposed that P-VanR binding at the promoter had a negative effect, as the binding site
overlapped the -35 region of the promoter (Holman et al., 1994). If this were indeed
the case, it would have helped to explain the enhanced gene expression that appears to
follow IS1542 insertion. The hybrid promoter would be distanced from the P-VanR
binding site by the IS1542 insertion, and thus be free from any inhibition. However,
subsequent studies have shown that P-VanR binding has a positive effect on the vanR
promoter (Arthur et al., 1997), and that it essentially acts as a catalyst for gene
expression from the vanR promoter, replacing the -35 region of the promoter. As the
-35 region of the native promoter is thus largely obsolete, no conclusions can be drawn
on the comparative strengths of the native and hybrid promoters solely on the basis of
their sequences, as they differ solely in their -35 region.
It remains to be explained why constitutive expression of the van genes from the
hybrid promoter formed by IS1542 insertion manifests itself as elevated teicoplanin
resistance, and why this is particularly apparent on rich media such as BHI. The fact
that this phenomenon has not been witnessed previously, despite similar studies
identifying similar transposon types to those described here, is most likely due to the
fact that the elevation in resistance is not prominent when susceptibility tests are
performed on standard, NCCLS-approved media such as ISTA orMHA.
Arthur et al. (1996a) described a gradual increase in vancomycin resistance levels
when the proportion of D-Ala-D-Ala-terminating precursors within the cell wall
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decreased from 43% to 2%, but a more complete elimination of such precursors was
required in order to achieve high-level teicoplanin resistance. Such differing abilities
of the two glycopeptides to act against residual D-Ala-D-Ala-terminating precursors
may offer some explanation for the elevation in teicoplanin resistance but not
vancomycin resistance. Significant constitutive expression of the van genes, mediated
by the IS/542-generated hybrid promoter in the absence of induction, would be
expected to lower the proportion ofD-Ala-D-Ala-terminating precursors within the cell
wall. With expression from the native vanR promoter then adding to that from the
hybrid promoter following induction, the removal of D-Ala-D-Ala-terminating
precursors may be more rapid and complete, given the already reduced levels present
within the cell wall. Analysis of the levels of the various cell wall precursors with and
without induction in strains with prototype and non-prototype Tn/546-related elements
would be required to confirm this hypothesis.
7.5 Conclusions
The results presented in this thesis have demonstrated a heterogeneous GRE
population within Scottish hospitals. Amongst the clinical nosocomial isolates, the
predominant glycopeptide resistance phenotype is VanA, with the majority being E.
faecium. PFGE analysis of the nosocomial isolates revealed an outbreak strain of
VanA E. faecium that was responsible for an outbreak within the renal unit of the Royal
Infirmary of Edinburgh in 1995. The same outbreak strain was identified in three
isolates from two other hospitals in the Edinburgh/Borders region, suggesting
interhospital spread. Discounting this outbreak strain, PFGE analysis revealed a
diverse set ofGRE isolates, with only small clusters of related isolates being identified.
PFGE analysis performed on a collection of glycopeptide-sensitive enterococcal
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isolates from hospital and general practice sources also revealed a diverse set of
isolates. Notably, however, at least one GSE strain appeared to be endemic within the
Royal Infirmary of Edinburgh, and many strains were found in both the hospital and
community settings. In addition, the two predominant strains of GSE identified were
closely related to GRE strains that were part of the outbreak in 1995, and may have
arisen from these GRE strains losing their glycopeptide resistance.
A common transferable genetic element was identified in the majority of VanA E.
faecium isolates on the basis of conjugation experiments, PFGE analysis and
hybridization studies. Whilst attempts at plasmid extraction were largely unsuccessful,
the combination ofPFGE analysis and hybridization studies suggested the element was,
indeed, a large plasmid ofapproximately 160-kb.
Tni54b-related elements within the VanA isolates studied showed the same degree
and types of variation as described previously. The majority of isolates harboured non-
prototype Tn1546 elements that contained IS1542 and an lS1216V-\ike insertion within
the orf2-vanR and vanX-vanY intergenic regions respectively. These same Tn1546-
related elements had substantial variation within the orfllorfl region of the VanA
transposon. Whilst the exact nature of this variation was not ascertained, it was at least
partly due to the insertion of an IS72/bF-like element that was accompanied by
deletions. Varying geographical distribution of Tn1546 types was described, as was
instability of Tn1546 variation, both within clonally-related isolates and in isolates
during prolonged cold storage. Despite this instability, the value of Tn1546 typing as
an epidemiology tool in localized studies was highlighted.
A hybrid promoter within non-prototype Tn/54<5-related elements was identified,
being generated by the insertion of IS1542 at nucleotide position 3932. The hybrid
promoter supplements, rather than replaces, the native vanR promoter, and leads to
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moderate-level constitutive expression of the van resistance genes, as demonstrated by
VanX activity in the absence of induction. The presence of this hybrid promoter and
constitutive expression of the van genes is associated with elevated teicoplanin
resistance, although the elevated resistance is, to an extent, media-dependent. The
mechanism behind the elevation in teicoplanin resistance is unclear, but may be due to
the more rapid and complete elimination of D-Ala-D-Ala-terminating cell wall








Aarestrup, F. M. 1995. Occurrence of glycopeptide resistance among Enterococcus
faecium isolates from conventional and ecological poultry farms. Microbial Drug
Resistance - Mechanisms, Epidemiology andDisease 1, 255-257.
Aarestrup, F. M., Ahrens, P., Madsen, M., Pallesen, L. V., Poulsen, R. L., & Westh,
H. 1996. Glycopeptide susceptibility among Danish Enterococcus faecium and
Enterococcus faecalis isolates of animal and human origin and PCR identification of
genes within the vanA cluster. Antimicrobial Agents and Chemotherapy 40, 1938-
1940.
Aarestrup, F. M., Emborg, H. D., Madsen, M., & Seyfarth, A. M. 2000.
Surveillance of antimicrobial resistance among enterococci from food animals in
Denmark, 1995-1999, abstr. 86. In Program and Abstracts of the 1st International
ASM Conference on Enterococci: Pathogenesis, Biology and Antibiotic Resistance.
American Society for Microbiology, Washington, D.C.
Abadia Patino, L., Reynolds, P., Fines, M., Courvalin, P., & Perichon, B. 2000.
Genetic organization of the vanE operon responsible for vancomycin resistance in
Enterococcus faecalis BM4405, abstr. 87. In Program and Abstracts of the 1st
International ASM Conference on Enterococci: Pathogenesis, Biology and Antibiotic
Resistance. American Society for Microbiology, Washington, D.C.
Arduino, R. C., Murray, B. E., & Rakita, R. M. 1994. Roles of antibodies and
complement in phagocytic killing of enterococci. Infection and Immunity 62, 987-
993.
Arthur, M., Depardieu, F., Gerbaud, G., Galimand, M., Leclercq, R., & Courvalin, P.
1997. The VanS sensor negatively controls VanR-mediated transcriptional
activation of glycopeptide resistance genes of Till546 and related elements in the
absence of induction. Journal ofBacteriology 179, 97-106.
Arthur, M., Depardieu, F., Molinas, C., Reynolds, P., & Courvalin, P. 1995. The
vanZ gene of Til/546 from Enterococcus faecium BM4147 confers resistance to
teicoplanin. Gene 154, 87-92.
202
Bibliography
Arthur, M., Depardieu, F., Reynolds, P., & Courvalin, P. 1996a. Quantitative
analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of
glycopeptide-resistant enterococci. Molecular Microbiology 21, 33-44.
Arthur, M., Depardieu, F., Snaith, H. A., Reynolds, P. E., & Courvalin, P. 1994.
Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in
Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrobial
Agents and Chemotherapy 38, 1899-1903.
Arthur, M., Molinas, C., Bugg, T. D. H., Wright, G. D., Walsh, C. T., & Courvalin,
P. 1992a. Evidence for in vivo incorporation of D-lactate into peptidoglycan
precursors of vancomycin-resistant enterococci. Antimicrobial Agents and
Chemotherapy 36, 867-869.
Arthur, M., Molinas, C., & Courvalin, P. 1992b. Sequence of the vanY gene
required for production of a vancomycin-inducible D,D-carboxypeptidase in
Enterococcusfaecium BM4147. Gene 120, 111-114.
Arthur, M., Molinas, C., & Courvalin, P. 1992c. The VanS-VanR two-component
regulatory system controls synthesis of depsipeptide peptidoglycan precursors in
Enterococcus faecium BM4147. Journal ofBacteriology 174, 2582-2591.
Arthur, M., Molinas, C., Depardieu, F., & Courvalin, P. 1993. Characterization of
Tnl546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of
depsipeptide peptidoglycan precursors in Enterococcus faecalis BM4147. Journal of
Bacteriology 175, 117-127.
Arthur, M., Molinas, C., Dutka-Malen, S., & Courvalin, P. 1991. Structural
relationship between the vancomycin resistance protein VanH and 2-
hydroxycarboxylic acid dehydrogenases. Gene 103, 133-134.
Arthur, M., Reynolds, P., & Courvalin, P. 1996b. Glycopeptide resistance in
enterococci. Trends in Microbiology 4, 401-407.
Basinger, S. F. & Jackson, R. W. 1968. Bacteriocin (hemolysin) of Streptococcus
zymogenes. Journal ofBacteriology 96,1895-1902.
203
Bibliography
Bates, J., Jordens, J. Z., & Griffiths, D. T. 1994. Farm animals as a putative
reservoir for vancomycin-resistant enterococcal infection in man. Journal of
Antimicrobial Chemotherapy 34, 507-514.
Bates, J., Jordens, Z., & Selkon, J. B. 1993. Evidence for an animal origin of
vancomycin-resistant enterococci. LancetMl, 490-491.
Bentorcha, F., Clermont, D., Decespedes, G., & Horaud, T. 1992. Natural
occurrence of structures in oral streptococci and enterococci with DNA homology to
Tn916. Antimicrobial Agents and Chemotherapy 36, 59-63.
Bentorcha, F., Decespedes, G., & Horaud, T. 1991. Tetracycline resistance
heterogeneity in Enterococcus faecium. Antimicrobial Agents and Chemotherapy 35,
808-812.
Bergeron, J., Ammirati, M., Danley, D., James, L., Norcia, M., Retsema, J., Strick,
C. A., Su, W. G., Sutcliffe, J., & Wondrack, L. 1996. Glycylcyclines bind to the
high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-
mediated ribosomal protection. Antimicrobial Agents and Chemotherapy 40, 2226-
2228.
Besnier, J. M., Guerout, T., Mion, P., Choutet, P., & Leport, C. 1994. Current
aspects of enterococcal endocarditis. Medecine et Maladies Infectieuses 24, 177-
190.
Bhakdi, S., Klonisch, T., Nuber, P., & Fischer, W. 1991. Stimulation ofmonokine
production by lipoteichoic acids. Infection and Immunity 59, 4614-4620.
Birnboim, H. C. 1983. A rapid alkaline extraction method for the isolation of
plasmid DNA. Methods in Enzymology. 100, 243-255.
Bonner, J. 1997. Hooked on drugs. New Scientist 153,24-27.
Bopp, L. H., Schoonmaker, D. J., Baltch, A. L., Smith, R. P., & Ritz, W. J. 1999.
Molecular epidemiology of vancomycin-resistant enterococci from 6 hospitals in
New York State. American Journal ofInfection Control 27, 411-417.
204
Bibliography
Bouanchard, D. H., Scavizzi, M. R., & Chabbert, Y. A. 1969. Elimination by
ethidium bromide of antibiotic resistance in Enterobacteriae and Staphylococci.
Journal ofGeneralMicrobiology 54, 417-425.
Bozdogan, B., Berrezouga, L., Kuo, M. S., Yurek, D. A., Farley, K. A., Stockman, B.
J., & Leclercq, R. 1999. A new resistance gene, linB, conferring resistance to
lincosamides by nucleotidylation in Enterococcus faecium HM1025. Antimicrobial
Agents and Chemotherapy 43, 925-929.
British Society for Antimicrobial Chemotherapy Working Party. 1991. A guide to
sensitivity testing. Journal ofAntimicrobial Chemotherapy 21 (Suppl. D), 1-50.
Brook, I. 1988. Effect of Streptococcus faecalis on the growth of Bacteroides
species and anaerobic cocci in mixed infection. Surgery 103, 107-110.
Brown, T. 1993. Analysis ofDNA sequences by blotting and hybridisation. In F.
M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith & K.
Struhl (eds.) Current Protocols in Molecular Biology, vol. 1. John Wiley and Sons,
Inc..
Brown, A. R., Amyes, S. G. B., Paton, R., Plant, W. D., Stevenson, G. M., Winney,
R. J., & Miles, R. S. 1998. Epidemiology and control of vancomycin-resistant
enterococci (VRE) in a renal unit. Journal ofHospital Infection 40, 115-124.
Bugg, T. D. H., Dutka-Malen, S., Arthur, M., Courvalin, P., & Walsh, C. T. 1991b.
Identification of vancomycin resistance protein VanA as a D-Alanine-D-Alanine
ligase ofaltered substrate specificity. Biochemistry 30, 2017-2021.
Bugg, T. D. H., Wright, G. D., Dutka-Malen, S., Arthur, M., Courvalin, P., & Walsh,
C. T. 1991a. Molecular basis for vancomycin resistance in Enterococcus faecium
BM4147 - biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin
resistance proteins VanH and VanA. Biochemistry 30, 10408-10415.
Bush, L. M., Calmon, J., Cherney, C. L., Wendeler, M., Pitsakis, P., Poupard, J.,
Levison, M. E., & Johnson, C. C. 1989. High-level penicillin resistance among
205
Bibliography
isolates of enterococci - implications for treatment of enterococcal infections.
Annals ofInternal Medicine 110, 515-520.
Carias, L. L., Rudin, S. D., Donskey, C. J., & Rice, L. B. 1998. Genetic linkage and
co-transfer of a novel, v<m5-containing transposon (Tn5382) and a low-affinity
penicillin binding protein 5 gene in a clinical vancomycin-resistant Enterococcus
faecium isolate. Journal ofBacteriology 180, 4426-4434.
Carlier, C. & Courvalin, P. 1990. Emergence of 4',4"-aminoglycoside
nucleotidyltransferase in enterococci. Antimicrobial Agents and Chemotherapy 34,
1565-1569.
Casadewall, B. & Courvalin, P. 1999. Characterization of the vanD glycopeptide
resistance gene cluster from Enterococcus faecium BM4339, abstr. 1452. In
Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents
and Chemotherapy. American Society for Microbiology, Washington, D.C..
CDC. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin -
United States, 1997. Morbidity andMortality Weekly Report 46, 765-766.
Chadwick, P. R., Oppenheim, B. A., Fox, A., Woodford, N., Morgenstern, G. R., &
Scarffe, J. H. 1996. Epidemiology of an outbreak due to glycopeptide-resistant
Enterococcus faecium on a leukaemia unit. Journal ofHospital Infection 34, 171-
182.
Charpentier, E., Gerbaud, G., & Courvalin, P. 1994. Presence of the Listeria
tetracycline resistance gene tet{S) in Enterococcus faecalis. Antimicrobial Agents
and Chemotherapy 38, 2330-2335.
Chen, H. W. 1986. Resistance of enterococci to antibiotic combinations. Journal of
Antimicrobial Chemotherapy 18, 1-8.
Chenoweth, C. E., Robinson, K. A., & Schaberg, D. R. 1990. Efficacy ofampicillin
versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal
peritonitis. AntimicrobialAgents and Chemotherapy 34, 1800-1802.
206
Bibliography
Chow, J. W. 2000. Aminoglycoside resistance in enterococci. Clinical Infectious
Diseases 31, 586-589.
Chow, J. W., Davidson, A., Sanford, E., & Zervos, M. J. 1997b. Superinfection with
Enterococcus faecalis during quinupristin/dalfopristin therapy. Clinical Infectious
Diseases 24, 91-92.
Chow, J. W., Donabedian, S. M., & Zervos, M. J. 1997c. Emergence of increased
resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium
bacteremia. Clinical Infectious Diseases 24, 90-91.
Chow, J. W., Thai, L. A., Perri, M. B., Vazquez, J. A., EJonabedian, S. M., Clewell,
D. B., & Zervos, M. J. 1993. Plasmid-associated hemolysin and aggregation
substance production contribute to virulence in experimental enterococcal
endocarditis. AntimicrobialAgents and Chemotherapy 37, 2474-2477.
Chow, J. W., Zervos, M. J., Lerner, S. A., Thai, L. A., Donabedian, S. M., Jaworski,
D. D., Tsai, S., Shaw, K. J., & Clewell, D. B. 1997a. A novel gentamicin resistance
gene in Enterococcus. Antimicrobial Agents and Chemotherapy 41, 511-514.
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. 1993.
Characterization of glycopeptide-resistant enterococci from U.S. hospitals.
Antimicrobial Agents and Chemotherapy 37, 2311 -2317.
Clewell, D. B. 1981. Plasmids, drug-resistance, and gene-transfer in the genus
Streptococcus. Microbiological Reviews 45, 409-436.
Clewell, D. B. & Gawronburke, C. 1986. Conjugative transposons and the
dissemination of antibiotic resistance in streptococci. Annual Review of
Microbiology 40, 635-659.
Coates, M. E., Fuller, R., Harison, G. F. et al. 1963. A comparison of the growth of
chickens in Gustafsson germ-free apparatus and in a conventional environment, with




Cohen, M. A., Yoder, S. L., Huband, M. D., Roland, G. E., & Courtney, C. L. 1995.
In vitro and in vivo activities of clinafloxacin, CI-990 (PD-131112), and PD-138312
versus enterococci. Antimicrobial Agents and Chemotherapy 39, 2123-2127.
Cohen, M. L. 1992. Epidemiology of drug-resistance - implications for a post-
antimicrobial era. Science 257, 1050-1055.
Collins, L. A., Malanoski, G. J., Eliopoulos, G. M., Wennerstein, C. B., Ferraro, M.
J., & Moellering, R. C. 1993. In vitro activity of RP59500, an injectable
streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Antimicrobial Agents and Chemotherapy 37, 598-601.
Collins, M. D., Facklam, R. R., Farrow, J. A. E., & Williamson, R. 1989.
Enterococcus raffinosus sp. nov, Enterococcus solitarius sp. nov and Enterococcus
pseudoavium sp. nov. FEMSMicrobiology Letters 57, 283-288.
Collins, M. D., Farrow, J. A. E., & Jones, D. 1986. Enterococcus mundtii sp. nov.
International Journal ofSystematic Bacteriology 36, 8-12.
Collins, M. D., Jones, D., Farrow, J. A. E., Kilpper-Balz, R., & Schleifer, K. H.
1984. Enterococcus avium nom rev, comb nov - Enterococcus casseliflavus nom
rev, comb nov - Enterococcus durans nom rev, comb nov - Enterococcus gallinarum
comb nov - and Enterococcus malodoratus sp. nov. International Journal of
Systematic Bacteriology 34, 220-223.
Collins, M. D., Rodrigues, U. M., Pigott, N. E., & Facklam, R. R. 1991.
Enterococcus dispar sp. nov - a new Enterococcus species from human sources.
Letters in AppliedMicrobiology 12, 95-98.
Collins, M. D., Williams, A. M., & Wallbanks, S. 1990. The phylogeny of
Aerococcus and Pediococcus as determined by 16S ribosomal-RNA sequence
analysis - description of Tetragenococcus gen. nov. FEMSMicrobiology Letters 70,
255-262.
Coque, T. M., Patterson, J. E., Steckelberg, J. M., & Murray, B. E. 1995. Incidence
ofhemolysin, gelatinase, and aggregation substance among enterococci isolated from
208
Bibliography
patients with endocarditis and other infections and from feces of hospitalized and
community-based persons. Journal of Infectious Diseases 171, 1223-1229.
Coque, T. M., Singh, K. V., Weinstock, G. M., & Murray, B. E. 1999.
Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and
trimethoprim-resistant strains of Enterococcus faecalis. Antimicrobial Agents and
Chemotherapy 43, 141-147.
Coque, T. M., Tomayko, J. F., Ricke, S. C., Okhyusen, P. C., & Murray, B. E. 1996.
Vancomycin-resistant enterococci from nosocomial, community, and animal sources
in the United States. AntimicrobialAgents and Chemotherapy 40, 2605-2609.
Crosa, J. H., Tomalsky, M. E., Actis, L. A., & Falkow, S. 1994. Plasmids. pp. 365-
386. In P. Gerhardt, R. G. E. Murray, W. A. Wood & N. R. Krieg (eds.) Methods for
General and Molecular Bacteriology. American Society for Microbiology,
Washington, D.C.,.
Darini, A. L. C., Palepou, M-F. I., James, D., & Woodford, N. 1999b. Disruption of
vanS by IS1216V in a clinical isolate of Enterococcus faecium with VanA
glycopeptide resistance. Antimicrobial Agents and Chemotherapy 43, 995-996.
Darini, A. L. C., Palepou, M-F. I., & Woodford, N. 1999. Nucleotide sequence of
IS/542, an insertion sequence identified within VanA glycopeptide resistance
elements of enterococci. FEMSMicrobiology Letters 173, 341-346.
Darini, A. L. C., Palepou, M-F. I., & Woodford, N. 2000. Effects of the movement
of insertion sequences on the structure ofVanA glycopeptide resistance elements in
Enterococcusfaecium. Antimicrobial Agents and Chemotherapy 44,1362-1364.
Descheemaeker, P. R. M., Chapelle, S., Devriese, L. A., Butaye, P., Vandamme, P.,
& Goossens, H. 1999. Comparison of glycopeptide-resistant Enterococcus faecium
isolates and glycopeptide resistance genes of human and animal origins.
AntimicrobialAgents and Chemotherapy 43, 2032-2037.
209
Bibliography
Devriese, L. A., Ceyssens, K., Rodrigues, U. M., & Collins, M. D. 1990.
Enterococcus columbae, a species from pigeon intestines. FEMS Microbiology
Letters 71, 247-252.
Devriese, L. A., Ieven, M., Goossens, H., Vandamme, P., Pot, B., Hommez, J., &
Haesebrouck, F. 1996. Presence of vancomycin-resistant enterococci in farm and
pet animals. AntimicrobialAgents and Chemotherapy 40, 2285-2287.
Devriese, L. A., Pot, B., & Collins, M. D. 1993. Phenotypic identification of the
genus Enterococcus and differentiation of phylogenetically distinct enterococcal
species and species groups. Journal ofAppliedBacteriology 75, 399-408.
Dunne, W. M. J., Dunne, B. S., & Smith, D. 1996. Watch out where the huskies go.
ASMNews 62, 283-283.
Dunny, G. M., Leonard, B. A. B., & Hedberg, P. J. 1995. Pheromone-inducible
conjugation in Enterococcus faecalis - interbacterial and host-parasite chemical
communication. Journal ofBacteriology 177, 871-876.
Dupont, H., Montravers, P., Mohler, J., & Carbon, C. 1998. Disparate findings on
the role of virulence factors of Enterococcus faecalis in mouse and rat models of
peritonitis. Infection and Immunity 66, 2570-2575.
Dutka-Malen, S., Evers, S., & Courvalin, P. 1995. Detection of glycopeptide
resistance genotypes and identification to the species level of clinically relevant
enterococci by PCR. Journal ofClinicalMicrobiology 33, 24-27.
Dutka-Malen, S., Leclercq, R., Coutant, V., Duval, J., & Courvalin, P. 1990a.
Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in
Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 34, 1875-1879.
Dutka-Malen, S., Molinas, C., Arthur, M., & Courvalin, P. 1990b. The VanA
glycopeptide resistance protein is related to D-alanyl-D-alanine ligase cell-wall
biosynthesis enzymes. Molecular & General Genetics 224, 364-372.
210
Bibliography
Dutka-Malen, S., Molinas, C., Arthur, M., & Courvalin, P. 1992. Sequence of the
vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanyl-D-alanine
ligase-related protein necessary for vancomycin resistance. Gene 112, 53-58.
Edmond, M. B., Ober, J. F., Weinbaum, D. L., Pfaller, M. A., Hwang, T., Sanford,
M. D., & Wenzel, R. P. 1995. Vancomycin-resistant Enterococcus faecium
bacteremia - risk factors for infection. Clinical Infectious Diseases 20, 1126-1133.
El-Amin, N., Jalal, S., & Wretlind, B. 1999. Alterations in GyrA and ParC
associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrobial
Agents and Chemotherapy 43, 947-949.
Eldar, A., Ghittino, C., Asanta, L., Bozzetta, E., Goria, M., Prearo, M., & Bercovier,
H. 1996. Enterococcus seriolicida is a junior synonym of Lactococcus garvieae, a
causative agent of septicemia and meningoencephalitis in fish. Current
Microbiology 32, 85-88.
Eliopoulos, G. M., Farber, B. F., Murray, B. E., Wennersten, C., & Moellering, R. C.
1984. Ribosomal resistance of clinical enterococcal isolates to streptomycin.
AntimicrobialAgents and Chemotherapy 25, 398-399.
Eliopoulos, G. M., Wennersten, C., & Moellering, R. C. 1982. Resistance to beta-
lactam antibiotics in Streptococcus faecium. Antimicrobial Agents and
Chemotherapy 22, 295-301.
Eliopoulos, G. M., Wennersten, C. B., Cole, G., & Moellering, R. C. 1994. In vitro
activities of 2 glycylcyclines against Gram-positive bacteria. Antimicrobial Agents
and Chemotherapy 38, 534-541.
Ember, J. A. & Hugh, T. E. 1989. Characterization of the human neutrophil
response to sex-pheromones from Streptococcus faecalis. American Journal of
Pathology 134, 797-805.
Emborg, H. D., Tornoe, N., Heuer, O. E., & Madsen, M. 1999. The effect of
discontinued use of antimicrobial growth promoters in broilers, abstr. 712. In
211
Bibliography
Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents
and Chemotherapy. American Society for Microbiology, Washington, D.C.
Evers, S. & Courvalin, P. 1996. Regulation of VanB-type vancomycin resistance
gene expression by the VanS(B)-VanR(B) two-component regulatory system in
Enterococcusfaecalis V583. Journal ofBacteriology 178, 1302-1309.
Evers, S., Quintiliani, R., & Courvalin, P. 1996. Genetics of glycopeptide resistance
in enterococci. Microbial Drug Resistance - Mechanisms, Epidemiology and Disease
2, 219-223.
Evers, S., Reynolds, P. E., & Courvalin, P. 1994. Sequence of the vanB and ddl
genes encoding D-alanine-D-lactate and D-alanine-D-alanine ligases in vancomycin-
resistant Enterococcus faecalis V583. Gene 140, 97-102.
Facklam, R., Hollis, D., & Collins, M. D. 1989. Identification of Gram-positive
coccal and coccobacillary vancomycin-resistant bacteria. Journal of Clinical
Microbiology 27, 724-730.
Facklam, R. R. & Collins, M. D. 1989. Identification of Enterococcus species
isolated from human infections by a conventional test scheme. Journal of Clinical
Microbiology 21 731-734.
Farrag, N., Eltringham, I., & Liddy, H. 1996. Vancomycin-dependent Enterococcus
faecalis. Lancet 348, 1581-1582.
Farrow, J. A. E. & Collins, M. D. 1985. Enterococcus hirae, a new species that
includes amino-acid assay strain NCDO-1258 and strains causing growth depression
in young chickens. International Journal ofSystematic Bacteriology 35, 73-75.
Felmingham, D., Wilson, A. P. R., Quintana, A. I., & Gruneberg, R. N. 1992.
Enterococcus species in urinary-tract infection. Clinical Infectious Diseases 15, 295-
301.
Ferguson, J. (Division of Microbiology and Infectious Diseases, Hunter Area
Pathology Service, Newcastle, Australia). 2000. Personal communication.
212
Bibliography
Fernandez-Guerrero, M. L., Barros, C., Tudela, J. L. R, roblas, R. F., & soriano, F.
1988. Aortic endocarditis caused by gentamicin-resistant Enterococcus faecalis.
European Journal ofClinical Microbiology & Infectious Diseases 7, 525-527.
Ferretti, J. J., Gilmore, K. S., & Courvalin, P. 1986. Nucleotide-sequence analysis
of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2"-
aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and
identification and cloning of gene regions specifying the 2 activities. Journal of
Bacteriology 167, 631-638.
Fines, M., Perichon, B., Reynolds, P., Sahm, D. F., & Courvalin, P. 1999. VanE, a
new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405.
AntimicrobialAgents and Chemotherapy 43, 2161-2164.
Fontana, R., Boaretti, M., Grossato, A., Tonin, E. A., Lleo, M. M., & Satta, G. 1990.
Paradoxical response of Enterococcus faecalis to the bactericidal activity of
penicillin is associated with reduced activity of one autolysin. Antimicrobial Agents
and Chemotherapy 34, 314-320.
Fontana, R., Ligozzi, M., Pittaluga, F., & Satta, G. 1996. Intrinsic penicillin
resistance in enterococci. Microbial Drug Resistance-Mechanisms Epidemiology
andDisease 2, 209-213.
Fraimow, H. S., Jungkind, D. L., Lander, D. W., Delso, D. R., & Dean, J. L. 1994.
Urinary-tract infection with an Enterococcus faecalis isolate that requires
vancomycin for growth. Annals ofInternal Medicine 121, 22-26.
Franke, A. E. & Clewell, D. B. 1981. Evidence for a chromosome-borne resistance
transposon (Tn916) in Streptococcus faecalis that is capable of conjugal transfer in
the absence of a conjugative plasmid. Journal ofBacteriology 145,494-502.
French, G., Abdulla, Y., Heathcock, R., Poston, S., & Cameron, J. 1992.
Vancomycin resistance in south London. Lancet 339, 818-819.
Fukushima, J., Yamamoto, S., Morihara, K., Atsumi, Y., Takeuchi, H., Kawamoto,
S., & Okuda, K. 1989. Structural gene and complete amino-acid sequence of
213
Bibliography
Pseudomonas aeruginosa IFO-3455 elastase. Journal of Bacteriology 171, 1698-
1704.
Galas, D. J. & Chandler, M. 1989. Bacterial Insertion Sequences, pp. 109-162 In D.
E. Berg & M. M. Howe (eds.) Mobile DNA. American Society for Microbiology,
Washington, D.C.
Gilpin, M. L. & Milner, P. H. 1997. Resisting Changes, http://www.chemsoc.org/
chembytes/ezine/1997/resist.htm
Gootz, T. D. & Brighty, K. E. 1996. Fluoroquinolone antibacterials: SAR,
mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews
16, 433-486.
Graninger, W. & Ragette, R. 1992. Nosocomial bacteremia due to Enterococcus
faecalis without endocarditis. Clinical Infectious Diseases 15, 49-57.
Gray, J. W. & Pedler, S. J. 1992. Antibiotic-resistant enterococci. Journal of
Hospital Infection 21, 1-14.
Grayson, M. L., Thauvin-Eliopoulos, C., Eliopoulos, G. M., Yao, J. D. C., Deangelis,
D. V., Walton, L., Woolley, J. L., & Moellering, R. C. 1990. Failure of
trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis.
AntimicrobialAgents and Chemotherapy 34, 1792-1794.
Greenwood, D. 1988. Microbiological properties of teicoplanin. Journal of
Antimicrobial Chemotherapy 21, 1-13.
Guzman, C. A., Pruzzo, C., Lipira, G., & Calegari, L. 1989. Role of adherence in
pathogenesis of Enterococcus faecalis urinary-tract infection and endocarditis.
Infection and Immunity 57, 1834-1838.
Guzman, C. A., Pruzzo, C., Plate, M., Guardati, M. C., & Calegari, L. 1991. Serum-
dependent expression ofEnterococcus faecalis adhesins involved in the colonization
ofheart cells. Microbial Pathogenesis 11, 399-409.
214
Bibliography
Haldimann, A., Fisher, S. L., Daniels, L. L., Walsh, C. T., & Wanner, B. L. 1997.
Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin
resistance gene cluster by the VanS-VanR two-component regulatory system in
Escherichia coli K-12. Journal ofBacteriology 179, 5903-5913
Hamilton-Miller, J. M. T. & Purves, D. 1986. Enterococci and antifolate antibiotics.
European Journal ofClinical Microbiology & Infectious Diseases 5, 391-394.
Hanaki, H., KuwaharaArai, K., Boyle-Vavra, S., Daum, R. S., Labischinski, H., &
Hiramatsu, K. 1998. Activated cell-wall synthesis is associated with vancomycin
resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and
Mu50. Journal ofAntimicrobial Chemotherapy 42, 199-209
Hancock, L. E. & Gilmore, M. S. 2000. Pathogenicity of enterococci. In V.
Fischetti, R. Novick, J. Ferretti, D. Portnoy & J. Rood (eds.) Gram-positive
pathogens. American Society for Microbiology, Washington, D.C.
Handwerger, S., Pucci, M. J., Volk, K. J., Liu, J. P., & Lee, M. S. 1992. The
cytoplasmic peptidoglycan precursor of vancomycin-resistant Enterococcus faecalis
terminates in lactate. Journal ofBacteriology 174, 5982-5984.
Handwerger, S., Raucher, B., Altarac, D., Monka, J., Marchione, S., Singh, K. V.,
Murray, B. E., Wolff, J., & Walters, B. 1993. Nosocomial outbreak due to
Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.
Clinical Infectious Diseases 16, 750-755.
Handwerger, S. & Skoble, J. 1995. Identification of chromosomal mobile element
conferring high-level vancomycin resistance in Enterococcusfaecium. Antimicrobial
Agents and Chemotherapy 39, 2446-2453.
Handwerger, S., Skoble, J., Discotto, L. F., & Pucci, M. J. 1995. Heterogeneity of
the vanA gene cluster in clinical isolates of enterococci from the north-eastern United
States. AntimicrobialAgents and Chemotherapy 39, 362-368.
Hase, C. C. & Finkelstein, R. A. 1993. Bacterial extracellular zinc-containing
metalloproteases. Microbiological Reviews 57, 823-837.
215
Bibliography
Hayden, M. K., Trenholme, G. M., Schultz, J. E., & Sahm, D. F. 1993. In vivo
development of teicoplanin resistance in a VanB Enterococcus faecium isolate.
Journal ofInfectious Diseases 167, 1224-1227.
Heaton, M. P. & Handwerger, S. 1995. Conjugative mobilization of a vancomycin
resistance plasmid by a putative Enterococcus faecium sex pheromone response
plasmid. Microbial Drug Resistance - Mechanisms Epidemiology and Disease 1,
177-183.
Heilig, J. S., Elbing, K. L., & Brent, R. 1998. Large-scale preparations of plasmid
DNA. pp. 1.7.1-1.7.16. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J.
G. Seidman, J. A. Smith & K. Struhl (eds.) Current Protocols in Molecular Biology,
vol. 1. John Wiley and Sons, Inc.
Hewitt, W. L., Seligman, S. J., & Deigh, R. A. 1966. Kinetics of the synergism of
penicillin-streptomycin and penicillin-kanamycin for enterococci and its relationship
to L-phase variants. Journal ofLaboratory and ClinicalMedicine 67, 792-807.
Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., & Tenover, F. C. 1997.
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin
susceptibility. Journal ofAntimicrobial Chemotherapy 40, 135-146.
Hite, K. E., Locke, M., & Hesseltine, H. C. 1949. Synergism in experimental
infections with non-sporulating anaerobic bacteria. Journal ofInfectious Diseases 84,
1-9.
HMSO. 1969. Joint Committee on the Use ofAntibiotics in Animal Husbandry and
Veterinary Medicine. HMSO, London.
Hodges, T. L., Zighelboimdaum, S., Eliopoulos, G. M., Wennersten, C., &
Moellering, R. C. 1992. Antimicrobial susceptibility changes in Enterococcus




Holman, T. R, Wu, Z., Wanner, B. L., & Walsh, C. T. 1994. Identification of the
DNA-binding site for the phosphorylated VanR protein required for vancomycin
resistance in Enterococcus faecium. Biochemistry 33, 4625-4631.
Horodniceanu, T., Bougueleret, L., El-Sohl, N., Bieth, G., & Delbos, F. 1979. High-
level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp.
zymogenes. AntimicrobialAgents and Chemotherapy 16, 686-689.
Howarth, F. & Poulter, D. 1996. Vancomycin resistance: time to ban avoparcin?
Lancet 347, 1047.
Howe, R. A., Bowker, K. E., Walsh, T. R, Feest, T. G., & MacGowan, A. P. 1998.
Vancomycin-resistant Staphylococcus aureus. Lancet 351, 602-602.
Huycke, M. M., Sahm, D. F., & Gilmore, M. S. 1998. Multiple-drug resistant
enterococci: the nature of the problem and an agenda for the future. Emerging
Infectious Diseases 4, 239-249.
Ike, Y., Hashimoto, H., & Clewell, D. B. 1984. Hemolysin ofStreptococcus faecalis
subspecies zymogenes contributes to virulence in mice. Infection and Immunity 45,
528-530.
Ike, Y., Hashimoto, H., & Clewell, D. B. 1987. High-incidence of hemolysin
production by Enterococcus (,Streptococcus) faecalis strains associated with human
parenteral infections. Journal ofClinical Microbiology 25, 1524-1528.
Iwen, P. C., Kelly, D. M., Linder, J., Hinrichs, S. H., Dominguez, E. A., Rupp, M. E.,
& Patil, K. D. 1997. Change in prevalence and antibiotic resistance ofEnterococcus
species isolated from blood cultures over an 8-year period. Antimicrobial Agents and
Chemotherapy 41, 494-495.
Jacob, A. F. & Hobbs, S. J. 1974. Conjugal transfer of plasmid-borne multiple




Jarvis, W. R., Gaynes, R. P., Horan, T. C., Emori, T. G., Archibald, L. K., Fridkin, S.
K., Richards, M. J., Stroud, L. A., Culver, D. H., Edwards, J. R., Henderson, T. S.,
Tolson, J. S., Peavy, G. E., & Abshire, J. P. 1997. National Nosocomial Infections
Surveillance (NNIS) Report, data summary from October 1986-April 1997, issued
May 1997. American Journal ofInfection Control 25, 477-487.
Jensen, L. B. 1998. Internal size variations in Tni576-like elements due to the
presence of ISi2i<5K FEMSMicrobiology Letters 169, 349-354.
Jensen, L. B., Ahrens, P., Dons, L., Jones, R. N., Hammerum, A. M., & Aarestrup, F.
M. 1998. Molecular analysis of Tn1546 in Enterococcus faecium isolated from
animals and humans. Journal ofClinical Microbiology 36,437-442.
Jett, B. D., Huycke, M. M., & Gilmore, M. S. 1994. Virulence of enterococci.
ClinicalMicrobiology Reviews 7, 462-478.
Jett, B. D., Jensen, H. G., Nordquist, R. E., & Gilmore, M. S. 1992. Contribution of
the pADl-encoded cytolysin to the severity of experimental Enterococcus faecalis
endophthalmitis. Infection and Immunity 60, 2445-2452.
Jones, R. N., Johnson, D. M., & Erwin, M. E. 1996. In vitro antimicrobial activities
and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrobial Agents and Chemotherapy 40, 720-726.
Kalina, A. P. 1970. The taxonomy and nomenclature of enterococci. International
Journal ofSystematic Bacteriology 20, 185-189.
Kanematsu, E., Deguchi, T., Yasuda, M., Kawamura, T., Nishino, Y., & Kawada, Y.
1998. Alterations in the GyrA subunit ofDNA gyrase and the ParC subunit ofDNA
topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
Antimicrobial Agents and Chemotherapy 42, 433-435.
Kaye, D. 1982. Enterococci - biologic and epidemiologic characteristics and in vitro
susceptibility. Archives ofInternalMedicine 142, 2006-2009.
218
Bibliography
Kaye, D. 1985. Changing pattern of infective endocarditis. American Journal of
Medicine 78 (Suppl. 6B), 157-162.
Kirst, H. A., Thompson, D. G., & Nicas, T. I. 1998. Historical yearly usage of
vancomycin. Antimicrobial Agents and Chemotherapy 42, 1303-1304.
Klare, I., Badstubner, D., Konstabel, C., Bohme, G., Claus, H., & Witte, W. 1999b.
Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from
poultry meat and from fecal samples of humans in the community after
discontinuation of avoparcin usage in animal husbandry. Microbial Drug
Resistance-Mechanisms Epidemiology andDisease 5, 45-52.
Klare, I., Heier, H., Claus, H., Bohme, G., Marin, S., Seltmann, G., Hakenbeck, R.,
Antanassova, V., & Witte, W. 1995b. Enterococcus faecium strains with vanA-
mediated high-level glycopeptide resistance isolated from animal foodstuffs and
fecal samples of humans in the community. Microbial Drug Resistance -
Mechanisms Epidemiology andDisease 1, 265-272.
Klare, I., Heier, H., Claus, H., Reissbrodt, R., & Witte, W. 1995a. vand-mediated
high-level glycopeptide resistance in Enterococcus faecium from animal husbandry.
FEMSMicrobiology Letters 127, 273-273.
Klare, I., Werner, G., Conrads, G., Schlaeger, J. J., Lutticken, R., Witte, W., &
Reinert, R. R. 1999a. Antibiotic resistance in clinical isolates of enterococci from
North-Rhine Westphalia and analysis of clonal relatedness of glycopeptide-resistant
strains from German hospitals. Presented at European Congress of Clinical
Microbiology and Infectious Diseases.
Kreft, B., Marre, R., Schramm, U., & Wirth, R. 1992. Aggregation substance of
Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infection
and Immunity 60, 25-30.
Krogstad, D. J. & Parquette, A. R. 1980. Defective killing of enterococci: a
common property of antimicrobial agents acting on the cell wall. Antimicrobial
Agents and Chemotherapy 17, 965-968.
219
Bibliography
Kusuda, R., Kawai, K., Salati, F., Banner, C. R., & Fryer, J. L. 1991. Enterococcus
seriolicida sp. nov., a fish pathogen. International Journal of Systematic
Bacteriology 41, 406-409.
Lancefield, R. C. 1933. A serological differentiation of human and other groups of
hemolytic streptococci. Journal ofExperimental Medicine 57, 571-595.
Leach, T. S., Oefinger, P., Styers, D., Zurenko, G., Todd, W. M., & Hafkin, B. 2000.
Comparative antibiotic susceptibilities of 141 U.S. clinical isolates of vancomycin-
resistant E. faecium, abstr. 61. In Program and Abstracts of the 1st International
ASM Conference on Enterococci: Pathogenesis, Biology and Antibiotic Resistance.
American Society for Microbiology, Washington, D.C.
Leclercq, R., Derlot, E., Duval, J., & Courvalin, P. 1988. Plasmid-mediated
resistance to vancomycin and teicoplanin in Enterococcus faecium. New England
Journal ofMedicine 319, 157-161.
Leclercq, R., Derlot, E., Weber, M., Duval, J., & Courvalin, P. 1989. Transferable
vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrobial
Agents and Chemotherapy 33, 10-15.
Ligozzi, M., Lo Cascio, G., & Fontana, R. 1998. vanA gene cluster in a
vancomycin-resistant clinical isolate ofBacillus circulans. Antimicrobial Agents and
Chemotherapy 42, 2055-2059.
Linden, P. K., Pasculle, A. W., Manez, R., Kramer, D. J., Fung, J. J., Pinna, A. D., &
Kusne, S. 1996. Differences in outcomes for patients with bacteremia due to
vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.
Clinical Infectious Diseases 22, 663-670.
Livornese, L. L., Dias, S., Samel, C., Romanowski, B., Taylor, S., May, P., Pitsakis,
P., Woods, G., Kaye, D., Levison, M. E., & Johnson, C. C. 1992. Hospital-acquired
infection with vancomycin-resistant Enterococcus faecium transmitted by electronic
thermometers. Annals ofInternal Medicine 117,112-116.
220
Bibliography
Lowe, A. M., Lambert, P. A., & Smith, A. W. 1995. Cloning of an Enterococcus
faecalis endocarditis antigen - homology with adhesins from some oral streptococci.
Infection and Immunity 63, 703-706.
Lucas, G. M., Lechtzin, N., Puryear, D. W., Yau, L. L., Flexner, C. W., & Moore, R.
D. 1998. Vancomycin-resistant and vancomycin-susceptible enterococcal
bacteremia: Comparison of clinical features and outcomes. Clinical Infectious
Diseases 26, 1127-1133.
McAshan, S. K., Vergin, K. L., Giovannoni, S. J., & Thaler, D. S. 1999.
Interspecies recombination between enterococci: Genetic and phenotypic diversity of
vancomycin-resistant transconjugants. Microbial Drug Resistance-Mechanisms
Epidemiology and Disease 5, 101-112.
MacCallum, W. G. & Hastings, T. W. 1899. A case of acute endocarditis caused by
Micrococcus zymogenes (nov. spec.), with a description of the microorganism.
Journal ofExperimental Medicine 4, 521-534.
MacKinnon, J. D. 1993. The proper use and benefits of veterinary antimicrobial
agents in swine practice. VeterinaryMicrobiology 35, 357-367.
MacKinnon, M. G., Drebot, M. A., & Tyrrell, G. J. 1997. Identification and
characterization of IS1476, an insertion sequence-like element that disrupts vanY
function in a vancomycin-resistant Enterococcus faecium strain. Antimicrobial
Agents and Chemotherapy 41, 1805-1807.
Mainous, M. R., Lipsett, P. A., & O'Brien, M. 1997. Enterococcal bacteremia in the
surgical intensive care unit - Does vancomycin resistance affect mortality? Archives
ofSurgery 132, 76-81.
Makinen, P. L., Clewell, D. B., An, F., & Makinen, K. K. 1989. Purification and
substrate-specificity of a strongly hydrophobic extracellular metalloendopeptidase




Marshall, C. G., Broadhead, G., Leskiw, B. K., & Wright, G. D. 1997. D-Ala-D-Ala
ligases from glycopeptide antibiotic-producing organisms are highly homologous to
the enterococcal vancomycin-resistance ligases VanA and VanB. Proceedings of the
NationalAcademy ofSciences ofthe United States ofAmerica 94, 6480-6483.
Marshall, C. G., Lessard, I. A. D., Park, I. S., & Wright, G. D. 1998. Glycopeptide
antibiotic resistance genes in glycopeptide-producing organisms. Antimicrobial
Agents and Chemotherapy 42, 2215-2220.
Martinez-Murcia, A. J. & Collins, M. D. 1991. Enterococcus sulfureus, a new
yellow-pigmented Enterococcus species. FEMSMicrobiology Letters 80, 69-73.
Matlow, A. G., Bohnen, J. M. A., Nohr, C., Christou, N., & Meakins, J. 1989.
Pathogenicity of enterococci in a rat model of fecal peritonitis. Journal ofInfectious
Diseases 160, 142-144.
McKessar, S. J., Berry, A. M., Bell, J. M., Turnidge, J. D., & Paton, J. C. 2000.
Genetic characterization of vanG, a novel vancomycin resistance locus of
Enterococcusfaecalis. Antimicrobial Agents and Chemotherapy 44, 3224-3228.
Megran, D. W. 1992. Enterococcal endocarditis. Clinical Infectious Diseases 15,
63-71.
Mevius, D., Devriese, L., Butaye, P., Vandamme, P., Verschure, M., & Veldman, K.
1998. Isolation of glycopeptide-resistant Streptococcus gallolyticus strains with
vanA, vanB and both vanA and vanB genotypes from faecal samples of veal calves in
The Netherlands. Journal ofAntimicrobial Chemotherapy 42,275-276.
Miele, A., Bandera, M., & Goldstein, B. P. 1995. Use of primers selective for
vancomycin resistance genes to determine van genotype in enterococci and to study
gene organization in VanA isolates. Antimicrobial Agents and Chemotherapy 39,
1772-1778.
Miranda, A. G., Singh, K. V., & Murray, B. E. 1991. DNA fingerprinting of
Enterococcus faecium by pulsed-field gel electrophoresis may be a useful
epidemiologic tool. Journal ofClinicalMicrobiology 29, 2752-2757.
222
Bibliography
Moellering, R. C. & Weinberg, A. N. 1971. Studies on the antibiotic synergism
against enterococci: Effects of various antibiotics on the uptake of 14C-labelled
streptomycin by enterococci. Journal ofClinical Investigation 50,2580-2584.
Moellering, R. C., Wennersten, C., Medrek, T., & Weinberg, A. N. 1971.
Prevalence of high-level resistance to aminoglycosides in clinical isolates of
enterococci. Antimicrobial Agents and Chemotherapy 7, 335-340.
Moore, D. & Chory, J. 1998. Preparation and analysis of DNA. In F. M. Ausubel,
R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith & K. Struhl (eds.)
Current Protocols in Molecular Biology. John Wiley and Sons, Inc.
Morrison, A. J. & Wenzel, R. P. 1986. Nosocomial urinary-tract infections due to
Enterococcus - 10 years experience at a university hospital. Archives of Internal
Medicine 146, 1549-1551.
Morrison, D., Woodford, N., Barrett, S. P., Sisson, P., & Cookson, B. D. 1999.
DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium
and criteria for defining strains. Journal ofClinicalMicrobiology 37, 1084-1091.
Morrison, D., Woodford, N., & Cookson, B. 1997. Enterococci as emerging
pathogens ofhumans. Journal ofAppliedMicrobiology 83, S89-S99.
Murray, B. E. 1992. Beta-lactamase-producing enterococci. Antimicrobial Agents
and Chemotherapy 36, 2355-2359.
Murray, B. E. 1995. What can we do about vancomycin-resistant enterococci -
response. Clinical Infectious Diseases 20, 1134-1136.
Murray, B. E. 1997. Vancomycin-resistant enterococci. American Journal of
Medicine 102, 284-293.
Murray, B. E. 1998. Diversity among multidrug-resistant enterococci. Emerging
Infectious Diseases 4, 37-47.
223
Bibliography
Murray, B. E. & Mederski-Samoraj, B. 1983. Transferable beta-lactamase - a new
mechanism for in vitro penicillin resistance in Streptococcus faecalis. Journal of
Clinical Investigation 72, 1168-1171.
Murray, B. E., Mederski-Samoraj, B., Foster, S. K., Brunton, J. L., & Harford, P.
1986. In vitro studies ofplasmid-mediated penicillinase from Streptococcus faecalis
suggest a staphylococcal origin. Journal ofClinical Investigation 77, 289-293.
Murray, B. E., Singh, K. V., Markowitz, S. M., Lopardo, H. A., Patterson, J. E.,
Zervos, M. J., Rubeglio, E., Eliopoulos, G. M., Rice, L. B., Goldstein, F. W.,
Jenkins, S. G., Caputo, G. M., Nasnas, R., Moore, L. S., Wong, E. S., & Weinstock,
G. 1991. Evidence for clonal spread of a single strain of beta-lactamase-producing
Enterococcus (,Streptococcus) faecalis to 6 hospitals in 5 states. Journal of
Infectious Diseases 163, 780-785.
Navarro, F. & Courvalin, P. 1994. Analysis of genes encoding D-alanine-D-alanine
ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens.
AntimicrobialAgents and Chemotherapy 38, 1788-1793.
Nelson, R. R. S., McGregor, K. F., Brown, A. R., Amyes, S. G. B., & Young, H. K.
2000. Isolation and characterization of glycopeptide-resistant enterococci from
hospitalized patients over a 30-month period. Journal ofClinical Microbiology 38,
2112-2116.
Neu, J. M. & Wright, G. D. 2000. Vancomycin resistance in Streptomyces
coelicolor A3(2), abstr. 679. In Program and Abstracts of the 40th Interscience
Conference on Antimicrobial Agents and Chemotherapy. American Society for
Microbiology, Washington, D.C.
Neuhaus, F. 1962. The enzymatic synthesis of D-alanyl-D-alanine. I. Purification
and properties of D-alanyl-D-alanine synthetase. Journal of Biological Chemistry
237, 778-786.
Nicas, T. I., Mullen, D. L., Flokowitsch, J. E., Preston, D. A., Snyder, N. J., Zweifel,
M. J., Wilkie, S. C., Rodriguez, M. J., Thompson, R. C., & Cooper, R. D. G. 1996.
224
Bibliography
Semisynthetic glycopeptide antibiotics derived from LY264826 active against
vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy 40,
2194-2199.
Nicas, T. I., Zeckel, M. L., & Braun, D. K. 1997. Beyond vancomycin: New
therapies to meet the challenge of glycopeptide resistance. Trends in Microbiology
5, 240-249.
Noble, C. J. 1978. Carriage of group D streptococci in the human bowel. Journal of
Clinical Pathology 31, 1182-1186
Noble, W. C., Virani, Z., & Cree, R. G. A. 1992. Co-transfer of vancomycin and
other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus
aureus. FEMSMicrobiology Letters 93, 195-198.
Norris, A. H., Reilly, J. P., Edelstein, P. H., Brennan, P. J., & Schuster, M. G. 1995.
Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.
Clinical Infectious Diseases 20, 1137-1144.
Onderdonk, A. B., Bartlett, J. G., Louie, T., Sullivan-Seigler, N., & Gorbach, S. L.
1976. Microbial synergy in experimental intraabdominal abscess. Infection and
Immunity 13, 22-26.
Palepou, M. F. I., Adebiyi, A. M. A., Tremlett, C. H., Jensen, L. B., & Woodford, N.
1998. Molecular analysis of diverse elements mediating VanA glycopeptide
resistance in enterococci. Journal ofAntimicrobial Chemotherapy 42, 605-612.
Parenti, F., Beretta, G., Berti, M., & Arioli, V. 1978. Teichomycins, new antibiotics
from Actinoplanes teichomyceticus nov. sp. I. Description of the producer strain,
fermentation studies and biological properties. Journal ofAntibiotics 31, 276-283.
PateL, R., Piper, K., Cockerill, F. R., Steckelberg, J. M., & Yousten, A. A. 2000.
The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster
homologous to the enterococcal VanA vancomycin resistance gene cluster.
Antimicrobial Agents and Chemotherapy 44, 705-709.
225
Bibliography
Patel, R., Piper, K. E., Rouse, M. S., Steckelberg, J. M., Uhl, J. R., Kohner, P.,
Hopkins, M. K., Cockerill, F. R., & Kline, B. C. 1998. Determination of 16S rRNA
sequences of enterococci and application to species identification of nonmotile
Enterococcus gallinarum isolates. Journal ofClinicalMicrobiology 36, 3399-3407.
Patterson, J. E., Singh, K. V., & Murray, B. E. 1991. Epidemiology of an endemic
strain of P-lactamase-producing Enterococcus faecalis. Journal of Clinical
Microbiology 29, 2513-2516.
Pechere, J. C. 1996. Streptogramins - a unique class of antibiotics. Drugs 51, 13-
19.
Perichon, B., Reynolds, P., & Courvalin, P. 1997. VanD-type glycopeptide-resistant
Enterococcus faecium BM4339. Antimicrobial Agents and Chemotherapy 41, 2016-
2018.
Pitcher, D. G., Saunders, N. A., & Owen, R. J. 1989. Rapid extraction of bacterial
genomic DNA with guanidium thiocyanate. Letters in Applied Microbiology 8, 151-
156.
Ploy, M. C., Grelaud, C., Martin, C., de Lumley, L., & Denis, F. 1998. First clinical
isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.
Lancet 351, 1212-1212.
Pompei, R., Berlutti, F., Thaller, M. C., Ingianni, A., Cortis, G., & Dainelli, B. 1992.
Enterococcus flavescens sp. nov., a new species of enterococci of clinical-origin.
International Journal ofSystematic Bacteriology 42, 365-369.
Portillo, A., Ruiz-Larrea, F., Zarazaga, M., Alonso, A., Martinez, J. L., & Torres, C.
2000. Macrolide resistance genes in Enterococcus spp. Antimicrobial Agents and
Chemotherapy 44, 967-971.
Power, E. G. M., Abdulla, Y. H., Talsania, H. G., Spice, W., Aathithan, S., & French,
G. L. 1995. vanA genes in vancomycin-resistant clinical isolates of Oerskovia
turbata and Arcanobacterium (Corynebacterium) haemolyticum. Journal of
Antimicrobial Chemotherapy 36, 595-606.
226
Bibliography
Quintiliani, R. & Courvalin, P. 1994. Conjugal transfer of the vancomycin
resistance determinant vanB between enterococci involves the movement of large
genetic elements from chromosome to chromosome. FEMS Microbiology Letters
119, 359-364.
Quintiliani, R. & Courvalin, P. 1996. Characterization of Tn1547, a composite
transposon flanked by the ISi<5 and IS25<5-like elements, that confers vancomycin-
resistance in Enterococcusfaecalis BN4281. Gene 172,1-8.
Rende-Fournier, R., Leclercq, R., Galimand, M., Duval, J., & Courvalin, P. 1993.
Identification of the satA gene encoding a streptogramin-A acetyltransferase in
Enterococcus faecium BM4145. Antimicrobial Agents and Chemotherapy 37, 2119-
2125.
Reynolds, P. E. 1985. Inhibitors of bacterial cell wall synthesis, pp. 13-40 In D.
Greenwood & F. O'Grady (eds.), The Scientific Basis of Antimicrobial
Chemotherapy. Cambridge University Press, Cambridge.
Reynolds, P. E., Depardieu, F., Dutka-Malen, S., Arthur, M., & Courvalin, P. 1994.
Glycopeptide resistance mediated by enterococcal transposon TnJ546 requires
production of VanX for hydrolysis of D-alanyl-D-alanine. Molecular Microbiology
13, 1065-1070.
Rodrigues, U. & Collins, M. D. 1990. Phylogenetic analysis of Streptococcus
saccharolyticus based on 16S RNA sequencing. FEMS Microbiology Letters 71,
231-234.
Sader, H. S., Pfaller, M. A., Tenover, F. C., Hollis, R. J., & Jones, R. N. 1994.
Evaluation and characterization ofmultiresistant Enterococcus faecium from 12 U.S.
medical centers. Journal ofClinicalMicrobiology 32, 2840-2842.
Salyers, A. A., Shoemaker, N. B., Stevens, A. M., & Li, L.Y. 1995. Conjugative
transposons - an unusual and diverse set of integrated gene-transfer elements.
Microbiological Reviews 59, 579-590
227
Bibliography
Sannomiya, P., Craig, R. A., Clewell, D. B., Suzuki, A., Fujino, M., Till, G. O., &
Marasco, W. A. 1990. Characterization of a class of nonformylated Enterococcus
faecalis-derived neutrophil chemotactic peptides - the sex-pheromones. Proceedings
ofthe National Academy ofSciences ofthe United States ofAmerica 87, 66-70.
Sapico, F. L., Canawati, H. N., Ginunas, V. J., Gilmore, D. S., Montgomerie, J. Z.,
Tuddenham, W. J., & Facklam, R. R. 1989. Enterococci highly resistant to
penicillin and ampicillin - an emerging clinical problem. Journal of Clinical
Microbiology 27, 2091-2095.
Sartingen, S., Leonard, B., Marre, R., & Rodzinski, E. 1998. Aggregation substance
promotes the adherence and internalization of Enterococcus faecalis by intestinal
epithelial cells, abstr. B-79. In Program and Abstracts of the 98th General Meeting of
the American Society for Microbiology. American Society for Microbiology,
Washington, D.C.
Schleifer, K. H. & Kilpper- Balz, R. 1984. Transfer of Streptococcus faecalis and
Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis
comb. nov. and Enterococcus faecium comb. nov. International Journal of
Systematic Bacteriology, 34, 31-34.
Schmitz, F. J., Sadurski, R., Kray, A., Boos, M., Geisel, R., Kohrer, K., Verhoef, J.,
& Fluit, A. C. 2000. Prevalence of macrolide-resistance genes in Staphylococcus
aureus and Enterococcus faecium isolates from 24 European university hospitals.
Journal ofAntimicrobial Chemotherapy 45, 891-894.
Schwalbe, R. S., Mcintosh, A. C., Qaiyumi, S., Johnson, J. A., & Morris, J. G. 1999.
Isolation of vancomycin-resistant enterococci from animal feed in the USA. Lancet
353, 722.
Shankar, V., Baghdayan, A. S., Huycke, M. M., Lindahl, G., & Gilmore, M. S. 1999.
Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding
a novel surface protein. Infection and Immunity 67, 193-200.
228
Bibliography
Simonsen, G. S., Myhre, M. R. M., Dahl, K. H., Olsvik, O., & Sundsfjord, A. 2000.
Typeability ofTn7546-like elements in vancomycin-resistant enterococci using long-
range PCR and specific analysis ofpolymorphic regions. Microbial Drug Resistance
- Mechanisms, Epidemiology & Disease 6, 49-57.
Sherman, J. M. 1937. The streptococci. Bacteriological Reviews 1, 3-97.
Smith, W. J. 1993. Antibiotics in feed, with special reference to pigs - a veterinary
viewpoint. Animal Feed Science and Technology 45, 57-64.
Someya, Y., Yamaguchi, A., & Sawai, T. 1995. A novel glycylcycline, 9-(N,N-
dimethylglycylamido)-6-demethyl- 6-deoxytetracycline, is neither transported nor
recognized by the transposon TniO-encoded metal-tetracycline/H+ antiporter.
AntimicrobialAgents and Chemotherapy 39, 247-249.
Struelens, M. J., and Members of the European Study Group on Epidemiological
Markers (ESGEM) of the European Society of Clinical Microbiology and Infectious
Diseases (ESCMCD). 1996. Consensus guidelines for appropriate use and evaluation
ofmicrobial epidemiologic typing systems. Clinical Microbiol. Infect. 2, 2-11.
Su, Y. A., Sulavik, M. C., He, P., Makinen, K. K., Makinen, P. L., Fiedler, S., Wirth,
R., & Clewell, D. B. 1991. Nucleotide-sequence of the gelatinase gene (gelE) from
Enterococcus faecalis subsp. liquefaciens. Infection and Immunity 59, 415-420.
Suessmuth, S., Susa, M., Sartingen, S., Marre, R., & Rodzinski, E. 1998.
Enterococcus faecalis: adherence, entry and survival in macrophages is promoted by
aggregation substance (AS), abstr. B-84. In Program and Abstracts of the 98th
General Meeting of the American Society for Microbiology. American Society for
Microbiology, Washington, D.C.
Swenson, J. M., Clark, N. C., Sahm, D. F., Ferraro, M. L., Doern, G., Hindler, J.,
Jorgensen, J. H., Pfaller, M. A., Reller, L. B., Weinstein, M. P., Zabransky, R. J., &
Tenover, F. C. 1995. Molecular characterization and multilaboratory evaluation of
Enterococcus faecalis ATCC 51299 for quality-control of screening-tests for
229
Bibliography
vancomycin and high-level aminoglycoside resistance in enterococci. Journal of
ClinicalMicrobiology 33, 3019-3021.
Tankovic, J., Mahjoubi, F., Courvalin, P., Duval, J., & Leclercq, R. 1996.
Development of fluoroquinolone resistance in Enterococcus faecalis and role of
mutations in the DNA gyrase gyrA gene. Antimicrobial Agents and Chemotherapy
40, 2558-2561.
Taylor, M. E., Oppenheim, B. A., Chadwick, P. R., Weston, D., Palepou, M. F.,
Woodford, N., & Bellis, M. 1999. Detection of glycopeptide-resistant enterococci
in routine diagnostic faeces specimens. Journal ofHospital Infection 43, 25-32.
Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E.,
Persing, D. H., & Swaminathan, B. 1995. Interpreting chromosomal DNA
restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial
strain typing. Journal ofClinicalMicrobiology 33,2233-2239.
Todd, E. W. 1934. A comparitive serological study of streptolysins derived from
human and from animal infections, with notes on pneumococcal haemolysin,
tetanolysin and staphylococcus toxin. Journal of Pathology and Bacteriology 39,
299-321.
Toon, P., Brown, P. E., & Baddiley, J. 1972. The lipo-teichoic acid complex in the
cytoplasmic membrane of Streptococcus faecalis N.C.I.B. 8191. Biochemical
Journal 127, 399-409,
Trieucuot, P., Decespedes, G., Bentorcha, F., Delbos, F., Gaspar, E., & Horaud, T.
1993. Study of heterogeneity of chloramphenicol acetyltransferase (cat) genes in
streptococci and enterococci by polymerase chain-reaction - characterization of a
new cat determinant. AntimicrobialAgents and Chemotherapy 37, 2593-2598.
Tsutsui, O., Kokeguchi, S., Matsumura, T., & Kato, K. 1991. Relationship of the
chemical-structure and immunobiological activities of lipoteichoic acid from




Uttley, A. H. C., Collins, C. H., Naidoo, J., & George, R. C. 1988. Vancomycin-
resistant enterococci. Lancet 1, 57-58.
van Bambeke, F., Chauvel, M., Reynolds, P. E., Fraimow, H. S., & Courvalin, P.
1999. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant
mutants. AntimicrobialAgents and Chemotherapy 43,41-47.
van den Bogaard, A. E., Jensen, L. B., & Stobberingh, E. 1997. Vancomycin-
resistant enterococci in turkeys and farmers. New England Journal ofMedicine 337,
1558-1559.
van der Auwera, P., Pensart, N., Korten, V., Murray, B. E., & Leclercq, R. 1996.
Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of
highly glycopeptide-resistant enterococci. Journal ofInfectious Diseases 173, 1129-
1136.
van Laethem, Y., Hermans, P., Dewit, S., Goosens, H., & Clumeck, N. 1988.
Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus
aureus infections - preliminary-results. Journal ofAntimicrobial Chemotherapy 21
(Suppl. A), 81-87.
Walsh, C. T. 1989. Enzymes in the D-alanine branch of bacterial-cell wall
peptidoglycan assembly. Journal ofBiological Chemistry 264, 2393-2396.
Watanakunakorn, C. 1989. The prevalence of high-level aminoglycoside resistance
among enterococci isolated from blood cultures during 1980-1988. Journal of
Antimicrobial Chemotherapy 24, 63-68.
Wegener, H. C. 1998. Historical yearly usage of glycopeptides for animals and
humans: The American-European paradox revisited. Antimicrobial Agents and
Chemotherapy 42, 3049-3049.
Wells, C. L., Jechorek, R. P., & Erlandsen, S. L. 1990. Evidence for the
translocation of Enterococcus faecalis across the mouse intestinal-tract. Journal of
Infectious Diseases 162, 82-90.
231
Bibliography
Wells, V. D., Wong, E. S., Murray, B. E., Coudron, P. E., Williams, D. S., &
Markowitz, S. M. 1992. Infections due to beta-lactamase-producing, high-level
gentamicin-resistant Enterococcus faecalis. Annals of Internal Medicine 116, 285-
292.
Werner, G., Klare, I., & Witte, W. 1999. Large conjugative vanA plasmids in
vancomycin-resistant Enterococcus faecium. Journal ofClinical Microbiology 37,
2383-2384.
Werner, G. & Witte, W. 1999. Characterization of a new enterococcal gene, satG,
encoding a putative acetyltransferase conferring resistance to streptogramin A
compounds. AntimicrobialAgents and Chemotherapy 43, 1813-1814.
Wicken, A. J., Elliott, S. D., & Baddiley, J. 1963. The identity of streptococcal
group D antigen with teichoic acid. Journal ofGeneral Microbiology 31,231-239.
Willems, R. J. L., Top, J., van den Braak, N., van Belkum, A., Mevius, D. J.,
Hendriks, G., Santen-Verheuvel, M., & van Embden, J. D. A. 1999. Molecular
diversity and evolutionary relationships ofTni5¥6-like elements in enterococci from
humans and animals. AntimicrobialAgents and Chemotherapy 43, 483-491.
Williams, A. M., Farrow, J. A. E., & Collins, M. D. 1989. Reverse-transcriptase
sequencing of 16S ribosomal-RNA from Streptococcus cecorum. Letters in Applied
Microbiology 8, 185-189.
Williams, A. M., Rodrigues, U. M., & Collins, M. D. 1991. Intrageneric
relationships of enterococci as determined by reverse-transcriptase sequencing of
small-subunit ribosomal-RNA. Research in Microbiology 142, 67-74.
Williamson, R., Alobeid, S., Shlaes, J. H., Goldstein, F. W., & Shlaes, D. M. 1989.
Inducible resistance to vancomycin in Enterococcus faecium D366. Journal of
Infectious Diseases 159, 1095-1104.
Williamson, R., Lebouguenec, C., Gutmann, L., & Horaud, T. 1985. One or 2 low
affinity penicillin-binding proteins may be responsible for the range of susceptibility
232
Bibliography
ofEnterococcus faecium to benzylpenicillin. Journal ofGeneral Microbiology 131,
1933-1940.
Woodford, N. 1998. Glycopeptide-resistant enterococci: a decade of experience.
Journal ofMedicalMicrobiology 47, 849-862.
Woodford, N., Adebiyi, A. M. A., Palepou, M. F. I., & Cookson, B. D. 1998.
Diversity ofVanA glycopeptide resistance elements in enterococci from humans and
nonhuman sources. Antimicrobial Agents and Chemotherapy 42, 502-508.
Woodford, N., Chadwick, P. R, Morrison, D., & Cookson, B. D. 1997b. Strains of
glycopeptide-resistant Enterococcus faecium can alter their van genotype during an
outbreak. Journal ofClinicalMicrobiology 35, 2966-2968.
Woodford, N., Johnson, A. P., Morrison, D., Hastings, J. G. M., Elliott, T. S. J.,
Worthington, A., Stephenson, J. R., Chin, A. T., & Tolley, J. L. 1994. Vancomycin-
dependent enterococci in the United Kingdom. Journal of Antimicrobial
Chemotherapy 33, 1066.
Woodford, N., Jones, B. L., Baccus, Z., Ludlam, H. A., & Brown, D. F. J. 1995a.
Linkage of vancomycin and high-level gentamicin resistance genes on the same
plasmid in a clinical isolate of Enterococcus faecalis. Journal of Antimicrobial
Chemotherapy 35, 179-184.
Woodford, N., Morrison, D., Cookson, B., & George, R. C. 1993. Comparison of
high-level gentamicin-resistant Enterococcus faecium isolates from different
continents. Antimicrobial Agents and Chemotherapy 37, 681-684.
Woodford, N., Morrison, D., Johnson, A. P., Bateman, A. C., Hastings, J. G. M.,
Elliott, T. S. J., & Cookson, B. 1995b. Plasmid-mediated vanB glycopeptide
resistance in enterococci. Microbial Drug Resistance - Mechanisms, Epidemiology
andDisease 1, 235-240.
Woodford, N., Morrison, D., Johnson, A. P., Briant, V., George, R. C., & Cookson,
B. 1993b. Application ofDNA probes for rRNA and vanA genes to investigation of
233
Bibliography
a nosocomial cluster of vancomycin-resistant enterococci. Journal of Clinical
Microbiology 31, 653-658.
Woodford, N., Watson, A. P., & Chadwick, P. R. 1997a. Investigation by long PCR
of the genetic elements mediating VanA glycopeptide resistance in enterococci from
uncooked meat in South Manchester, pp. 409-412 In Horaud, T., A Bouvet, R.
Leclercq, H. de Montclos & M. Sicard (eds.) Streptococci and the Host. Plenum
Publishing Corporation, New York.
Wright, G. D., Holman, T. R., & Walsh, C. T. 1993. Purification and
characterization of VanR and the cytosolic domain of VanS - a two-component
regulatory system required for vancomycin resistance in Enterococcus faecium
BM4147. Biochemistry 32, 5057-5063.
Wright, G. D., Molinas, C., Arthur, M., Courvalin, P., & Walsh, C. T. 1992.
Characterization of VanY, a D,D,-carboxypeptidase from vancomycin-resistant
Enterococcus faecium BM4147. Antimicrobial Agents and Chemotherapy 36, 1514-
1518.
Zervos, M. J. & Schaberg, D. R. 1985. Reversal of the in vitro susceptibility of
enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrobial Agents
and Chemotherapy 28, 446-448.
Zscheck, K. K. & Murray, B. E. 1991. Nucleotide-sequence of the beta-lactamase
gene from Enterococcus faecalis HH22 and its similarity to staphylococcal beta-















The PFGE type, as assigned by visual
comparison, is specified adjacent to each
isolate. Where no PFGE type is specified the







































The PFGE type, as assigned by visual
comparison, is specified adjacent to each
isolate. Where no PFGE type is specified the













































The PFGE type, as assigned by visual
comparison, is specified adjacent to each
isolate. Where no PFGE type is specified the















Appendix D: Teicoplanin MICs for a selection of VanA GRE harbouring
prototype and non-prototype Tnl546-related elements
Media used for
sensitivity testing
Isolate ISTA MHA BHIA
Prototype Tn1546 elements
ECH-01 16 64 8
ARI-OI 32 64 32
NIN-01 32 64 32
NIN-02 16 16 32
NIN-03 16 16 32
NIN-04 8 4 16
GWI-02 32 64 32
GWI-03 4 8 8
GWI-04 8 64 16
GWI-05 8 8 32
GWI-09 16 16 32
GWI-10 4 8 16
GWI-11 4 8 8
RIE-31 4 8 8
Non-prototype Tn1546 elements
RIE-02 64 32 512
RIE-03 64 64 256
RIE-04 16 64 32
RIE-05 128 64 256
RIE-06 128 64 512
RIE-07 64 32 128
WGH-01 128 32 1024
RIE-08 128 64 1024
RIE-09 32 32 256
BGH-01 32 32 256
BGH-02 32 128 64
RIE-11 128 64 512
RIE-I2 16 32 128
RIE-13 16 32 64
RIE-15 32 32 256
RIE-16 32 32 512
RIE-I8 64 32 128
RIE-19 64 32 32
RIE-23 64 32 64
ISTA - Iso-Sensitest agar; MHA - Mueller-Hinton agar; BHIA - Brain heart
infusion agar. Teicoplanin MICs are shown in mg/L.
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Appendix E: Teicoplanin MICs determined with or without pyruvate/lactate
supplementation
TEICOPLANIN MICs (mg/L)
ISOLATE ISTA ISTA + 0.1mM ISTA + O.OlmM ISTA + 0.1% ISTA + 0.01%
sodium pyruvate sodium pyruvate lactic acid lactic acid
Prototype Tn1546 elements
ECH-01 32 64 64 64
ARI-01 32 64 64 32
NIN-01 32 64 64 32
NIN-02 32 64 64 64
NIN-03 32 64 64 128
NIN-04 32 64 64 64
GWI-02 32 64 64 64
GWI-03 16 16 8 16
GWI-04 32 64 32 32
GWI-05 32 64 32 64
GWI-09 32 32 32 32
GWI-10 16 16 32 32
GWI-ll 16 16 16 32
RIE-31 8 16 8 16
Von-prototype TnlS46 elements
RIE-02 250 250 500 250
RIE-03 250 250 250 250
REE-04 32 128 128 128
RIE-05 250 250 250 250
RIE-06 250 250 500 500
RIE-07 128 128 250 500
WGH-01 250 250 500 250
RIE-08 250 250 250 250
REE-09 128 250 250 250
BGH-01 128 128 128 250
BGH-02 64 32 128 128
RIE-11 250 250 500 500
RIE-12 64 64 128 64
RIE-13 128 128 128 128
RIE-15 128 250 250 128
RIE-16 128 250 250 250
RIE-18 128 250 128 250
RIE-19 64 64 64 64
RIE-23 64 64 128 64
0.1% lactic acid inhibited bacterial growth.
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Appendix F: API profile, antibiogram, PFGE type and Tnl546 type of GRE




Antibiotic resistance profile PFGE Till546
type
RIE-01 FM 7357511 Vm, Te, Am, Amp, HLSR A B
RIE-02 FM 7357510 Vm, Te, HLSR A B
RIE-03 FM 7357511 Vm, Te, Em, Amp, Tet, HLSR A C
RIE-04 FM 7357511 Vm, Te, Em, Amp, Tet, HLSR A
RIE-05 FM 7357511 Vm, Te, Em, Amp, HLSR Ai B
RIE-06 FM 7357511 Vm, Te, Em, Amp, HLSR A B
RIE-07 FM 7357511 Vm, Te, Em, Amp, HLSR A B
RIE-08 FM 7357511 Vm, Te, Em, Amp, Tet, HLSR A C
RIE-09 FM 7357511 Vm, Te, Em, Amp, Tet, HLSR A B
RIE-10 FM 7357511 Vm, Te, Em, Amp, Tet, HLSR a2 B
RIE-11 FM 7357511 Vm, Te, Em, Amp, HLSR A D
RIE-12 FM 7357510 Vm, Te, Em, Amp a3
REE-13 FM 7156511 Vm, Te, Em, Amp, Tet, HLSR A4
RIE-14 FM 7557511 Vm, Te, Em, Amp, Tet, HLSR A5
RIE-15 FM 7357711 Vm, Te, Em, Amp, Tet, HLSR
RIE-16 FM 6357510 Vm, Te, Em, Amp, HLSR a7 K
RIE-17 FM 6357510 ND As n/a
RtE-18 FM 7357711 Vm, Te, Em, Amp, HLSR B B
RIE-19 FM 7357510 Vm, Te, Em, HLSR B B
RIE-21 FS 7143711 ND ci n/a
RIE-22 FS 7153711 ND c2 n/a
RDE-24 FS 7173711 Vm, Te, Em, Amp, HLSR c B
RIE-25 FS 7143311 Vm, Te, Em, Cm, Tet, HLSR, HLGR d, E
RIE-26 FS 5143311 Vm, Te, Em, Cm, Tet, HLSR, HLGR d2
RIE-27 FS 7143311 Vm, Te, Em, Amp, Tet, HLSR
RIE-28 FS 5153711 ND n/a
Antibiotic resistance profile was only established for VanA isolates. ND denotes VanB isolates for
which the resistance profile was not determined. Where no Tn1546 type is stated, it could not be
assigned due to failure of L-PCR or insufficient yield to enable restriction analysis, 'n/a' denotes not
applicable (VanB isolates).
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Epidemiology and control of vancomycin-
resistant enterococci (VRE) in a renal
unit
A. R. Brown*, S. G. B. Amyes*, R. Paton*, W. D. Plantf, G. M. Stevenson*,
R. J. Winneyf and R. S. Miles*
*Department of Medical Microbiology, Edinburgh University Medical School, Teviot Place,
Edinburgh EH8 9AG; and fDepartment of Renal Medicine, Edinburgh Royal Infirmary,
Lauriston Place, Edinburgh EH3 9YW
Summary: This study reports an outbreak of infection and colonization caused by vancomycin-
resistant enterococci (VRE) in the renal service of a large teaching hospital. The polymerase chain
reaction and pulsed-field gel electrophoresis were used to study the epidemiology of 26/34 strains
of vancomycin-resistant Enterococcus faecalis and Enterococcus faecium from the outbreak in
comparison with five strains from other hospitals in Edinburgh and the Borders, and three from
other wards in the Royal Infirmary. The study revealed a heterogeneous population of vancomycin-
resistant E. faecalis. Over 60% of E. faecium isolates had matching pulsed-field gel electrophoresis
patterns and all of these were of VanA phenotype. These results suggest that clonal spread of VanA
phenotype E. faecium within and possibly between hospitals is the major vancomycin-resistant
enterococcal problem in Edinburgh. Screening of patients and isolation of colonized and infected
patients appear to have been successful in controlling the spread of VRE.
Keywords: Vancomycin-resistant enterococci (VRE); bacterial resistance; renal unit.
Introduction
Enterococci are frequent causes of urinary tract
infections,1 bacteremia and endocarditis.2
Enterococcus faecalis is most commonly isolated
but Enterococcus faecium is more inherently re¬
sistant to a wide range of antibiotics including
penicillin and ampicillin.3 Vancomycin some¬
times in combination with gentamicin is often
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the treatment of choice for serious enterococcal
infections;4 but the emergence and spread of
glycopeptide and aminoglycoside resistance has
made therapy considerably more difficult.
Four classes of vancomycin resistance have
been identified based on the level of resistance
and whether resistance is constitutive or in¬
ducible.3 The VanA phenotype is characterized
by high-level, inducible resistance to vanco¬
mycin and teicoplanin whilst VanB phenotypes
show inducible moderate resistance to van¬
comycin but remain susceptible to teicoplanin.3,
6 VanC resistance, characterized by constitutive
low-level resistance to vancomycin, is a property
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of Enterococcus gallinarum and Enterococcus cas-
seliflavus''1 both of which are rarely encountered
clinically. The vanA gene is frequently plasmid-
borne, carried by Tnl546 whilst vanC is re¬
garded as chromosomal.5 Conjugal transfer of
vanB has been demonstrated, being associated
with both conjugative transposons and plasm-
ids.8,9 The recently-described VanD phenotype
exhibits constitutive resistance to vancomycin
and to low levels of teicoplanin.10
This paper describes the epidemiology,
laboratory characterization and control methods
employed to contain an outbreak of VRE in¬




Stool samples and sometimes rectal swabs from
patients on the affected renal wards were ex¬
amined weekly until no new cases were detected
for three consecutive weeks. Re-admitted
patients were screened on admission and weekly
thereafter. Samples from appropriate sites were
taken from patients thought to be clinically
infected. It was not considered necessary to
screen new admissions to the unit from other
hospitals. Staff were not screened. En¬
vironmental samples were not taken.
Microbiological methods
Enterococci were sought in clinical material
from infected renal patients and in stools from
patients undergoing screening by culture on
Columbia base agar (Unipath) supplemented
with 5% horse blood and lOmg/L added neo¬
mycin. Two antibiotic discs containing 5 (tg and
30 pg of vancomycin were placed in the in¬
oculum well and the plates were incubated at
37°C overnight in air.
All vancomycin resistant, Lancefield group
D streptococci were identified to species level
using the API 20 Strep system (BioMerieux,
Marcy-l'Ftoile, France). MIC tests were per¬
formed on Columbia base agar supplemented
with 5% horse blood.
Five VRE isolates from other hospitals; two
from the City Elospital, Edinburgh, two from
the Borders General Hospital, Melrose and one
from the Eastern General Hospital, Edinburgh,
were included in the study together with three
from other wards in the hospital to ascertain
whether there was any relationship between
these strains and those isolated from renal
patients.
Isolates were stored frozen on beads (Pro-
Lab diagnostics, Wirral, UK) at — 70°C. These
were recovered by plating on Columbia base
agar containing 5% horse blood. Broth cultures
were made in brain—heart infusion broth. All
cultures were incubated at 37°C.
Polymerase chain reaction (PCR)
Olignocleotides specific for internal fragments
of the vanA and vanB genes11 were synthesized
(Oswel DNA service, Southampton). Cells were
harvested from 5 mL of an overnight culture;
suspended in 20 pL of a 50mM Tris—HC1 (pH
8 0)/10mM EDTA solution; and placed in a
boiling water-bath for 1 min. Five microlitres
of the resulting suspension was used in the PCR
mixture. The PCR protocol was a modification
of that described by Dutka-Malen et al.n The
PCR was performed in a final volume of lOOpL
containing the 5pL cell suspension; SOpmol
of each oligonucleotide primer; 500 pM dATP,
dTTP, dCTP, dGTP; 7mM MgClp lOpL of
10 x PCR buffer (GibcoBRL, Life Tech¬
nologies Ltd., Paisley); and 2U Taq DNA poly¬
merase (GibcoBRL, Life Technologies Ltd.).
The cycles were 94°C for 2 min for the first
cycle; 94°C for 1 min, 54°C for 1 min, 72°C for
1 min for the next 24 cycles; and 72°C for 10
min for the last cycle in a Techne thermal cycler
(Cambridge). PCR^products were run on 1-5%
agarose-Tris—acetic—EDTA gel at 100V. Gels
were stained with ethidium bromide, destained
in distilled water, and photographed with UV
illumination. E. faecalis ATCC 51299 and E.
faecalis NCTC 12697 were used as vanB posi¬
tive and negative controls, respectively. All VRE
isolates were screened with a mixture of vanA
and vanB-specific PCR primers.
The identify of a selection of PCR products
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was checked by PstI restriction analysis. Forty
microlitres of PCR product was added to 4pL
distilled water and 5|iL of lOxRE buffer (Pro-
mega, Southampton). Ten units of Pst I (Pro-
mega, Southampton) was added and the samples
incubated at 37°C for lh. Digests were run on
a 4% agarose—Tris—acetic—EDTA gel containing
0-5|tg/mL ethidium bromide.
Pulsed-field gel electrophoresis (PFGE)
The method used for PFGE was based upon
that described by Miranda et al.3 Cells from an
overnight culture grown in 5mL brain-heart
infusion broth were harvested and suspended
in L2mL of PIV solution [1m NaCl, 10mM
Tris-FlCl (pH 7-6)]. Ninety microlitres of this
suspension was mixed with 90|tl of 1-6% low-
melting preparative grade agarose (Bio-Rad
Laboratories Ltd., Herts) and pipetted into
small rectangular moulds. The cells in the agar¬
ose plugs were lysed overnight by incubation
with gentle shaking at 37°C in lysis solution
[6mM Tris—HC1 (pH 7-6), 1m NaCl, 100mM
EDTA (pH 7-5), 0-5% Brij 58, 0-2% de-
oxycholate, 0-5% sodium lauroyl sarcosine,
20pg/mL RNase (Sigma Chemical Co., Dorset),
and 1 mg/mL lysozyme (Sigma Chemical Co.)].
The plugs were then incubated overnight at
50°C in ESP solution [0 5 M EDTA (pH 9 0-
9-5), 1% sodium lauroyl sarcosine, and 50pg/ml
proteinase K (Sigma Chemical Co.)]. The plugs
were washed (3 x 30 min) with TE buffer
[lOmM Tris—HCI (pH 7-5), 01 mM EDTA] and
stored at 4°C in TE until restriction.
SmaI was used to restrict the DNA; a slice
of each plug was placed in 200 pL of 0-1 mg/
mL BSA and 25pL of lOxRE buffer Y (MBI
Fermentas, Immunogen International Ltd.,
Tyne and Wear). Twenty units of Sma I (MBI
Fermentas) was added and the plugs were in¬
cubated for 6h at 30°C. The plugs were then
washed in TE buffer for 1 h at 37°C before
being transferred and sealed into the wells of
1-2% agarose gels in 0-5 x TBE buffer. Electro¬
phoresis was performed on a contour-clamped
homogeneous electric fields device (CHEF-
DRII; Bio-Rad Laboratories Ltd.). The gel was
run for 24h at 200V with pulse times increasing
from 5 to 40 s. Gels were stained with ethidium
bromide for 15 min and destained for 2x-15
min in distilled water before being photo¬
graphed with UV illumination.
Results
Description of the outbreak
The outbreak affected the renal service of a
large teaching hospital, accommodated in two
ten-bedded areas, with one isolation cubicle and
one four-bed area. Rapid intermixing of patients
occurred. At frequent intervals, patients were
moved for short periods to beds throughout
the hospital. The renal high-dependency unit
contained six high-dependency beds, including
one isolation cubicle and two dialysis stations
providing haemodialysis for six to eight patients
per day ('bouncing beds'). This unit received
patients from other wards and other hospitals.
A chronic dialysis unit contained 13 stations
each used three times daily so accommodating
75—85 patients per week. Dialysis was also car¬
ried out in other high-dependency areas and
required constant movement of all grades of
staff.
Secure long-term vascular access was im¬
possible in many patients. As a consequence,
some patients had multiple infections ne¬
cessitating removal and replacement of large
bore internal jugular and femoral venous cath¬
eters. When line-associated sepsis was sus¬
pected, patients were treated with parental
vancomycin. Vancomycin has a particular appeal
because its pharmacokinetics in renal failure
means less frequent dosing.
In January 1995, VRE (from urine) were
isolated from an elderly maintenance peritoneal
dialysis patient who had been an inpatient for
over two months. The patient had multiple
medical and surgical problems, and had been
treated in ITU as well as in a variety of renal
wards. The patient was isolated but died eleven
weeks later from multiple clinical problems.
One week later VRE were isolated from blood
culture from another elderly patient who had
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recently commenced maintenance haemo-
dialysis. This patient had spent a protracted
period in another hospital several weeks pre¬
viously. The hospital stays of the two patients
overlapped and both had received vancomycin
for line-associated sepsis or Clostridium difficile
associated diarrhoea. The second patient died
after nine weeks in hospital.
No further cases occurred until 17 March
1995 when VRE were found in blood cultures
from a patient undergoing long-term haemo-
dialysis in hospital because of vascular access
problems. This patient had been empirically
treated with IV vancomycin for line-associated
sepsis. The fourth patient was admitted in late
March 1995 from Northern Ireland for assess¬
ment by the liver unit but died in early April
in the renal high-dependency unit. VRE was
isolated from blood and urine cultures but was
not felt to have contributed to the patient's
death.
At this point it was decided to screen all
patients (including those attending the chronic
dialysis unit). Major concerns were: recent in¬
tense clinical activity; the high usage of van¬
comycin in renal medicine; poor standards of
cleaning in wards, sluices and toilet areas, and
the risk of spread of VRE to the rest of the
hospital.
Control measures
By 1 May 1995 five patients had been clinically
infected and seven were colonized with VRE. Of
this group of 12, five were receiving maintenance
haemodialysis, two were maintenance peritoneal
dialysis patients and five had acute renal failure.
A segregated dialysis area was set up for the
colonized and infected patients. These patients
were not allowed entry to the chronic dialysis
unit or to the 'bouncing beds'. The segregated
area was also used for outpatients requiring
dialysis until they were shown not to be col¬
onized with VRE.
Patients with VRE were nursed in one ward
area to which no new VRE-free admissions
were permitted. Of necessity, this meant that
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Figure I Vancomycin consumption within the renal unit of
Edinburgh Royal Infirmary (1995). (H) High dependancy
unit; (□) Main ward; (I) Chronic dialysis unit.
colonized. Transfers required consultant ap¬
proval. Discharge to the community was en¬
couraged. Once empty the ward would be
cleaned before re-use. A new ward area was
opened for medically stable renal patients free
from VRE.
Use of glycopeptides (particularly van¬
comycin) was reviewed (see Figure 1). Metro¬
nidazole was instituted as first choice treatment
for proven Clostridium difficile associated colitis.
Antibiotic treatment of proven infection was
begun only after consultant approval and re¬
viewed according to clinical response and bac¬
teriological results. A memorandum was issued
to all hospital consultants and middle-grade
staff indicating the problem in renal medicine
and discouraging use of glycopeptides. Fol¬
lowing this the hospital-wide usage of van¬
comycin dropped significantly.
Netilmicin and flucloxacillin were used as
the major antistaphylococcal agents. Previous
surveillance had indicated that 99% of co-
agulase-negative staphylococci from renal
patients were sensitive to netilmicin. The oc¬
casional use of vancomycin for the treatment of
CAPD peritonitis was permitted.
Doctors white coats were banned from ward
areas. A fresh plastic apron was worn by staff
when examining or carrying out procedures
on all patients. Gloves were worn for all
procedures. Stethoscopes and sphygmo¬
manometers were allocated to individual bed
spaces. Fland disinfection between patients
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Figure 2 Graphical representation of the VRE isolates
indicating time of isolation (some patients were infected/
colonized with more than one strain). Arrow indicates
introduction of control measures.
using alcoholic chlorhexidine was rigorously in¬
sisted upon. A fresh cleaning contract was ne¬
gotiated to allow at least thrice daily cleaning
of ward toilet and sluice areas. Bedside lockers
and major items of equipment were washed
down daily with hot water and detergent. The
ward washer/disinfectors were checked by en¬
gineers. Procedures performed elsewhere in the
hospital on renal patients were scheduled at the
end of lists to allow routine cleaning thereafter.
Following introduction of these measures
three more patients became clinically infected
and 10 were found to be colonized. Nine oc¬
curred in May, and the remainder sporadically
up to the end of September. A graphical rep¬
resentation of the VRE isolates indicating time
of isolation and introduction of control measures
is shown in Figure 2. None of the patients
attending the chronic dialysis unit were col¬
onized.
Characteristics of VRE
In total, 30 isolates were obtained from renal
patients infected/colonized with VRE. Un¬
fortunately four were unavailable for further
study. The remaining 26 isolates together with
three from other ward areas within the hospital
and five from other hospitals were evaluated.
Some patients had more than one stain iden¬
tified. Twenty-three of the 34 isolates examined
were identified as E.faecium (Table I) and eleven
as E. faecalis (Table II). Fourteen E. faechim
isolates belonged to one of two API Strep profile
groups (7357510 or 735751 1). E. faecalis isolates
demonstrated a more diverse range of API pro¬
files. The minimum inhibitory concentrations
(MICs) of vancomycin fell into two groups. (1)
4—32mg/L; (2) >512mg/L. The vancomycin
resistance phenotype could be predicted from
these values and all were subsequently con¬
firmed by PGR (Figure 3). Twenty-five isolates
had MICs of >512mg/L and were identified
as VanA. Nine isolates had MICs of 4—32mg/
L and were identified as VanB. Eighty-seven
percent of E. faecium isolates were VanA com¬
pared with only 45% of E. faecalis isolates.
Tables I and II show the resistance type and
the API profile of the isolates together with their
clinical origin. A selection of PCR fragments had
their identity confirmed with restriction enzyme
PstI which cuts the vanA PCR fragment once
but not the vanB fragment.
The criteria described by Tenover et al.u
were used to interpret the PFGE patterns. Isol¬
ates were designated indistinguishable if their
patterns matched band for band. Patterns which
differed by a few bands were considered to
indicate closely related isolates which were
probably epidemiologically related. Four to six
band differences implied that isolates were pos¬
sibly related; seven or more differences in¬
dicated unrelatedness. The 23 E.faecium isolates
exhibited nine distinct patterns. One was iden¬
tified as the outbreak pattern (PFGE type A);
being shared by 15 different isolates, all of which
were VanA (Figure 4). The remaining eight
E. faecium isolates had distinguishable PFGE
patterns although five differed from the out¬
break pattern by no more than two or three
bands and were accordingly classed as PFGE
subtypes of A; A,—A5. Isolates apparently un¬
related to the outbreak strain were classed as
PFGE types B, B, and C. Two of the E. faecalis
isolates had matching PFGE patterns and were
classed as PFGE type D with subtypes Di-3-
Similarly the remaining isolates were designated
as types Ew, F and G. The PFGE patterns of
the E. faecalis isolates are shown in Figure 4
alongside the outbreak pattern (PFGE type A).
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Table I Origin and relevant information for vancomycin resistant strains of Enterococcus faecium.
Patient ID
number Location API profile MIC (mg/L) Van gene PFGE type
i Renal 63575 10 1024 A A4
2 Renal 7357511 >1024 A A
4 Renal 73575 10 >1024 A A
5 Renal 6357510 8 B as
6 Renal 7i43311 >1024 A A
9 Renal 7357511 >1024 A A
10 Renal 7357511 1024 A A
12 Renal 7357711 1024 A A
13 Renal 7357511 >1024 A A
16 EGH* 7357510 >1024 A A
17 Renal 73575 11 >1024 A A
18 Renal 7357510 >1024 A A
19 Renal 7357510 >1024 A A
20 Renal 73575 10 16 B B,
21 Renal 735771 i >1024 A A3
23 Renal 7156511 >1024 A A,
24 Renal 735751 i >1024 A A
25 Renal 735751 i >1024 A B
25 Renal 735751 i 512 A A
26 ECHf 7157511 1024 A C
27 Renal 7557511 32 B A2
28 BGH^; 7357511 >1024 A A
29 BGHt 7357711 >1024 A A
* Eastern General Hospital
f Edinburgh City Hospital
£ Borders General Hospital
MIC, minimum inhibitory concentration; PFGE, pulsed-field gel electrophoresis.
Table II Origin and relevant information for vancomycin resistant strains of Enterococcus faecalis.
Patient ID
number Location API profile MIC (mg/L) Van gene PFGE type
3 Renal 7143311 >1024 A E,
5 Renal 5153711 4 b F
7 ECH* 714331 1 >1024 A E2
8 Renal 5143311 16 b E3
10 Renal 7153711 4 b d,
1 1 Medical 7173311 1024 A d2
12 Renal 717371 1 16 b d3
14 Transplant 7173711 16 b d
15 G.l./liver 71733 11 >1024 A G
22 Renal 7143311 1024 A E4
22 Renal 7143711 16 b d
* Edinburgh City Hospital.
MIC, minimum inhibitory concentration; PFGE, pulsed-field gel electrophoresis.
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Figure 3 PCR analysis of vancomycin-resistant enterococci.
Lanes 1—4 show PCR product of the vanA gene (732 base
pairs); lanes 5 and 6 show vanB gene PCR products (635 base
pairs). On subsequent gels PCR products were run alongside
a 100-bp ladder.
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 4 PFGE patterns of E. faecalis and £. faecium generated
by Smol. Lanes l-l I show E. faecalis; lanes 12 and 13 E. faecium.
The two E. faecium isolates show the outbreak pattern (type
A) as exhibited by 15 VanA E. faecium isolates. Lanes 8 and 10
show pattern type D; lanes 4, 5, and 6 show subtypes DI-D3;
lanes I, 2, 3, and I I were classed as types EI-E4; lanes 7 and
9 as types F and G, respectively.
Table III Total numbers of isolates of VRE obtained from both
clinical specimens and screening sampling of renal patients (some
patients were infectedIcolonized with more than one strain).
Infected Colonized
patients patients
E. faecium VanA phenotype 4 12
E. faecium VanB phenotype — 3
Not studied 3 —
E. faecalis VanA phenotype 1 1
E. faecalis VanB phenotype — 5
Not studied 1 —
Epidemiology in renal patients
E. faecium
Infected patients:. Eight patients had clinical in¬
fections with VRE. Strains from four were not
analysed by PFGE. However, the two initial
strains and one strain isolated late in the out¬
break were all E. faecium and two had MICs of
>256mg/L to vancomycin. It is therefore likely
that these were vanA strains.
Three other patients were infected with E.
faecium-, all three isolates were vanA genotype
PFGE type A. One was also infected with a
second strain of E. faecium, which typed as
vanA genotype PFGE type B (See Tables I and
III).
Colonized patients:. Fifteen patients were col¬
onized with E. faecium. Twelve strains typed as
vanA genotype and all were epidemiologicallv
related to PFGE type A. Three patients were
colonized with E. faecium of vanB genotype
with PFGE types A2, A5 and B,.
E. faecalis
The pattern of colonization or infection with E.
faecalis was heterogeneous. One patient was
infected with E. faecalis of vanA genotype
PFGE type E,. Five patients were colonized
with E. faecalis of genotype vanB. One of the
latter was also colonized with E. faecalis geno¬
type vanA PFGE type E4 and two with E.
faecium [one with vanA genotype PFGE type
A; one with vanB genotype PFGE type A5 (see
Tables I, II and III)].
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Epidemiology in non-renal patients
Of the four E. faecium isolates obtained from
other hospitals three were vanA PFGE type A,
and one was vanA PFGE type C (see Table
I). Three of the four vancomycin-resistant E.
faecalis strains emanated from other wards
within the hospital. A patient from the liver
transplant unit was colonized with E. faecalis
of vanB genotype. The patient had not been
admitted to the renal unit but had been treated
by the renal physicians. Another patient from
the gastrointestinal liver unit was colonized with
E. faecalis of vanA genotype PFGE type G; but
had no known contact with the renal unit or it's
staff. A geriatric patient from a medical ward
was colonized with E. faecalis of vanA genotype
with PFGE type D2 (see Table II).
Discussion
The techniques described here have made it pos¬
sible to evaluate the nature of nosocomial enter-
ococcal outbreaks with ease. The combination of
MIC tests and PCR proved to be a rapid and
reliable way of establishing the resistance geno¬
type of clinical isolates. When outbreaks occur it
is important to have a reliable typing scheme with
which to compare isolates, but until relatively
recently no such system has been developed for
enterococci. The pulsed-field technique de¬
scribed by Miranda et al. proved to be reliable
and provided very effective discrimination.
API profile numbers alone could not be relied
upon to determine the relatedness of isolates. For
both E. faecium and E. faecalis, matching PFGE
patterns were exhibited by isolates with different
profile numbers, and isolates with the same pro¬
file number often gave distinct PFGE patterns.
The cultural technique used in this study was
not optimal. Isolation of E. faecium from mixed
bacterial populations especially during epi¬
demiological surveillance using heavily con¬
taminated faecal specimens is problematic.
Ford et al.u demonstrated that cephalexin—
aztreonam—arabinose agar is a more suitable
medium, and it has now been adopted for routine
use.
No isolates with identical PFGE patterns had
different resistance genotypes. All E. faecium
isolates of the outbreak strain (PFGE-type A)
were vanA genotype. Similarly, the E. faecalis
isolates from the renal unit (PFGE type D) were
all vanB genotype. Only within PFGE subtypes
were seemingly related strains carrying different
genes. This may cast doubt on the relatedness of
these supposedly related strains but it may be at
least partially explained by the transfer or loss of
vanA or vanB.
The two E. faecalis isolates with the type D
PFGE pattern, although displaying slightly dif¬
ferent API profiles, were otherwise identical and
are therefore the same strain; despite being isol¬
ated from different areas. No other E. faecalis
isolates had identical PFGE patterns although
many were either closely or possibly related sug¬
gesting an epidemiologic relationship (Table II).
In general, however, the E. faecalis isolates were
more heterogeneous than those of E. faecium.
The large group of vanA genotype E. faecium
isolates exhibiting the type A PFGE pattern is of
particular interest. Within this group are the two
isolates from the Borders General Hospital
(BGH), Melrose, and the one isolate from the
Eastern General Hospital, Edinburgh [the isolate
from Edinburgh's City Hospital was unique in
this study (PFGE type C)]. The remaining 12
isolates are from the Royal Infirmary. The 15
isolates had very similar, but not identical API
profiles. Twelve of the 15 type A strains had one
of two API profiles — 7357510 or 73575 11. The
remaining three isolates had similar profiles; dif¬
fering only by either positive sorbitol fer¬
mentation (7357711) or negative lactose
fermentation (7357110). The five E. faecium isol¬
ates classed as PFGE types A,—A5 were closely
related to the outbreak strain and are probably
epidemiologically related.
Clonal spread of identical and closely related
strains within hospitals is highly possible. More
interesting is the possibility of spread between
hospitals — particularly in the case of the apparent
identity of the Borders General Hospital isolates
with those in Edinburgh. Such spread of a single
strain is certainly possible as demonstrated by
Murray et al.u when studying isolates from hos¬
pitals in five different states.
With vanA frequently being plasmid-borne it
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may have been expected that a greater diversity
ofenterococcal strains would be found to be vanA
positive. However the results suggest that, cer¬
tainly in Edinburgh, high-level vanA genotype
resistance is the result of clonal spread of a single
strain and not widespread distribution of vanA
carrying plasmids. Are the vanA geneswithin the
isolates from this study largely chromosomally
located? Work is now being undertaken to deter¬
mine the transferability of the vanA and vanB
resistance genes in our isolates. Determining the
location of these genes will enhance the under¬
standing of VRE epidemiology.
We believe that the control measures were
helpful in containing the outbreak of VRE in¬
fection. Specific recommendations for pre¬
vention and control of infection with VRE are
included in a report of the Hospital Infections
Control Practices Advisory Committee of the
Centres for Disease Control and Prevention.1''
Screening of staffwas not undertaken because no
useful action could be taken in the eventof finding
VRE colonisation. The deaths of four patients
were not solely due to VRE infection although
this was probably a contributory element in some
cases. The VRE strains from BGH were isolated
in 1996 from female patients in separate long stay
accommodations in Kelso and Cornhill-on-
Tweed. There was no known contact with the
teaching hospital renal unit. However, without
further epidemiological corroboration and ex¬
amining more isolates from these hospitals, par¬
ticularly after a screening programme, it is
presumptive to say that clonal spread has been
shown between these hospitals.
The importance of a multi-faceted approach is
emphasized. The last PFGE type A VRE were
isolated at the end of September. None have been
isolated from clinical material since then, either
in the renal wards or elsewhere in the hospital.
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Vancomycin-Resistant Enterococci: Epidemiology and control of an
epidemic in a Renal Unit. W.D. Plant1, R.J. Winney1, A. Brown1, R.H.
Paton2, S.G.B. Amyes2, G.M. Stevenson2, and R.S. Miles2,1Dept ofRenal
Medicine, Royal Infirmary of Edinburgh NHS Trust & 2Department
of Clinical Bacteriology, Edinburgh University, Edinburgh, Scotland.
Glycopeptide-resistant enterococcus species, especially E. faecalis and
E. faecium, are increasingly important causes of nosocomial infection.
We report an epidemic affecting 25 patients under the care of a univer¬
sity teaching hospital renal service. Vancomycin-resistant strains (VRE)
of E. faecium were cultured in clinical samples from 2 maintenance
dialysis patients. Both had multiple medical problems, had spent a
protracted period in hospital, and been treated with vancomycin. Two
months later, VRE were cultured in clinical samples from 2 other in¬
patients. Subsequently all in-patients in areas where these patients had
been cared for were screened (rectal swab and faecal culture) for VRE.
17/77 (22%) screened patients were colonised and treated as potentially
infectious. VRE was isolated in clinical samples from a further 4 pa¬
tients. 9 patients died whilst colonised/infected, 12 became free from
colonisation after a period of time and 4 were discharged into the
community. No patient died directly as a result of VRE infection, but
it may have contributed as an additional clinical problem in those
already seriously ill. Isolates were identified to species level using the
API 20 Strep system. MIC tests and PCR was used to evaluate the
resistance genotype of each organism. Relatedness was evaluated using
restriction endonuclease digestion (RED) and pulsed-flow gel electro¬
phoresis. E. faecium was isolated from 21 patients and E. faecalis from
6 patients (some were colonised with both). The outbreak strain was
identified as an E. faecium RED type A with VanA genotype. In the
majority of cases this or a related strain was isolated suggesting that
the epidemic resulted from clonal spread of this strain. All colonised
patients were isolated within a single ward area. Segregated dialysis
facilities were provided. Patient transfer between clinical areas was
restricted. The frequency of cleaning of surfaces and toilet areas was
increased. The use of parenteral and oral vancomycin was severely
curtailed. Rigorous attention was paid to hand-washing and wearing
plastic aprons. With this approach the epidemic was contained and no
new cases have developed in the following 18 months.
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In February 1996, a Hospital Infection Control Practices Advisory Committee-style screening program was
commenced to isolate and subsequently characterize glycopeptide-resistant enterococci (GRE) from patients at
a hospital trust in Glasgow, Scotland. Over the next 30 months, GRE were isolated from 154 patients. GRE
were isolated from patients in traditionally high-risk areas such as the renal unit and intensive care unit and
also in areas considered to be lower risk, including medical wards and associated long-stay geriatric hospitals.
The majority (90%) of isolates were Enterococcus faecium vanB. The remaining isolates consisted of seven
E.faecalis (vanA), three E. gallinarum (vanC), and a further six E. faecium (five vanA, one both vanA and vanB)
isolates. Analysis of Smol-digested DNA by pulsed-field gel electrophoresis revealed that 34 of 40 (85%) VanB
E. faecium isolates were identical or closely related, while 11 of 13 (85%) VanA GRE were distinct. High-level
aminoglycoside resistance was seen in less than 8% of isolates. VanB E. faecium isolates were almost uniformly
resistant to ampicillin and tetracycline. In this study, GRE have been isolated over a prolonged period from
a broad range of patients. Glycopeptide resistance within the study hospital trust appeared to be mainly due
to the clonal dissemination of a single strain of E. faecium VanB.
Following their initial discovery in the United Kingdom and
France in 1986 (15, 26), glycopeptide-resistant enterococci
(GRE) have now spread worldwide, with the percentage of
enterococcal infections in the United States resistant to vanco¬
mycin rising from 0.3% in 1989 to 7.9% in 1993 (4). A number
of outbreaks of colonization and infection with GRE have
been described. VanA-type Enterococcus faecium strains typi¬
cally predominate in clinical areas such as transplantation and
oncology units and the intensive care unit (ICU) (3, 7, 9, 19,
21).
The Hospital Infection Control Practices Advisory Commit¬
tee (HICPAC) of the Centers for Disease Control and Pre¬
vention has published recommendations for prevention of the
spread of glycopeptide resistance (12) which, although pub¬
lished in the United States, are believed to be relevant in the
United Kingdom also (10). The recommendations include
screening of enterococcal isolates for vancomycin resistance
and establishment of a fecal screening program to detect pa¬
tients with intestinal colonization with GRE. It is also recom¬
mended that control efforts be intensified once GRE are
known to be present within a hospital, particularly in high-risk
areas such as transplantation and oncology units and the ICU.
An isolate of GRE was obtained from the routine culture of
a femoral line tip from a renal unit patient in the ward of a
Scottish hospital trust in October 1995. In response to this, all
enterococcal isolates from clinical specimens were examined
for glycopeptide resistance. A fecal screening program was also
established and involved thrice-weekly screening of all ICU
patients and routine screening of all fecal specimens or rectal
swabs submitted to the laboratory.
This paper presents the findings of this program over a
30-month period.
* Corresponding author. Mailing address: Department of Biological
Sciences, University of Dundee, Dundee DDI 4HN, United Kingdom.
Phone: 44-1382-344270. Fax: 44-1382-344275. E-mail: h.k.young@dundee
.ac.uk.
MATERIALS AND METHODS
Hospital setting. The study hospital trust is a tertiary referral center that
comprises two major hospitals with a combined total of 1,100 beds, together with
three smaller, long-stay geriatric hospitals. One of the major hospitals has a
33-bed renal unit located in two adjacent wards on a single floor that comprises
a mixture of single- and four-bed rooms. An eight-bed ICU is located two floors
below.
Fecal screening program. Routine screening of all fecal specimens submitted
to the laboratory was instituted in February 1996. Additionally, rectal swabs were
taken thrice weekly from all patients on the ICU. Fecal suspensions or rectal
swabs were inoculated directly onto esculin azide agar base (Oxoid, Basingstoke,
United Kingdom) supplemented with 6 pg of vancomycin (Sigma, Poole, United
Kingdom) per ml and with 10 pg of colistin sulfate per ml and 15 pg of nalidixic
acid per ml (both from Oxoid). The plates were incubated for 18 h in air at 37°C.
Isolates that were esculin positive, catalase negative, gram-positive cocci, and
vancomycin resistant by the E-test were tentatively identified as GRE.
Identification. Clinical enterocOcci and those from the fecal screens were
identified to the species level in the laboratory with the API 20 STREP system
(Biomerieux, Marcy l'Etoile, France). The identities of all isolates were con¬
firmed by PCR and biochemical tests (see Table 1).
PCR amplification of intergenic rRNA spacer regions (ITS-PCR) was based
on the methods of Jensen et al. (13) and Tyrrell et al. (25) with primers LI
(5' -CAAGGCATCCACCGT) and G1 (5 '-GAAGTCGTAACAAGG). Amplifi¬
cation was performed with a Hybaid Omn-E thermal cycler with 20 pmol of each
primer, 100 pM deoxynucleoside triphosphates, 1.5 mM MgCl2,10 mM Tris-HCl
(pH 8.8), 50 mM KC1, and 0.1% Triton X-100. Template DNA was prepared
from whole cells by mixing 200 pi of a culture grown overnight in brain heart
infusion broth (Oxoid) with 800 pi of water and boiling for 10 min. Following
centrifugation, 5 pi of supernatant was added to each PCR mixture, and the final
volume was adjusted to 50 pi. The PCR mixture was heated to 95°C for 5 min,
and 1 U of BioTaq DNA polymerase (Bioline, London, United Kingdom) was
added. Amplification conditions were 94°C for 1 min, 55°C for 7 min, and 72°C
for 2 min for a total of 25 cycles, followed by an additional 7 min at 72°C.
Arabinose fermentation was detected in a 1% (wt/vol) sugar solution in An-
drade's peptone water. The identities of E. gallinarum and E. casseliflavus strains
were confirmed by PCR amplification of the vanC ligase gene specific for each
organism (6).
Antimicrobial susceptibility. All isolates were tested for susceptibility to van¬
comycin, ampicillin, gentamicin, and streptomycin (all from Sigma), teicoplanin
(Marion Merrell, Uxbridge, United Kingdom), and ciprofloxacin (Bayer, New¬
bury, United Kingdom) by an agar incorporation method in accordance with the
British Society for Antimicrobial Chemotherapy guidelines (28).
Glycopeptide-resistant isolates were characterized phenotypically on the basis
of susceptibility levels to vancomycin and teicoplanin. Isolates were defined as
having a VanA phenotype if the vancomycin MIC was ^64 pg/ml and the tei-
2112
Vol. 38, 2000 GRE IN A SCOTTISH HOSPITAL 2113






Pattern 1 2 2 2 2 1
FIG. 1. ITS-PCR profiles of enterococcal species. Lanes: 1, Generuler 1-kb
DNA ladder (MBI Fermentas); 2, E. faecium ATCC 19434; 3, E. faecalis ATCC
19433; 4, E. casseliflavus ATCC 25788; 5, E. gallinarum ATCC 49573; 6, strain
G-089 (E. faecalis); 7, strain G-090 IE. faecium). The image was generated with
Adobe Photoshop, version 4.0.
coplanin MIC was 2:2 jig/ml. For isolates with a VanB phenotype the vancomy¬
cin MIC was 2:8 pg/ml and the teicoplanin MIC was <2 (xg/ml.
The MIC breakpoints for susceptibility to an antibiotic were as follows: am-
picillin, s8 |xg/ml; tetracycline, si pg/ml; and ciprofloxacin, s4 pg/ml. The
numbers of isolates with high-level gentamicin resistance (MICs, >500 |xg/ml)
and high-level streptomycin resistance (MICs, >2,000 pg/ml) were determined.
Cell suspensions were tested for p-lactamase production in a solution of 20 pg of
nitrocefin per ml.
PCR amplification of glycopeptide resistance elements. Glycopeptide resis¬
tance determinants vanA, vanB, vanCl, and vanC2-vanC3 were detected by
multiplex PCR with the primers described by Dutka-Malen et al. (6). Amplifi¬
cation reactions were performed in 50-p.l volumes containing 20 pi of template
(prepared from boiled whole cells as for ITS-PCR), 20 pmol of each primer, 200
pM deoxynucleoside triphosphates, 3 mM MgCl2, 16 mM (NH4)2S04, 67 mM
Tris-HCl (pH 8.8), 0.01% Tween-20, and 1 U of BioTaq DNA polymerase. The
reaction mixtures were denatured at 94°C for 2 min, followed by 30 cycles of 94°C
for 1 min, 54°C for 1 min, and 72°C for 2 min, with a final extension at 72°C for
10 min.
PFGE typing. Genomic DNA was prepared in agarose plugs as described by
Murray et al. (20). DNA was digested with 20 U of SmaI (Promega, Madison,
Wis.) for 6 h at 25°C and was electrophoresed with the contour-clamped homog¬
enous electric fields device (CHEF-DRII; Bio-Rad, Hercules, Calif.). The switch
interval was ramped from 5 to 35 s over a 24-h period at 6 V/cm2. A pulsed-field
gel electrophoresis (PFGE) type was assigned to each strain in accordance with
the criteria outlined by Tenover et al. (23).
Control strains. E. faecium NCTC 12202 (vanA), E. faecium ATCC 19434
(glycopeptide susceptible), E. faecalis ATCC 51299 (vanB), E. faecalis ATCC
19433 (glycopeptide susceptible), E. gallinarum ATCC 49573 (vanCl), and E. cas¬
seliflavus ATCC 25788 (vanC2) were used as control strains.
RESULTS
Isolates. Between February 1996 and July 1998, GRE were
obtained from 154 patients. Only the initial isolate from each
patient was used for further study. The majority of isolates (134
of 154) were obtained from the two major hospitals.
Thirty-six isolates were from clinical specimens, including 21
from urine, 10 from wounds, 3 from continuous ambulatory
peritoneal dialysis effluents, and 2 from blood cultures. Twenty
nine (80.5%) of the 36 clinical GRE were from patients in the
primary hospital unit, of which 17 were renal unit patients. A
single clinical GRE isolate was recovered from an ICU patient
during the study period. Two isolates were from patients in the
long-stay geriatric hospitals. These patients represented 0.87%
of the 4,130 patients from whom clinically significant entero-
cocci were isolated by the laboratory during the study period.
The remaining 118 GRE were from 8,549 patients screened
for fecal carriage (carriage rate, 1.4%). Of these, 23 were
recovered from 1,117 ICU patients (carriage rate, 2.1%), 36
were recovered from 316 renal unit patients (11.5%), and 6
were recovered from 153 oncology and hematology unit pa¬
tients (1.2%). A further 45 were isolated from 6,843 patients
TABLE 1. Tests used for differentiating between E. faecalis,
E. faecium, E. gallinarum, and E. casseliflavus species groups
Test
Test result
E. faecalis E. faecium E. gallinarum E. casseliflavus
ITS-PCR
Pattern 1
Pattern 2 + 1+ +1 +1
Arabinose
fermentation




- - + -
- - +
(0.7%) in the two major hospitals, including patients from
surgical and medical wards, patients from the obstetrics unit,
and outpatients. The final eight fecal isolates were recovered
from 124 patients (6.5%) within the long-stay geriatric hospi¬
tals. There were no apparent associations between coloniza¬
tion with GRE and the clinical indication for the submission of
fecal specimens.
Identification. The use of ITS-PCR with primers LI and G1
to produce unique patterns of bands for different enterococcal
species has been described previously (25). In our hands, these
primers amplified only two distinct patterns of bands from
isolates collected for this study and control strains (Fig. 1).
Isolates of E. faecium gave two bands of approximately 430
and 520 bp (pattern 1). A single distinct pattern (pattern 2),
with bands of approximately 295 and 420 bp, was produced by
E. faecalis, E. gallinarum, and E. casseliflavus isolates. Thus,
species identity was determined by a combination of ITS-PCR,
arabinose fermentation, and PCR amplification of van genes,
as outlined in Table 1. By using these criteria, 144 (93.5%)
isolates were identified as E. faecium, 7 (4.5%) were identified
as E. faecalis, and 3 (2%) were identified as E. gallinarum. No
E. casseliflavus isolates were obtained.
The identities of the isolates determined by these tests did
not always correlate with the identifies determined with the
API 20 STREP system (Table 2). The API 20 STREP kit failed
to identify any of the three E. gallinarum strains. Furthermore,
29 strains of E. faecium were incorrectly identified as E. cas¬
seliflavus by the API 20 STREP system.
Characterization of glycopeptide resistance elements. The
Van phenotype of each isolate was determined on the basis of
its levels of susceptibility to vancomycin and teicoplanin (Table
3). All seven E. faecalis isolates had a VanA phenofype. The
majority, 138 of 142 (97%), of E. faecium strains were VanB,
while the remaining 6 isolates had susceptibility levels that
TABLE 2. Comparison of species identification methods
for enterococcal isolates
No. of strains identified with API 20 STREP system'
Species*
E. faecalis E. faecium E. gallinarum E. casseliflavus Total
E. faecalis 6 1 0 0 7
E. faecium 1 114 0 29 144
E. gallinarum 0 1 0 2 3
E. casseliflavus 0 0 0 0 0
Total 7 116 0 31 154
" Species determined by using the criteria described in Table 1.
h API 20 STREP profiles analyzed by using APILAB, version 5.1, software.
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TABLE 3. In vitro susceptibilities of E. faecalis and E. faecium











Vancomycin 128 512 64-512 7(100)
Teicoplanin 8 64 4-64 7(100)
Ampicillin 2 4 IA 0(0)
Tetracycline 128 >128 64->128 7(100)
Streptomycin 512 >2,048 512->2,048 2 (28.6)
Gentamicin 64 >1,024 32->l,024 1 (14.3)
Ciprofloxacin 1 1 0.5-1 0(0)
E. faecium (VanA)
(" = 6")
Vancomycin 256 >256 128->256 6(100)
Teicoplanin 32 >128 8->128 6(100)
Ampicillin 32 >256 0.5->256 5 (83.3)
Tetracycline 0.25 128 <0.25-128 1 (16.7)
Streptomycin 256 >2,048 128->2,048 1 (16.7)
Gentamicin 32 >1,024 16-> 1,024 1 (16.7)
Ciprofloxacin 2 >128 0.5->128 2 (33.3)
E. faecium (VanB)
(n = 138)
Vancomycin 16 16 8-128 138(100)
Teicoplanin 0.5 0.5 <0.25-1 0(0)
Ampicillin 128 128 1-256 137 (99.3)
Tetracycline 32 64 0.25-64 134 (97.1)
Streptomycin 256 256 64->2,048 5 (3.6)
Gentamicin 64 64 32-> 1,024 1 (0.7)
Ciprofloxacin 2 4 0.5-32 4(2.9)
" 50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respec¬
tively.
b Includes an E. faecium strain with both vanA and vanB ligase genes.
suggested a VanA phenotype. The PCR-determined genotypes
were consistent with the phenotypes for all but one isolate.
One strain of E. faecium with a VanA phenotype produced
both vanA and vanB PCR products. A vanCl gene was ampli¬
fied from the three E. gallinarum isolates.
Interestingly, the VanB E. faecium strains showed low-level
resistance to vancomycin, and the vancomycin MIC was great¬
er than 32 p-g/ml for only one isolate.
Antimicrobial susceptibility. Strains were tested for suscep¬
tibility to ampicillin, tetracycline, streptomycin, gentamicin,
and ciprofloxacin (Table 3). E. faecium isolates were almost
uniformly resistant to ampicillin, while E. faecalis isolates re¬
mained susceptible. Twenty isolates for which ampicillin MICs
covered a wide range were tested for (3-lactamase activity.
None produced a detectable (3-lactamase enzyme. Of the
VanB E. faecium isolates, 97% were resistant to both ampicil¬
lin and tetracycline. Overall, 4% of isolates were resistant to
ciprofloxacin. High-level aminoglycoside resistance was seen in
less than 8% of isolates, and no isolate was resistant to both
streptomycin and gentamicin. The three E. gallinarum strains
were susceptible to all antibiotics tested.
Typing. The 13 VanA ORE were typed by PFGE. All E. fae¬
calis isolates had distinct PFGE patterns. Of the six E. faecium
isolates, three were distinct types and three were identical. The
three identical isolates were recovered from fecal screens for
patients located in a single four-bed room within the renal unit
over a 2-week period in June and July 1997, suggesting that
person-to-person spread had occurred.
Forty VanB E. faecium isolates were selected for typing,
including both fecal and nonfecal isolates from the 30-month
period. Thirty-five isolates were from the primary hospital unit
(from which 70% of GRE were isolated) and comprised 9
nonfecal isolates from the renal unit and ICU and 26 fecal
isolates (23 from the renal unit and ICU, 3 from otheT wards).
Four GRE were isolated from patients in the second hospital
unit, and one was from a patient in a geriatric hospital. Twenty-
eight of 40 (70%) VanB E. faecium isolates had identical
PFGE patterns, including both fecal and nonfecal isolates from
the two major hospitals. A further six isolates were closely
related (two or three band differences), including the isolate
from the patient in the geriatric hospital. Five isolates were
possibly related (four to six band differences), and one (a fecal
isolate from the renal unit) was unrelated.
DISCUSSION
GRE have become an increasing problem in hospitals from
the standpoint of nosocomial infection and infection control.
HICPAC has published guidelines on the control of GRE
within hospitals, and these recommend the routine screening
of enterococcal isolates for resistance to vancomycin and in¬
tensified fecal screening to detect patients with gastrointestinal
colonization. In this study the findings from such a screening
program are presented. These differ from many other studies
of colonization with GRE in that they are not restricted solely
to patients in high-risk areas over short time periods.
The vancomycin-containing indicator medium used in this
study proved useful for the isolation of GRE from fecal spec¬
imens. Identification to the species level proved more prob¬
lematic. Other investigators have reported discrepancies be¬
tween the identities obtained with the API 20 STREP system
and by genotypic methods (16, 27). In this study, the API 20
STREP kit was particularly unreliable at distinguishing E. fae¬
cium and E. casseliflavus isolates. The epidemiological and
infection control implications of enterococci with intrinsic
(vanC) and acquired (vanA, vanB) resistance to vancomycin
are very different, with intrinsically resistant species failing to
demonstrate person-to-person spread (24). Failure to correctly
identify patients colonized with intrinsically resistant strains
entails subjecting them to unnecessary infection control mea¬
sures. Reanalysis of the API 20 STREP profiles on uprated
software correctly identified all strains of E. faecium but was
still unable to identify two of the three strains oiE. gallinarum.
It would appear that accurate differentiation of intrinsically
glycopeptide-resistant species from those with acquired resis¬
tance during screening requires a molecular biological meth¬
odology such as PCR.
One such method uses amplification of species-specific ddl
ligase genes to identify E. faecalis and E. faecium (6). This
method appears to be particularly useful as it can be per¬
formed in combination with amplification of glycopeptide re¬
sistance elements. In this study, we assessed the ITS-PCR
method, which has been reported to give distinct bands for a
number of enterococcal species, in addition to E. faecalis and
E. faecium (25), for species identification. In our hands, this
method could be used to identify E. faecium isolates, but fur¬
ther tests were required to distinguish E. faecalis from the
intrinsically resistant species.
Although only 12% of isolates of GRE in the United King¬
dom have the vanB genotype (18), the predominance of the
vanB genotype within a hospital setting has been reported
previously (2, 17, 22). However, the low level of vancomycin
resistance present within the vanB strains (MIC at which 90%
of isolates are inhibited, 16 pg/ml) in this study is unusual and
may be partially explained by the lower concentration of van¬
comycin in the selective medium than that used in earlier
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FIG. 2. Isolation of GRE from a Scottish hospital trust over a 30-month period.
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studies. The incidence of high-level gentamicin resistance was
also low, being found only in a single strain. The rate of high-
level gentamicin resistance found in this study (0.7%) is much
lower than rates of 6.7 to 13.4% found among all species of
enterococci, both vancomycin resistant and sensitive, in the
United Kingdom (11). The retention of sensitivity to teicopla-
nin is fortuitous in that it provides a synergistic therapeutic
option in combination with an aminoglycoside should the need
arise (14). All E. faecalis isolates retained sensitivity to ampi-
cillin, giving an alternative therapeutic option.
The resistance genotype determined by PCR was consistent
with the phenotype for all but one isolate, despite reports of
mismatching in previous studies (1, 5, 8, 16). There does, how¬
ever, exist an area of overlap between MICs at the bottom of
the range for VanB strains (an area into which most of the
VanB study isolates fell) and those at the top of the range for
VanC strains, making distinction by phenotypic methods be¬
tween intrinsic and acquired resistance impossible for certain
strains. The failure of phenotypic methods of identification and
antimicrobial sensitivity testing to distinguish between ac¬
quired and intrinsic resistance consequently necessitates the
use of a molecular biological method for accurate differentia¬
tion of all strains.
The carriage of GRE described in this study gives a much
fuller picture than that often obtained, given the prolonged
study period and broad area screened. GRE colonization oc¬
curred throughout the study period among patients admitted
to the renal unit and ICU, areas traditionally regarded as high
risk (12). However, this may reflect the regular nature of the
screening protocol in these areas. Among patients in the he¬
matology and oncology units colonization was infrequent in
this study, despite frequent use of glycopeptide agents in both
units. Colonization was detected in patients in traditionally
lower-risk areas, such as medicine and surgery, as well as pa¬
tients within the long-stay geriatric hospitals over the 30-month
period.
Carriage and infection with VanB E. faecium occurred at a
relatively constant level throughout the 30-month period (Fig.
2). Although only a selection of VanB E. faecium isolates were
typed in this study, it appears that a dominant clone is present
in a number of hospital units and patient groups in Glasgow. In
contrast, isolation of VanA and VanC GRE was sporadic.
PFGE analysis suggests these isolates were distinct (except for
one cluster of VanA E. faecium isolates for which nosocomial
spread was indicated).
The finding of a single vanB E. faecium clone that dissemi¬
nated within and between hospitals parallels that seen in other
studies (17, 22). The free movement of patients between the
two major hospital units in this study may well have contrib¬
uted to the dissemination of the clone in this instance. Fur¬
thermore, medical staff rotated between both sites, and al¬
though nursing staff usually worked on only a single ward,
many worked extra shifts at other sites. Patients within the
long-stay geriatric hospitals had often been previously admit¬
ted to either of the major hospitals.
The introduction of a fecal screening program greatly in¬
creased the rate of detection of GRE among inpatients. Thirty-
six of 154 isolates originated from nonfecal sources and would
have been detected by routine methods, as all were ampicillin
resistant, necessitating testing for glycopeptide resistance. The
isolates from the remaining 118 colonized patients, however,
would not otherwise have manifested themselves, as during the
study period none of the patients yielded GRE from nonfecal
routine specimens. Detection of colonized patients allowed
their isolation and reduced their risk as a source of infection.
However, steady acquisition continued to occur despite these
precautions. As detection of GRE outside the ICU relied on
clinical staff deciding to send fecal specimens for other reasons,
detection rates are probably far from complete and many pa¬
tients colonized with GRE but in whom GRE were not de¬
tected are likely to have remained on the open ward.
The HICPAC-style fecal screening program did demon¬
strate a far greater extent of colonization than that which
would have been revealed by more selective programs. How¬
ever, colonization continued to occur, despite the knowledge
obtained, and resources may have been better directed toward
improving overall infection control and hand washing, as any
patient, even in traditionally low-risk areas, may be potentially
colonized with GRE. A point prevalence study in which every
patient in the hospital on a given day is screened for the
presence of GRE would give useful information on coloniza¬
tion and potential empirical treatment with considerable sav¬
ings in resources.
Data collected from this program have given us an indication
2116 NELSON ET AL. J. Clin. Microbiol.
of the background level of GRE at the study hospital trust, and
this information will be of benefit should an outbreak of clin¬
ically significant GRE occur.
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Tn 1546 Heterogeneity in VanA Enterococci from Scotland:
Correlation between Genotype and Teicoplanin Resistance.
A.R. BROWN, S.G.B.AMYES
Background: The genetic determinants responsible for conferring VanA-type
glycopeptide resistance in enterococci frequently vary from the prototype Tn 1546
element described in Enterococcus faecium BM4147. Often these differences are
attributable to insertion or deletion events upstream of vanR or downstream of vanX.
In this study, the Tn 1546 elements of 48 VanA enterococcal isolates were studied for
such variation.
Methods: Isolates were obtained from Scottish hospitals and confirmed as VanA-
type GRE by standard methods. Tn7546-specific PCR primers were designed to
amplify the orfl-vanR, vanS-vanH and vanX-vanZ regions of Tn7546. PCR products
were subjected to RFLP analysis and some products were subsequently sequenced
to confirm insertions or deletions.
Results: No isolates showed any variation from the prototype Tn1546 element
within the vanS-vanH and vanYZ regions. However, the 48 isolates could be grouped
into three groups according to variation within the orf2-vanR and vanX-vanY
intergenic regions of theTn 1546 elements. Fifteen of the 48 isolates have no
variation from the prototype Tn 1546 sequence (in terms of insertions/deletions). All
of the remaining isolates harbor two distinct insertions: \S1542 immediately upstream
of vanR, and IS7276\/-like element within the vanX-vanY intergenic region. Twenty-
seven of these isolates also have a 93-bp deletion at the point of IS7276V-like
insertion. The 34 isolates harboring both IS elements have a significantly higher
teicoplanin MIC (MIC50 & MIC90 >1024mg/L) than those isolates with the prototype
Tn 1546 (MIC50 64mg/L; MIC90 128mg/L). Sequencing of the IS 1542/vanR region
reveals a strong promoter sequence upstream of vanR that is generated by the
insertion of IS 1542.
Conclusions: The lack of variation within the vanS-vanH intergenic region is
consistent with other European studies. Although IS7276\/-like elements and IS 1542
have frequently been reported within Tn 1546, we believe this to be the first
correlation made between the presence of such IS elements and an increase in
teicoplanin resistance. The insertion of IS 1542 generates a strong promoter
sequence upstream of vanR, and also separates this promoter from the recognised
phospho-VanR binding site that is thought, ordinarily, to repress vanR expression. It
is proposed that these factors result in enhanced induction of resistance and may
have a role in the mechanism for elevated teicoplanin resistance.
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